Treatment of cancer with tor kinase inhibitors

ABSTRACT

Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

This application claims the benefit of U.S. Provisional Application No.61/549,034, filed Oct. 19, 2011, claims the benefit of U.S. ProvisionalApplication No. 61/591,401, filed Jan. 27, 2012, claims the benefit ofU.S. Provisional Application No. 61/647,233, filed May 15, 2012 andclaims the benefit of U.S. Provisional Application No. 61/653,436, filedMay 31, 2012, the entire contents of each of which are incorporatedherein by reference.

1. FIELD

Provided herein are methods for treating or preventing a solid tumor,non-Hodgkin lymphoma or multiple myeloma in a patient, comprisingadministering an effective amount of a TOR kinase inhibitor to a patienthaving a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

2. BACKGROUND

The connection between abnormal protein phosphorylation and the cause orconsequence of diseases has been known for over 20 years. Accordingly,protein kinases have become a very important group of drug targets. SeeCohen, Nature, 1:309-315 (2002). Various protein kinase inhibitors havebeen used clinically in the treatment of a wide variety of diseases,such as cancer and chronic inflammatory diseases, including diabetes andstroke. See Cohen, Eur. J. Biochem., 268:5001-5010 (2001), ProteinKinase Inhibitors for the Treatment of Disease: The Promise and theProblems, Handbook of Experimental Pharmacology, Springer BerlinHeidelberg, 167 (2005).

The protein kinases are a large and diverse family of enzymes thatcatalyze protein phosphorylation and play a critical role in cellularsignaling. Protein kinases may exert positive or negative regulatoryeffects, depending upon their target protein. Protein kinases areinvolved in specific signaling pathways which regulate cell functionssuch as, but not limited to, metabolism, cell cycle progression, celladhesion, vascular function, apoptosis, and angiogenesis. Malfunctionsof cellular signaling have been associated with many diseases, the mostcharacterized of which include cancer and diabetes. The regulation ofsignal transduction by cytokines and the association of signal moleculeswith protooncogenes and tumor suppressor genes have been welldocumented. Similarly, the connection between diabetes and relatedconditions, and deregulated levels of protein kinases, has beendemonstrated. See e.g., Sridhar et al. Pharmaceutical Research,17(11):1345-1353 (2000). Viral infections and the conditions relatedthereto have also been associated with the regulation of proteinkinases. Park et al. Cell 101 (7): 777-787 (2000).

Because protein kinases regulate nearly every cellular process,including metabolism, cell proliferation, cell differentiation, and cellsurvival, they are attractive targets for therapeutic intervention forvarious disease states. For example, cell-cycle control andangiogenesis, in which protein kinases play a pivotal role are cellularprocesses associated with numerous disease conditions such as but notlimited to cancer, inflammatory diseases, abnormal angiogenesis anddiseases related thereto, atherosclerosis, macular degeneration,diabetes, obesity, and pain.

Protein kinases have become attractive targets for the treatment ofcancers. Fabbro et al., Pharmacology & Therapeutics 93:79-98 (2002). Ithas been proposed that the involvement of protein kinases in thedevelopment of human malignancies may occur by:

(1) genomic rearrangements (e.g., BCR-ABL in chronic myelogenousleukemia),(2) mutations leading to constitutively active kinase activity, such asacute myelogenous leukemia and gastrointestinal tumors, (3) deregulationof kinase activity by activation of oncogenes or loss of tumorsuppressor functions, such as in cancers with oncogenic RAS,(4) deregulation of kinase activity by over-expression, as in the caseof EGFR and(5) ectopic expression of growth factors that can contribute to thedevelopment and maintenance of the neoplastic phenotype. Fabbro et al.,Pharmacology & Therapeutics 93:79-98 (2002).

The elucidation of the intricacy of protein kinase pathways and thecomplexity of the relationship and interaction among and between thevarious protein kinases and kinase pathways highlights the importance ofdeveloping pharmaceutical agents capable of acting as protein kinasemodulators, regulators or inhibitors that have beneficial activity onmultiple kinases or multiple kinase pathways. Accordingly, there remainsa need for new kinase modulators.

The protein named mTOR (mammalian target of rapamycin), which is alsocalled FRAP, RAFTI or RAPT1), is a 2549-amino acid Ser/Thr proteinkinase, that has been shown to be one of the most critical proteins inthe mTOR/PI3K/Akt pathway that regulates cell growth and proliferation.Georgakis and Younes Expert Rev. Anticancer Ther. 6(1):131-140 (2006).mTOR exists within two complexes, mTORC1 and mTORC2. While mTORC1 issensitive to rapamycin analogs (such as temsirolimus or everolimus),mTORC2 is largely rapamycin-insensitive. Notably, rapamycin is not a TORkinase inhibitor. Several mTOR inhibitors have been or are beingevaluated in clinical trials for the treatment of cancer. Temsirolimuswas approved for use in renal cell carcinoma in 2007 and sirolimus wasapproved in 1999 for the prophylaxis of renal transplant rejection.Everolimus was approved in 2009 for renal cell carcinoma patients thathave progressed on vascular endothelial growth factor receptorinhibitors, in 2010 for subependymal giant cell astrocytoma (SEGA)associated with tuberous sclerosis (TS) in patients who require therapybut are not candidates for surgical resection, and in 2011 forprogressive neuroendocrine tumors of pancreatic origin (PNET) inpatients with unresectable, locally advanced or metastatic disease.There remains a need for TOR kinase inhibitors that inhibit both mTORC1and mTORC2 complexes.

Citation or identification of any reference in Section 2 of thisapplication is not to be construed as an admission that the reference isprior art to the present application.

3. SUMMARY

Provided herein are methods for treating or preventing a solid tumor,non-Hodgkin lymphoma or multiple myeloma, comprising administering aneffective amount of a TOR kinase inhibitor to a patient having a solidtumor, non-Hodgkin lymphoma or multiple myeloma.

In certain embodiments, provided herein are methods for achieving aResponse Evaluation Criteria in Solid Tumors (RECIST 1.1) of completeresponse, partial response or stable disease, improving InternationalWorkshop Criteria (IWC) for NHL, improving International UniformResponse Criteria for Multiple Myeloma (IURC), improving EasternCooperative Oncology Group Performance Status (ECOG) or improvingResponse Assessment for Neuro-Oncology (RANO) Working Group for GBMcomprising administering an effective amount of a TOR kinase inhibitorto a patient having a solid tumor, non-Hodgkin lymphoma or multiplemyeloma. In some embodiments, the TOR kinase inhibitor is a compound asdescribed herein.

The present embodiments can be understood more fully by reference to thedetailed description and examples, which are intended to exemplifynon-limiting embodiments.

4. DETAILED DESCRIPTION 4.1 Definitions

An “alkyl” group is a saturated, partially saturated, or unsaturatedstraight chain or branched non-cyclic hydrocarbon having from 1 to 10carbon atoms, typically from 1 to 8 carbons or, in some embodiments,from 1 to 6, 1 to 4, or 2 to 6 or carbon atoms. Representative alkylgroups include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl and-n-hexyl; while saturated branched alkyls include -isopropyl,-sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylpentyl,3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl and the like. Examplesof unsaturated alkyl groups include, but are not limited to, vinyl,allyl, —CH═CH(CH₃), —CH═C(CH₃)₂, —C(CH₃)═CH₂, —C(CH₃)═CH(CH₃),—C(CH₂CH₃)═CH₂, —C≡CH, —C≡C(CH₃), —C≡C(CH₂CH₃), —CH₂C≡CH, —CH₂C≡C(CH₃)and —CH₂C≡C(CH₇CH₃), among others. An alkyl group can be substituted orunsubstituted. In certain embodiments, when the alkyl groups describedherein are said to be “substituted,” they may be substituted with anysubstituent or substituents as those found in the exemplary compoundsand embodiments disclosed herein, as well as halogen (chloro, iodo,bromo, or fluoro); hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino;carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine;guanidine; enamine; aminocarbonyl; acylamino; phosphonato; phosphine;thiocarbonyl; sulfonyl; sulfone; sulfonamide; ketone; aldehyde; ester;urea; urethane; oxime; hydroxylamine; alkoxyamine; aralkoxyamine;N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate;isothiocyanate; cyanate; thiocyanate; B(OH)₂, or O(alkyl)aminocarbonyl.

An “alkenyl” group is a straight chain or branched non-cyclichydrocarbon having from 2 to 10 carbon atoms, typically from 2 to 8carbon atoms, and including at least one carbon-carbon double bond.Representative straight chain and branched (C₂-C₈)alkenyls include-vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl, -1-pentenyl,-2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl,-2,3-dimethyl-2-butenyl, -1-hexenyl, -2-hexenyl, -3-hexenyl,-1-heptenyl, -2-heptenyl, -3-heptenyl, -1-octenyl, -2-octenyl,-3-octenyl and the like. The double bond of an alkenyl group can beunconjugated or conjugated to another unsaturated group. An alkenylgroup can be unsubstituted or substituted.

A “cycloalkyl” group is a saturated, partially saturated, or unsaturatedcyclic alkyl group of from 3 to 10 carbon atoms having a single cyclicring or multiple condensed or bridged rings which can be optionallysubstituted with from 1 to 3 alkyl groups. In some embodiments, thecycloalkyl group has 3 to 8 ring members, whereas in other embodimentsthe number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7.Such cycloalkyl groups include, by way of example, single ringstructures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl,2-methylcyclooctyl, and the like, or multiple or bridged ring structuressuch as adamantyl and the like. Examples of unsaturated cycloalkylgroups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl,pentadienyl, hexadienyl, among others. A cycloalkyl group can besubstituted or unsubstituted. Such substituted cycloalkyl groupsinclude, by way of example, cyclohexanone and the like.

An “aryl” group is an aromatic carbocyclic group of from 6 to 14 carbonatoms having a single ring (e.g., phenyl) or multiple condensed rings(e.g., naphthyl or anthryl). In some embodiments, aryl groups contain6-14 carbons, and in others from 6 to 12 or even 6 to 10 carbon atoms inthe ring portions of the groups. Particular aryls include phenyl,biphenyl, naphthyl and the like. An aryl group can be substituted orunsubstituted. The phrase “aryl groups” also includes groups containingfused rings, such as fused aromatic-aliphatic ring systems (e.g.,indanyl, tetrahydronaphthyl, and the like).

A “heteroaryl” group is an aryl ring system having one to fourheteroatoms as ring atoms in a heteroaromatic ring system, wherein theremainder of the atoms are carbon atoms. In some embodiments, heteroarylgroups contain 5 to 6 ring atoms, and in others from 6 to 9 or even 6 to10 atoms in the ring portions of the groups. Suitable heteroatomsinclude oxygen, sulfur and nitrogen. In certain embodiments, theheteroaryl ring system is monocyclic or bicyclic. Non-limiting examplesinclude but are not limited to, groups such as pyrrolyl, pyrazolyl,imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl,pyrolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl,benzothiophenyl, furanyl, benzofuranyl (for example,isobenzofuran-1,3-diimine), indolyl, azaindolyl (for example,pyrrolopyridyl or 1H-pyrrolo[2,3-b]pyridyl), indazolyl, benzimidazolyl(for example, 1H-benzo[d]imidazolyl), imidazopyridyl (for example,azabenzimidazolyl, 3H-imidazo[4,5-b]pyridyl or1H-imidazo[4,5-b]pyridyl), pyrazolopyridyl, triazolopyridyl,benzotriazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl,isoxazolopyridyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl,guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl,and quinazolinyl groups.

A “heterocyclyl” is an aromatic (also referred to as heteroaryl) ornon-aromatic cycloalkyl in which one to four of the ring carbon atomsare independently replaced with a heteroatom from the group consistingof O, S and N. In some embodiments, heterocyclyl groups include 3 to 10ring members, whereas other such groups have 3 to 5, 3 to 6, or 3 to 8ring members. Heterocyclyls can also be bonded to other groups at anyring atom (i.e., at any carbon atom or heteroatom of the heterocyclicring). A heterocyclylalkyl group can be substituted or unsubstituted.Heterocyclyl groups encompass unsaturated, partially saturated andsaturated ring systems, such as, for example, imidazolyl, imidazolinyland imidazolidinyl groups. The phrase heterocyclyl includes fused ringspecies, including those comprising fused aromatic and non-aromaticgroups, such as, for example, benzotriazolyl,2,3-dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl. The phrase alsoincludes bridged polycyclic ring systems containing a heteroatom suchas, but not limited to, quinuclidyl. Representative examples of aheterocyclyl group include, but are not limited to, aziridinyl,azetidinyl, pyrrolidyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl,tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl,pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl,triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiazolinyl,isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl,morpholinyl, thiomorpholinyl, tetrahydropyranyl (for example,tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathiane, dioxyl,dithianyl, pyranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl,triazinyl, dihydropyridyl, dihydrodithiinyl, dihydrodithionyl,homopiperazinyl, quinuclidyl, indolyl, indolinyl, isoindolyl, azaindolyl(pyrrolopyridyl), indazolyl, indolizinyl, benzotriazolyl,benzimidazolyl, benzofuranyl, benzothiophenyl, benzthiazolyl,benzoxadiazolyl, benzoxazinyl, benzodithiinyl, benzoxathiinyl,benzothiazinyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl,benzo[1,3]dioxolyl, pyrazolopyridyl, imidazopyridyl (azabenzimidazolyl;for example, 1H-imidazo[4,5-b]pyridyl, or1H-imidazo[4,5-b]pyridin-2(3H)-onyl), triazolopyridyl, isoxazolopyridyl,purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl,quinolizinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl,naphthyridinyl, pteridinyl, thianaphthalenyl, dihydrobenzothiazinyl,dihydrobenzofuranyl, dihydroindolyl, dihydrobenzodioxinyl,tetrahydroindolyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl,tetrahydrobenzotriazolyl, tetrahydropyrrolopyridyl,tetrahydropyrazolopyridyl, tetrahydroimidazopyridyl,tetrahydrotriazolopyridyl, and tetrahydroquinolinyl groups.Representative substituted heterocyclyl groups may be mono-substitutedor substituted more than once, such as, but not limited to, pyridyl ormorpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, ordisubstituted with various substituents such as those listed below.

An “cycloalkylalkyl” group is a radical of the formula:-alkyl-cycloalkyl, wherein alkyl and cycloalkyl are defined above.Substituted cycloalkylalkyl groups may be substituted at the alkyl, thecycloalkyl, or both the alkyl and the cycloalkyl portions of the group.Representative cycloalkylalkyl groups include but are not limited tocyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl,and cyclohexylpropyl. Representative substituted cycloalkylalkyl groupsmay be mono-substituted or substituted more than once.

An “aralkyl” group is a radical of the formula: -alkyl-aryl, whereinalkyl and aryl are defined above. Substituted aralkyl groups may besubstituted at the alkyl, the aryl, or both the alkyl and the arylportions of the group. Representative aralkyl groups include but are notlimited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkylgroups such as 4-ethyl-indanyl.

A “heterocyclylalkyl” group is a radical of the formula:-alkyl-heterocyclyl, wherein alkyl and heterocyclyl are defined above.Substituted heterocyclylalkyl groups may be substituted at the alkyl,the heterocyclyl, or both the alkyl and the heterocyclyl portions of thegroup. Representative heterocylylalkyl groups include but are notlimited to 4-ethyl-morpholinyl, 4-propylmorpholinyl, furan-2-yl methyl,furan-3-yl methyl, pyridine-3-yl methyl,(tetrahydro-2H-pyran-4-yl)methyl, (tetrahydro-2H-pyran-4-yl)ethyl,tetrahydrofuran-2-yl methyl, tetrahydrofuran-2-yl ethyl, and indol-2-ylpropyl.

A “halogen” is fluorine, chlorine, bromine or iodine.

A “hydroxyalkyl” group is an alkyl group as described above substitutedwith one or more hydroxy groups.

An “alkoxy” group is —O-(alkyl), wherein alkyl is defined above.

An “alkoxyalkyl” group is -(alkyl)-O-(alkyl), wherein alkyl is definedabove.

An “amino” group is a radical of the formula: —NH₂.

An “alkylamino” group is a radical of the formula: —NH-alkyl or—N(alkyl)₂, wherein each alkyl is independently as defined above.

A “carboxy” group is a radical of the formula: —C(O)OH.

An “aminocarbonyl” group is a radical of the formula: —C(O)N(R^(#))₂,—C(O)NH(R^(#)) or —C(O)NH₂, wherein each R^(#) is independently asubstituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl,heterocyclyl or heterocyclyl group as defined herein.

An “acylamino” group is a radical of the formula: —NHC(O)(R^(#)) or—N(alkyl)C(O)(R^(#)), wherein each alkyl and R^(#) are independently asdefined above.

An “alkylsulfonylamino” group is a radical of the formula: —NHSO₂(R^(#))or —N(alkyl)SO₂(R^(#)), wherein each alkyl and R^(#) are defined above.

A “urea” group is a radical of the formula: —N(alkyl)C(O)N(R^(#))₂,—N(alkyl)C(O)NH(R^(#)), —N(alkyl)C(O)NH₂, —NHC(O)N(R^(#))₂,—NHC(O)NH(R^(#)), or —NH(CO)NHR^(#), wherein each alkyl and R^(#) areindependently as defined above.

When the groups described herein, with the exception of alkyl group aresaid to be “substituted,” they may be substituted with any appropriatesubstituent or substituents. Illustrative examples of substituents arethose found in the exemplary compounds and embodiments disclosed herein,as well as halogen (chloro, iodo, bromo, or fluoro); alkyl; hydroxyl;alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol;thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl;acylamino; phosphonato; phosphine; thiocarbonyl; sulfonyl; sulfone;sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime;hydroxylamine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine;hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate;thiocyanate; oxygen (═O); B(OH)₂, O(alkyl)aminocarbonyl; cycloalkyl,which may be monocyclic or fused or non-fused polycyclic (e.g.,cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocyclyl,which may be monocyclic or fused or non-fused polycyclic (e.g.,pyrrolidyl, piperidyl, piperazinyl, morpholinyl, or thiazinyl);monocyclic or fused or non-fused polycyclic aryl or heteroaryl (e.g.,phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl,oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl,pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl,pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl) aryloxy;aralkyloxy; heterocyclyloxy; and heterocyclyl alkoxy.

As used herein, the term “pharmaceutically acceptable salt(s)” refers toa salt prepared from a pharmaceutically acceptable non-toxic acid orbase including an inorganic acid and base and an organic acid and base.Suitable pharmaceutically acceptable base addition salts of the TORkinase inhibitors include, but are not limited to metallic salts madefrom aluminum, calcium, lithium, magnesium, potassium, sodium and zincor organic salts made from lysine, N,N′-dibenzylethylenediamine,chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine(N-methylglucamine) and procaine. Suitable non-toxic acids include, butare not limited to, inorganic and organic acids such as acetic, alginic,anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric,ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic,glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic,lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic,pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic,succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonicacid. Specific non-toxic acids include hydrochloric, hydrobromic,phosphoric, sulfuric, and methanesulfonic acids. Examples of specificsalts thus include hydrochloride and mesylate salts. Others arewell-known in the art, see for example, Remington's PharmaceuticalSciences, 18^(th) eds., Mack Publishing, Easton Pa. (1990) or Remington:The Science and Practice of Pharmacy, 19^(th) eds., Mack Publishing,Easton Pa. (1995).

As used herein and unless otherwise indicated, the term “clathrate”means a TOR kinase inhibitor, or a salt thereof, in the form of acrystal lattice that contains spaces (e.g., channels) that have a guestmolecule (e.g., a solvent or water) trapped within or a crystal latticewherein a TOR kinase inhibitor is a guest molecule.

As used herein and unless otherwise indicated, the term “solvate” meansa TOR kinase inhibitor, or a salt thereof, that further includes astoichiometric or non-stoichiometric amount of a solvent bound bynon-covalent intermolecular forces. In one embodiment, the solvate is ahydrate.

As used herein and unless otherwise indicated, the term “hydrate” meansa TOR kinase inhibitor, or a salt thereof, that further includes astoichiometric or non-stoichiometric amount of water bound bynon-covalent intermolecular forces.

As used herein and unless otherwise indicated, the term “prodrug” meansa TOR kinase inhibitor derivative that can hydrolyze, oxidize, orotherwise react under biological conditions (in vitro or in vivo) toprovide an active compound, particularly a TOR kinase inhibitor.Examples of prodrugs include, but are not limited to, derivatives andmetabolites of a TOR kinase inhibitor that include biohydrolyzablemoieties such as biohydrolyzable amides, biohydrolyzable esters,biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzableureides, and biohydrolyzable phosphate analogues. In certainembodiments, prodrugs of compounds with carboxyl functional groups arethe lower alkyl esters of the carboxylic acid. The carboxylate estersare conveniently formed by esterifying any of the carboxylic acidmoieties present on the molecule. Prodrugs can typically be preparedusing well-known methods, such as those described by Burger's MedicinalChemistry and Drug Discovery 6^(th) ed. (Donald J. Abraham ed., 2001,Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985,Harwood Academic Publishers Gmfh).

As used herein and unless otherwise indicated, the term “stereoisomer”or “stereomerically pure” means one stereoisomer of a TOR kinaseinhibitor that is substantially free of other stereoisomers of thatcompound. For example, a stereomerically pure compound having one chiralcenter will be substantially free of the opposite enantiomer of thecompound. A stereomerically pure compound having two chiral centers willbe substantially free of other diastereomers of the compound. A typicalstereomerically pure compound comprises greater than about 80% by weightof one stereoisomer of the compound and less than about 20% by weight ofother stereoisomers of the compound, greater than about 90% by weight ofone stereoisomer of the compound and less than about 10% by weight ofthe other stereoisomers of the compound, greater than about 95% byweight of one stereoisomer of the compound and less than about 5% byweight of the other stereoisomers of the compound, or greater than about97% by weight of one stereoisomer of the compound and less than about 3%by weight of the other stereoisomers of the compound. The TOR kinaseinhibitors can have chiral centers and can occur as racemates,individual enantiomers or diastereomers, and mixtures thereof. All suchisomeric forms are included within the embodiments disclosed herein,including mixtures thereof. The use of stereomerically pure forms ofsuch TOR kinase inhibitors, as well as the use of mixtures of thoseforms are encompassed by the embodiments disclosed herein. For example,mixtures comprising equal or unequal amounts of the enantiomers of aparticular TOR kinase inhibitor may be used in methods and compositionsdisclosed herein. These isomers may be asymmetrically synthesized orresolved using standard techniques such as chiral columns or chiralresolving agents. See, e.g., Jacques, J., et al., Enantiomers, Racematesand Resolutions (Wiley-Interscience, New York, 1981); Wilen, S. H., etal., Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of CarbonCompounds (McGraw-Hill, NY, 1962); and Wilen, S. H., Tables of ResolvingAgents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of NotreDame Press, Notre Dame, Ind., 1972).

It should also be noted the TOR kinase inhibitors can include E and Zisomers, or a mixture thereof, and cis and trans isomers or a mixturethereof. In certain embodiments, the TOR kinase inhibitors are isolatedas either the cis or trans isomer. In other embodiments, the TOR kinaseinhibitors are a mixture of the cis and trans isomers.

“Tautomers” refers to isomeric forms of a compound that are inequilibrium with each other. The concentrations of the isomeric formswill depend on the environment the compound is found in and may bedifferent depending upon, for example, whether the compound is a solidor is in an organic or aqueous solution. For example, in aqueoussolution, pyrazoles may exhibit the following isomeric forms, which arereferred to as tautomers of each other:

As readily understood by one skilled in the art, a wide variety offunctional groups and other structures may exhibit tautomerism and alltautomers of the TOR kinase inhibitors are within the scope of thepresent invention.

It should also be noted the TOR kinase inhibitors can contain unnaturalproportions of atomic isotopes at one or more of the atoms. For example,the compounds may be radiolabeled with radioactive isotopes, such as forexample tritium (³H), iodine-125 (¹²⁵I), sulfur-35 (³⁵S), or carbon-14(¹⁴C), or may be isotopically enriched, such as with deuterium (²H),carbon-13 (¹³C), or nitrogen-15 (¹⁵N). As used herein, an “isotopologue”is an isotopically enriched compound. The term “isotopically enriched”refers to an atom having an isotopic composition other than the naturalisotopic composition of that atom. “Isotopically enriched” may alsorefer to a compound containing at least one atom having an isotopiccomposition other than the natural isotopic composition of that atom.The term “isotopic composition” refers to the amount of each isotopepresent for a given atom. Radiolabeled and isotopically enrichedcompounds are useful as therapeutic agents, e.g., cancer andinflammation therapeutic agents, research reagents, e.g., binding assayreagents, and diagnostic agents, e.g., in vivo imaging agents. Allisotopic variations of the TOR kinase inhibitors as described herein,whether radioactive or not, are intended to be encompassed within thescope of the embodiments provided herein. In some embodiments, there areprovided isotopologues of the TOR kinase inhibitors, for example, theisotopologues are deuterium, carbon-13, or nitrogen-15 enriched TORkinase inhibitors.

An “advanced solid tumor” as used herein, means a solid tumor that hasspread locally or metastasized or spread to another part of the body.

“Treating” as used herein, means an alleviation, in whole or in part, ofsymptoms associated with a disorder or disease (e.g., a solid tumor (forexample, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer), non-Hodgkin lymphoma or multiple myeloma), orslowing, or halting of further progression or worsening of thosesymptoms. In another embodiment, the solid tumor is esophageal cancer,renal cancer, leiomyosarcoma, or paraganglioma.

“Preventing” as used herein, means the prevention of the onset,recurrence or spread, in whole or in part, of the disease or disorder(e.g., a solid tumor (for example, a neuroendocrine tumor, non-smallcell lung cancer, glioblastoma multiforme, hepatocellular carcinoma,breast cancer, colorectal cancer, salivary cancer, pancreatic cancer,adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma or multiplemyeloma), or a symptom thereof. In another embodiment, the solid tumoris esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma.

The term “effective amount” in connection with an TOR kinase inhibitormeans an amount capable of alleviating, in whole or in part, symptomsassociated with a solid tumor (for example, a neuroendocrine tumor,non-small cell lung cancer, glioblastoma multiforme, hepatocellularcarcinoma, breast cancer, colorectal cancer, salivary cancer, pancreaticcancer, adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma ormultiple myeloma, or slowing or halting further progression or worseningof those symptoms, or treating or preventing a solid tumor (for example,a neuroendocrine tumor, non-small cell lung cancer, glioblastomamultiforme, hepatocellular carcinoma, breast cancer, colorectal cancer,salivary cancer, pancreatic cancer, adenocystic cancer or adrenalcancer), non-Hodgkin lymphoma or multiple myeloma in a subject having orat risk for having a solid tumor, non-Hodgkin lymphoma or multiplemyeloma. In another embodiment, the solid tumor is esophageal cancer,renal cancer, leiomyosarcoma, or paraganglioma. The effective amount ofthe TOR kinase inhibitor, for example in a pharmaceutical composition,may be at a level that will exercise the desired effect; for example,about 0.005 mg/kg of a subject's body weight to about 100 mg/kg of apatient's body weight in unit dosage for both oral and parenteraladministration. As will be apparent to those skilled in the art, it isto be expected that the effective amount of a TOR kinase inhibitordisclosed herein may vary depending on the severity of the indicationbeing treated.

The terms “patient” and “subject” as used herein include an animal,including, but not limited to, an animal such as a cow, monkey, horse,sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit orguinea pig, in one embodiment a mammal, in another embodiment a human.In one embodiment, a “patient” or “subject” is a human having a solidtumor, non-Hodgkin lymphoma or multiple myeloma. In one embodiment, apatient is a human having histologically or cytologically-confirmed,advanced non-Hodgkin lymphoma, multiple myeloma, or advancedunresectable solid tumors including subjects who have progressed on (ornot been able to tolerate) standard anticancer therapy or for whom nostandard anticancer therapy exists. In one embodiment, a “patient” or“subject” is a breast cancer patient who has previously had a mastectomyor who has previously undergone one or more of the following therapies:chemotherapy (including adjuvant chemotherapy (AC)) (for example,doxorubicin, amrubicin, cyclophosphamide, vinorelbine, methotrexate, or5-fluorouracil), taxane therapy (for example docetaxel or paclitaxel),ER receptor modulator therapy (for example tamoxifen or fulvestrant),gonadotropin-releasing hormone (GnRH) agonist therapy (for exampleLupron®); HER2/neu receptor directed antibody therapy (for example,trastuzumab), vascular endothelial growth factor A inhibitor therapy(for example bevacizumab), aromatase inhibitor therapy (for exampleanastrazole, letrozole, or exemestane), anti-IGFR mAb therapy, PI3Kinhibitor therapy, gemcitabine therapy, Mek inhibitor therapy, cMetinhibitor therapy (for example ARC197), PI3K/mTor inhibitor therapy (forexample XL765), capecitabine therapy, or whole breast external-beamradiation therapy (WB XRT).

In the context of a solid tumor (for example, a neuroendocrine tumor,non-small cell lung cancer, glioblastoma multiforme, hepatocellularcarcinoma, breast cancer, colorectal cancer, salivary cancer, pancreaticcancer, adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma ormultiple myeloma, treatment may be assessed by inhibition or retardingof disease progression, inhibition of tumor growth, reduction orregression of primary and/or secondary tumor(s), relief of tumor-relatedsymptoms, improvement in quality of life, inhibition of tumor-secretedfactors (including tumor-secreted hormones, such as those thatcontribute to carcinoid syndrome), reductions in endocrine hormonemarkers (for example, chromogranin, gastrin, serotonin, and/orglucagon), delayed appearance or recurrence of primary and/or secondarytumor(s), slowed development of primary and/or secondary tumor(s),decreased occurrence of primary and/or secondary tumor(s), slowed ordecreased severity of secondary effects of disease, arrested tumorgrowth and/or regression of tumors, increased Time To Progression (TTP),increased Progression Free Survival (PFS), increased Overall Survival(OS), among others. OS as used herein means the time from randomizationuntil death from any cause, and is measured in the intent-to-treatpopulation. TTP as used herein means the time from randomization untilobjective tumor progression; TTP does not include deaths. As usedherein, PFS means the time from randomization until objective tumorprogression or death. In one embodiment, PFS rates will be computedusing the Kaplan-Meier estimates. In another embodiment, the solid tumoris esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma.

In certain embodiments, the treatment of solid tumors may be assessed byResponse Evaluation Criteria in Solid Tumors (RECIST 1.1) (see ThereasseP., et al. New Guidelines to Evaluate the Response to Treatment in SolidTumors. J. of the National Cancer Institute; 2000; (92) 205-216 andEisenhauer E. A., Therasse P., Bogaerts J., et al. New responseevaluation criteria in solid tumours: Revised RECIST guideline (version1.1). European J. Cancer; 2009; (45) 228-247). Overall responses for allpossible combinations of tumor responses in target and non-targetlesions with our without the appearance of new lesions are as follows:

Target lesions Non-target lesions New lesions Overall response CR CR NoCR CR Incomplete No PR response/SD PR Non-PD No PR SD Non-PD No SD PDAny Yes or no PD Any PD Yes or no PD Any Any Yes PD CR = completeresponse; PR = partial response; SD = stable disease; and PD =progressive disease.

With respect to the evaluation of target lesions, complete response (CR)is the disappearance of all target lesions, partial response (PR) is atleast a 30% decrease in the sum of the longest diameter of targetlesions, taking as reference the baseline sum longest diameter,progressive disease (PD) is at least a 20% increase in the sum of thelongest diameter of target lesions, taking as reference the smallest sumlongest diameter recorded since the treatment started or the appearanceof one or more new lesions and stable disease (SD) is neither sufficientshrinkage to qualify for partial response nor sufficient increase toqualify for progressive disease, taking as reference the smallest sumlongest diameter since the treatment started.

With respect to the evaluation of non-target lesions, complete response(CR) is the disappearance of all non-target lesions and normalization oftumor marker level; incomplete response/stable disease (SD) is thepersistence of one or more non-target lesion(s) and/or the maintenanceof tumor marker level above the normal limits, and progressive disease(PD) is the appearance of one or more new lesions and/or unequivocalprogression of existing non-target lesions.

In certain embodiments, the treatment of lymphoma may be assessed by theInternational Workshop Criteria (IWC) for non-Hodgkin lymphoma (NHL)(see Cheson B D, Pfistner B, Juweid, M E, et. al. Revised ResponseCriteria for Malignant Lymphoma. J. Clin. Oncol: 2007: (25) 579-586),using the response and endpoint definitions shown below:

Response Definition Nodal Masses Spleen, liver Bone Marrow CRDisappearance (a) FDG-avid or PET Not Infiltrate cleared of all positiveprior to therapy; palpable, on repeat biopsy; if evidence mass of anysize permitted nodules indeterminate by of disease if PET negativedisappeared morphology, (b) Variably FDG-avid or immunohistochemistryPET negative; regression should be negative to normal size on CT PRRegression ≧50% decrease in SPD of ≧50% Irrelevant if of up to 6 largestdominant decrease in positive prior to measurable masses; no increase insize SPD of therapy; cell type disease and of other nodes nodules (forshould be specified no new sites (a) FDG-avid or PET single positiveprior to therapy; nodule in one or more PET positive greatest atpreviously involved site transverse (b) Variably FDG-avid or diameter);PET negative; regression no increase on CT in size of liver or spleen SDFailure to (a) FDG-avid or PET attain positive prior to therapy; CR/PRor PET positive at prior sites PD of disease and no new sites on CT orPET (b) Variably FDG-avid or PET negative; no change in size of previouslesions on CT PD or Any new Appearance of a new ≧50% New or recurrentrelapsed lesion or lesion(s) ≧1.5 cm in any increase involvement diseaseincrease by axis, ≧50% increase in from nadir in ≧50% of SPD of morethan one the SPD of previously node, any previous involved or ≧50%increase in lesions sites from longest diameter of a nadir previouslyidentifed node ≧1 cm in short axis Lesions PET positive if FDG-avidlymphoma or PET positive prior to therapy Abbreviations: CR, completeremission; FDG, [¹⁸F]fluorodeoxyglucose; PET, positron emissiontomography; CT, computed tomography; PR, partial remission; SPD, sum ofthe product of the diameters; SD, stable disease; PD, progressivedisease.

Measured End point Patients Definition from Primary Overall survival AllDeath as a result of any cause Entry onto study Progression-free AllDisease progression or death as a result of Entry onto survival anycause study Secondary Event-free All Failure of treatment or death asresult of Entry onto survival any cause study Time to All Time toprogression or death as a result of Entry onto progression lymphomastudy Disease-free In CR Time to relapse or death as a result ofDocumentation survival lymphoma or acute toxicity of treatment ofresponse Response duration In CR Time to relapse or progressionDocumentation or PR of response Lymphoma- All Time to death as a resultof lymphoma Entry onto specific survival study Time to next All Time tonew treatment End of primary treatment treatment Abbreviations: CR:complete remission; PR: partial remission

In one embodiment, the end point for lymphoma is evidence of clinicalbenefit. Clinical benefit may reflect improvement in quality of life, orreduction in patient symptoms, transfusion requirements, frequentinfections, or other parameters. Time to reappearance or progression oflymphoma-related symptoms can also be used in this end point.

In certain embodiments, the treatment of multiple myeloma may beassessed by the International Uniform Response Criteria for MultipleMyeloma (IURC) (see Durie B G M, Harousseau J- L, Miguel J S, et al.International uniform response criteria for multiple myeloma. Leukemia,2006; (10) 10:1-7), using the response and endpoint definitions shownbelow:

Response Subcategory Response Criteria^(a) sCR CR as defined below plusNormal FLC ratio and Absence of clonal cells in bone marrow^(b) byimmunohistochemistry or immunofluorescence^(c) CR Negativeimmunofixation on the serum and urine and Disappearance of any softtissue plasmacytomas and <5% plasma cells in bone marrow^(b) VGPR Serumand urine M-protein detectable by immunofixation but not onelectrophoresis or 90% or greater reduction in serum M-protein plusurine M-protein level <100 mg per 24 h PR ≧50% reduction of serumM-protein and reduction in 24-h urinary M-protein by≧90% or to <200 mgper 24 h If the serum and urine M-protein are unmeasurable, ^(d) a ≧50%decrease in the difference between involved and uninvolved FLC levels isrequired in place of the M- protein criteria If serum and urineM-protein are unmeasurable, and serum free light assay is alsounmeasurable, ≧50% reduction in plasma cells is required in place ofM-protein, provided baseline bone marrow plasma cell percentage was ≧30%In addition to the above listed criteria, if present at baseline, a ≧50%reduction in the size of soft tissue plasmacytomas is also required SD(not recom- Not meeting criteria for CR, VGPR, PR or progressive mendedfor use disease as an indicator of response; stability of disease isbest described by providing the time to progression estimates)Abbreviations: CR, complete response; FLC, free light chain; PR, partialresponse; SD, stable disease; sCR, stringent complete response; VGPR,very good partial response; ^(a)All response categories require twoconsecutive assessments made at anytime before the institution of anynew therapy; all categories also require no known evidence ofprogressive or new bone lesions if radiographic studies were performed.Radiographic studies are not required to satisfy these responserequirements; ^(b)Confirmation with repeat bone marrow biopsy notneeded; ^(c)Presence/absence of clonal cells is based upon the κ/λratio. An abnormal κ/λ ratio by immunohistochemistry and/orimmunofluorescence requires a minimum of 100 plasma cells for analysis.An abnormal ratio reflecting presence of an abnormal clone is κ/λof >4:1 or <1:2. ^(d)Measurable disease defined by at least one of thefollowing measurements: Bone marrow plasma cells ≧30%; Serum M-protein≧1 g/dl (≧10 gm/l)[10 g/l]; Urine M-protein ≧200 mg/24 h; Serum FLCassay: Involved FLC level ≧10 mg/dl (≧100 mg/l); provided serum FLCratio is abnormal.

The procedures, conventions, and definitions described below provideguidance for implementing the recommendations from the ResponseAssessment for Neuro-Oncology (RANO) Working Group regarding responsecriteria for high-grade gliomas (Wen P., Macdonald, D R., Reardon, D A.,et al. Updated response assessment criteria for highgrade gliomas:Response assessment in neuro-oncology working group. J Clin Oncol 2010;28: 1963-1972). Primary modifications to the RANO criteria for Criteriafor Time Point Responses (TPR) can include the addition of operationalconventions for defining changes in glucocorticoid dose, and the removalof subjects' clinical deterioration component to focus on objectiveradiologic assessments. The baseline MRI scan is defined as theassessment performed at the end of the post-surgery rest period, priorto re-initiating compound treatment. The baseline MRI is used as thereference for assessing complete response (CR) and partial response(PR). Whereas, the smallest SPD (sum of the products of perpendiculardiameters) obtained either at baseline or at subsequent assessments willbe designated the nadir assessment and utilized as the reference fordetermining progression. For the 5 days preceding any protocol-definedMRI scan, subjects receive either no glucocorticoids or are on a stabledose of glucocorticoids. A stable dose is defined as the same daily dosefor the 5 consecutive days preceding the MRI scan. If the prescribedglucocorticoid dose is changed in the 5 days before the baseline scan, anew baseline scan is required with glucocorticoid use meeting thecriteria described above. The following definitions will be used.

Measurable Lesions: Measurable lesions are contrast-enhancing lesionsthat can be measured bidimensionally. A measurement is made of themaximal enhancing tumor diameter (also known as the longest diameter,LD). The greatest perpendicular diameter is measured on the same image.The cross hairs of bidimensional measurements should cross and theproduct of these diameters will be calculated.

Minimal Diameter: T1-weighted image in which the sections are 5 mm with1 mm skip. The minimal LD of a measurable lesion is set as 5 mm by 5 mm.Larger diameters may be required for inclusion and/or designation astarget lesions. After baseline, target lesions that become smaller thanthe minimum requirement for measurement or become no longer amenable tobidimensional measurement will be recorded at the default value of 5 mmfor each diameter below 5 mm. Lesions that disappear will be recorded as0 mm by 0 mm.

Multicentric Lesions: Lesions that are considered multicentric (asopposed to continuous) are lesions where there is normal interveningbrain tissue between the two (or more) lesions. For multicentric lesionsthat are discrete foci of enhancement, the approach is to separatelymeasure each enhancing lesion that meets the inclusion criteria. Ifthere is no normal brain tissue between two (or more) lesions, they willbe considered the same lesion.

Nonmeasurable Lesions: All lesions that do not meet the criteria formeasurable disease as defined above will be considered non-measurablelesions, as well as all nonenhancing and other truly nonmeasurablelesions. Nonmeasurable lesions include foci of enhancement that are lessthan the specified smallest diameter (ie., less than 5 mm by 5 mm),nonenhancing lesions (eg., as seen on T1-weighted post-contrast,T2-weighted, or fluid-attenuated inversion recovery [FLAIR] images),hemorrhagic or predominantly cystic or necrotic lesions, andleptomeningeal tumor. Hemorrhagic lesions often have intrinsicT1-weighted hyperintensity that could be misinterpreted as enhancingtumor, and for this reason, the pre-contrast T1-weighted image may beexamined to exclude baseline or interval sub-acute hemorrhage.

At baseline, lesions will be classified as follows: Target lesions: Upto 5 measurable lesions can be selected as target lesions with eachmeasuring at least 10 mm by 5 mm, representative of the subject'sdisease; Non-target lesions: All other lesions, including allnonmeasurable lesions (including mass effects and T2/FLAIR findings) andany measurable lesion not selected as a target lesion. At baseline,target lesions are to be measured as described in the definition formeasurable lesions and the SPD of all target lesions is to bedetermined. The presence of all other lesions is to be documented. Atall post-treatment evaluations, the baseline classification of lesionsas target and non-target lesions will be maintained and lesions will bedocumented and described in a consistent fashion over time (eg.,recorded in the same order on source documents and eCRFs). Allmeasurable and nonmeasurable lesions must be assessed using the sametechnique as at baseline (e.g., subjects should be imaged on the sameMRI scanner or at least with the same magnet strength) for the durationof the study to reduce difficulties in interpreting changes. At eachevaluation, target lesions will be measured and the SPD calculated.Non-target lesions will be assessed qualitatively and new lesions, ifany, will be documented separately. At each evaluation, a time pointresponse will be determined for target lesions, non-target lesions, andnew lesion. Tumor progression can be established even if only a subsetof lesions is assessed. However, unless progression is observed,objective status (stable disease, PR or CR) can only be determined whenall lesions are assessed.

Confirmation assessments for overall time point responses of CR and PRwill be performed at the next scheduled assessment, but confirmation maynot occur if scans have an interval of <28 days. Best response,incorporating confirmation requirements, will be derived from the seriesof time points.

In certain embodiments, treatment of a solid tumor (for example, aneuroendocrine tumor, non-small cell lung cancer, glioblastomamultiforme, hepatocellular carcinoma or breast cancer) may be assessedby the inhibition of phosphorylation of S6RP, 4E-BP1 and/or AKT incirculating blood and/or tumor cells and/or skin biopsies or tumorbiopsies/aspirates, before, during and/or after treatment with a TORkinase inhibitor. For example, the inhibition of phosphorylation ofS6RP, 4E-BP1 and/or AKT is assessed in B-cells, T-cells and/ormonocytes. In other embodiments, treatment of a solid tumor (forexample, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer) may be assessed by the inhibition ofDNA-dependent protein kinase (DNA-PK) activity in skin samples and/ortumor biopsies/aspirates, such as by assessment of the amount of pDNA-PK52056 as a biomarker for DNA damage pathways, before, during, and/orafter TOR kinase inhibitor treatment. In another embodiment, the solidtumor is esophageal cancer, renal cancer, leiomyosarcoma, orparaganglioma. In one embodiment, the skin sample is irradiated by UVlight. In the extreme, complete inhibition, is referred to herein asprevention or chemoprevention. In this context, the term “prevention”includes either preventing the onset of clinically evident a solid tumoraltogether or preventing the onset of a preclinically evident stage of asolid tumor. Also intended to be encompassed by this definition is theprevention of transformation into malignant cells or to arrest orreverse the progression of premalignant cells to malignant cells. Thisincludes prophylactic treatment of those at risk of developing a solidtumor (for example, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer). In another embodiment, the solid tumor isesophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma

4.2 Brief Description of the Drawings

FIG. 1 provides GI₅₀ values of Compound 1 (FIG. 1A) and Compound 2 (FIG.1B) against certain NHL cell lines.

FIG. 2 depicts the effects of Compound 1 and Compound 2 on apoptosis ofcertain NHL cell lines.

FIG. 3 depicts the effects of Compound 2 on the proliferation (A) andviability (B) of certain multiple myeloma cell lines.

FIG. 4 depicts the effects of Compound 1 on the proliferation (A) andviability (B) of certain multiple myeloma cell lines.

FIG. 5 depicts the effects of Compound 2 on the proliferation (A) andviability (B) of certain multiple myeloma cell lines.

FIG. 6 depicts the effects of Compound 1 on the proliferation (A) andviability (B) of certain multiple myeloma cell lines.

FIG. 7A depicts the potency of Compound 1 in different subtypes(ER+/Her2−, ER+/Her2+, ER−/Her2+ and triple negative (TN)) of breastcancer cells lines. FIG. 7B depicts the correlation of Compound 1sensitivity to ER, HER, PIK3CA, and TP53 status in breast cancer celllines.

FIG. 8 depicts the effects of Compound 1 on proliferation of cell lineswith varying sensitivity to rapamycin.

FIG. 9 depicts anti-tumor activity of Compound 1 in a NCI-H441 non-smallcell lung cancer model.

FIGS. 10A and 10B depict anti-tumor activity of Compound 1 in a U87MGhuman glioblastoma xenograft model, using different dosing paradigms.FIG. 10C depicts the quantitation of apoptotic cells in U87MG tumors byTUNEL staining FIGS. 10D and 10E depict the quantitation of Ki67 andCD31, respectively, in U87MG tumors.

FIG. 11 depicts the body weight change of mice in the U87MG humanglioblastoma xenograft model.

FIG. 12 depicts anti-tumor activity of Compound 2 in a U87MG humanglioblastoma xenograft model with once daily dosing paradigms.

FIG. 13 depicts anti-tumor activity of Compound 2 in a U87MG humanglioblastoma xenograft model with twice daily dosing.

FIG. 14 depicts the Kaplan-Meier survival plot for Compound 1 in a U87MGintracranial glioblastoma model.

FIG. 15 depicts anti-tumor activity of Compound 1 in a G144 cancer stemcell derived intracranial glioblastoma model.

FIG. 16 depicts the Kaplan-Meier survival plot for Compound 2 in a U87MGintracranial glioblastoma model.

FIG. 17 depicts the efficacy of Compound 1 in the Hep3B2.1-7 orthotopicliver model.

FIG. 18 depicts the effect of Compound 1 on tumor size in the Hep3B2.1-7orthotopic liver model.

FIG. 19 depicts the efficacy of Compound 1 in the NCI-H929 human plasmacell myeloma xenograft model in SCID mice.

FIG. 20 depicts the anti-tumor activity of Compound 1 in the HCT-116human colorectal cancer xenograft model in SCID mice.

FIG. 21 depicts the baseline characteristics of the Part A subjects.

FIG. 22 depicts the Part A Accelerated (1+5) Dose Escalation design andDLT definition.

FIG. 23 depicts the most frequent Compound 1 related adverse events(overall frequency>20%) and all related grade 3/4 events (N=28).

FIG. 24 depicts the hyperglycemia associated elevations of insulin andC-peptide.

FIG. 25 depicts the mean (±SD) Steady-State plasma concentrations forCompound 1 on day 15 in human subjects.

FIG. 26 depicts the dose-related TOR pathway inhibition in blood ofhuman subjects.

FIG. 27 depicts the radiological response for a patient having ER+/Her2−breast cancer. This subject demonstrated a 30% reduction in targetlesions at the first restaging after 2 cycles of therapy.

FIG. 28 depicts the best Target Lesion Responses (n=19; 9 subjectswithout restaging (7 early withdrawal/PD; 1 ineligible; 1 myeloma)).

FIG. 29 depicts dose Level, Treatment Duration and Best Overall Response(n=27*).

4.3 TOR Kinase Inhibitors

The compounds provided herein are generally referred to as “TOR kinaseinhibitor(s).” In a specific embodiment, the TOR kinase inhibitors donot include rapamycin or rapamycin analogs (rapalogs).

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (I):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

X, Y and Z are at each occurrence independently N or CR³, wherein atleast one of X, Y and Z is N and at least one of X, Y and Z is CR³;

-A-B-Q- taken together form —CHR⁴C(O)NH—, —C(O)CHR⁴NH—, —C(O)NH—,—CH₂C(O)O—, —C(O)CH₂O—, —C(O)O— or C(O)NR³;

L is a direct bond, NH or O;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl;

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl;

R³ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, substituted or unsubstitutedheterocyclylalkyl, —NHR⁴ or —N(R⁴)₂; and

R⁴ is at each occurrence independently substituted or unsubstitutedC₁₋₈alkyl, substituted or unsubstituted aryl, substituted orunsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, orsubstituted or unsubstituted heterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (I) are thosewherein -A-B-Q- taken together form —CH₂C(O)NH—.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)CH₂NH—.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)NH—.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —CH₂C(O)O—.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)CH₂O—.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)O—.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)NR³—.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein Y is CR³.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein X and Z are N and Y is CR³.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein X and Z are N and Y is CH.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein X and Z are CH and Y is N.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein Y and Z are CH and X is N.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein X and Y are CH and Z is N.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)NH—, X and Z are N and Yis CH, R¹ is substituted or unsubstituted aryl or substituted orunsubstituted heteroaryl, L is a direct bond, and R² is substituted orunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)NH—, X and Z are N and Yis CH, R¹ is substituted or unsubstituted aryl, L is a direct bond, andR² is substituted or unsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)NH—, X and Z are N and Yis CH, R¹ is substituted or unsubstituted aryl, and R² is C₁₋₈alkylsubstituted with one or more substituents selected from alkoxy, amino,hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)NH—, X and Z are N and Yis CH, R¹ is substituted or unsubstituted aryl, and R² is substituted orunsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) arethose wherein -A-B-Q- taken together form —C(O)NH—, X and Z are N and Yis CH, R¹ is substituted phenyl, L is a direct bond, and R² issubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X and Z are both N and Y is CH, -A-B-Q- is—C(O)NH—, L is a direct bond, R¹ is substituted or unsubstituted aryl orsubstituted or unsubstituted heteroaryl, and R² is C₁₋₈alkyl substitutedwith substituted or unsubstituted aryl or substituted or unsubstitutedheteroaryl.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X and Z are both N and Y is CH, -A-B-Q- is—C(O)NH—, L is a direct bond, R¹ is phenyl, naphthyl, indanyl orbiphenyl, each of which may be optionally substituted with one or moresubstituents independently selected from the group consistingsubstituted or unsubstituted C₁₋₈alkyl, substituted or unsubstitutedC₂₋₈alkenyl, substituted or unsubstituted aryl, substituted orunsubstituted cycloalkyl or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X and Z are both N and Y is CH, -A-B-Q- is—C(O)NH—, L is a direct bond, R¹ is phenyl, naphthyl or biphenyl, eachof which may be optionally substituted with one or more substituentseach independently selected from the group consisting of C₁₋₄alkyl,amino, aminoC₁₋₁₂alkyl, halogen, hydroxy, hydroxyC₁₋₄alkyl,C₁₋₄alkyloxyC₁₋₄alkyl, —CF₃, C₁₋₁₂alkoxy, aryloxy, arylC₁₋₁₂alkoxy, —CN,—OCF₃, —COR_(g), —COOR_(g), —CONR_(g)R_(h), —NR_(g)COR_(h), —SO₂R_(g),—SO₃R_(g) or —SO₂NR_(g)R_(h), wherein each R_(g) and R_(h) areindependently selected from the group consisting of hydrogen, C₁₋₄alkyl,C₃₋₆cycloalkyl, aryl, arylC₁₋₆alkyl, heteroaryl or heteroarylC₁₋₆alkyl;or A is a 5- to 6-membered monocyclic heteroaromatic ring having fromone, two, three or four heteroatoms independently selected from thegroup consisting of N, O and S, that monocyclic heteroaromatic ring maybe optionally substituted with one or more substituents eachindependently selected from the group consisting of C₁₋₆alkyl, amino,aminoC₁₋₁₂alkyl, halogen, hydroxy, hydroxyC₁₋₄alkyl,C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₁₂alkoxy, aryloxy, aryl C₁₋₁₂alkoxy, —CN,—CF₃, —OCF₃, —COR_(i), —COOR_(i), —CONR_(i)R_(j), —NR_(i)COR_(j),—NR_(i)SO₂R_(j), —SO₂R_(i), —SO₃R_(i) or —SO₂NR_(i)R_(j), wherein eachR_(i) and R_(i) are independently selected from the group consisting ofhydrogen, C₁₋₄ alkyl, C₃₋₆cycloalkyl, aryl, arylC₁₋₆alkyl, heteroaryl orheteroarylC₁₋₆alkyl; or A is a 8- to 10 membered bicyclic heteroaromaticring from one, two, three or four heteroatoms selected from the groupconsisting of N, O and S, and may be optionally substituted with one,two or three substituents each independently selected from the groupconsisting of C₁₋₆alkyl, amino, aminoC₁₋₁₂alkyl, halogen, hydroxy,hydroxyC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, aryloxy, aryl C₁₋₁₂alkoxy, —CN,—CF₃, —COR_(k), —COOR_(k), —CONR_(k)R_(l), —NR_(k)COR_(l),—NR_(k)SO₂R_(l), —SO₂R_(k), —SO₃R_(k) or —SO₂NR_(k)R_(l), wherein eachR_(k) and R_(l) are independently selected from the group consisting ofhydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, aryl, arylC₁₋₆alkyl, heteroarylor heteroarylC₁₋₆alkyl, and R² is C₁₋₈alkyl substituted with substitutedor unsubstituted aryl or substituted or unsubstituted heteroaryl.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X and Y are both N and Z is CH, -A-B-Q- is—C(O)NH—, L is a direct bond, R¹ is substituted or unsubstituted phenylor substituted or unsubstituted heteroaryl, and R² is substituted orunsubstituted methyl, unsubstituted ethyl, unsubstituted propyl, or anacetamide.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X and Y are both N and Z is CH, -A-B-Q- is—C(O)NH—, L is a direct bond, R¹ is substituted or unsubstituted phenylor substituted or unsubstituted heteroaryl, and R² is an acetamide.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X is N and Y and Z are both CH, -A-B-Q- is—C(O)NH—, L is a direct bond, R¹ is a(2,5′-Bi-1H-benzimidazole)-5-carboxamide, and R² is H.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein one of X and Z is CH and the other is N, Y isCH, -A-B-Q- is —C(O)NH—, L is a direct bond, R¹ is unsubstitutedpyridine, and R² is H, methyl or substituted ethyl.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X and Z are both N and Y is CH, -A-B-Q- is—C(O)NH—, R¹ is H, C₁₋₈alkyl, C₂₋₈alkenyl, aryl or cycloalkyl, and L isNH.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein X and Z are both N and Y is CH, -A-B-Q- is—C(O)NR³—, R² is H, substituted or unsubstituted C₁₋₈alkyl, substitutedor unsubstituted phenyl, substituted or unsubstituted cycloalkyl, orsubstituted or unsubstituted heterocyclylalkyl, and L is NH.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude compounds wherein R¹ is a substituted or unsubstitutedoxazolidinone.

In another embodiment, the TOR kinase inhibitors of formula (I) do notinclude one or more of the following compounds:1,7-dihydro-2-phenyl-8H-Purin-8-one,1,2-dihydro-3-phenyl-6H-Imidazo[4,5-e]-1,2,4-triazin-6-one,1,3-dihydro-6-(4-pyridinyl)-2H-Imidazo[4,5-b]pyridin-2-one,6-(1,3-benzodioxol-5-yl)-1,3-dihydro-1-[(1S)-1-phenylethyl]-2H-Imidazo[4,5-b]pyrazin-2-one,3-[2,3-dihydro-2-oxo-3-(4-pyridinylmethyl)-1H-imidazo[4,5-b]pyrazin-5-yl]-Benzamide,1-[2-(dimethylamino)ethyl]-1,3-dihydro-6-(3,4,5-trimethoxyphenyl)-2H-Imidazo[4,5-b]pyrazin-2-one,N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N′-[4-(1,2,3,4-tetrahydro-2-oxopyrido[2,3-b]pyrazin-7-yl)-1-naphthalenyl]-Urea,N-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-6-yl)-1-naphthalenyl]-N′-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-Urea,1,3-dihydro-5-phenyl-2H-Imidazo[4,5-b]pyrazin-2-one,1,3-dihydro-5-phenoxy-2H-Imidazo[4,5-b]pyridin-2-one,1,3-dihydro-1-methyl-6-phenyl-2H-Imidazo[4,5-b]pyridin-2-one,1,3-dihydro-5-(1H-imidazol-1-yl) 2H-Imidazo[4,5-b]pyridin-2-one,6-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-6-yl)-8-methyl-2(1H)-Quinolinoneand 7,8-dihydro-8-oxo-2-phenyl-9H-purine-9-acetic acid.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (Ia):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

L is a direct bond, NH or O;

Y is N or CR³;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl;

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl;

R³ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, substituted or unsubstitutedheterocyclylalkyl, —NHR⁴ or —N(R⁴)₂; and

R⁴ is at each occurrence independently substituted or unsubstitutedC₁₋₈alkyl, substituted or unsubstituted aryl, substituted orunsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, orsubstituted or unsubstituted heterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (Ia) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein Y is CH.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R¹ is substituted or unsubstituted aryl and R² isunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R¹ is substituted or unsubstituted aryl and R² isC₁₋₈alkyl substituted with one or more substituents selected fromalkoxy, amino, hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) arethose wherein R¹ is substituted or unsubstituted aryl and R² issubstituted or unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ia) do notinclude compounds wherein Y is CH, L is a direct bond, R¹ is substitutedor unsubstituted aryl or substituted or unsubstituted heteroaryl, and R²is C₁₋₈alkyl substituted with substituted or unsubstituted aryl orsubstituted or unsubstituted heteroaryl.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (Ib):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

L is a direct bond, NH or O;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl; and

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (Ib) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R¹ is substituted or unsubstituted aryl and R² isunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R¹ is substituted or unsubstituted aryl and R² isC₁₋₈alkyl substituted with one or more substituents selected fromalkoxy, amino, hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ib) arethose wherein R¹ is substituted or unsubstituted aryl and R² issubstituted or unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (Ic):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

L is a direct bond, NH or O;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl; and

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (Ic) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R¹ is substituted or unsubstituted aryl and R² isunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R¹ is substituted or unsubstituted aryl and R² isC₁₋₈alkyl substituted with one or more substituents selected fromalkoxy, amino, hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ic) arethose wherein R¹ is substituted or unsubstituted aryl and R² issubstituted or unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (Id):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

L is a direct bond, NH or O;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl; and

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (Id) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the Heteroaryl Compounds of formula (Id) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R¹ is substituted or unsubstituted aryl and R² isunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R¹ is substituted or unsubstituted aryl and R² isC₁₋₈alkyl substituted with one or more substituents selected fromalkoxy, amino, hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Id) arethose wherein R¹ is substituted or unsubstituted aryl and R² issubstituted or unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (Ie):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

L is a direct bond, NH or O;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl; and

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (Ie) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R¹ is substituted or unsubstituted aryl and R² isunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R¹ is substituted or unsubstituted aryl and R² isC₁₋₈alkyl substituted with one or more substituents selected fromalkoxy, amino, hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ie) arethose wherein R¹ is substituted or unsubstituted aryl and R² issubstituted or unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors include compounds having

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

L is a direct bond, NH or O;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl; and

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (If) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R¹ is substituted or unsubstituted aryl and R² isunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R¹ is substituted or unsubstituted aryl and R² isC₁₋₈alkyl substituted with one or more substituents selected fromalkoxy, amino, hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (If) arethose wherein R¹ is substituted or unsubstituted aryl and R² issubstituted or unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (Ig):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

L is a direct bond, NH or O;

R¹ is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted C₂₋₈alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl or substituted or unsubstituted heterocyclylalkyl; and

R² is H, substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In one embodiment, the TOR kinase inhibitors of formula (Ig) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R¹ is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl or substituted or unsubstitutednaphthyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted quinoline, substituted or unsubstitutedpyridine, substituted or unsubstituted pyrimidine, substituted orunsubstituted indole, or substituted or unsubstituted thiophene.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R¹ is H.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R² is substituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R² is methyl or ethyl substituted with substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R² is substituted or unsubstituted cycloalkyl orsubstituted or unsubstituted heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R² is H.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R¹ is substituted or unsubstituted aryl and R² isunsubstituted C₁₋₈alkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R¹ is substituted or unsubstituted aryl and R² isC₁₋₈alkyl substituted with one or more substituents selected fromalkoxy, amino, hydroxy, cycloalkyl, or heterocyclylalkyl.

In another embodiment, the TOR kinase inhibitors of formula (Ig) arethose wherein R¹ is substituted or unsubstituted aryl and R² issubstituted or unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl.

Representative TOR kinase inhibitors of formula (I) include compoundsfrom Table A.

Table A

-   (S)-1-(1-hydroxy-3-methylbutan-2-yl)-6-phenyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-((tetrahydro-2H-pyran-4-yl)methyl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-6-(naphthalen-1-yl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(3-methoxybenzyl)-6-(4-(methylsulfonyl)phenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-1-(1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-hydroxyphenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-6-(naphthalen-1-yl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-1-(1-hydroxy-3-methylbutan-2-yl)-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-hydroxy-3-methylbutan-2-yl)-6-phenyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-1-(1-hydroxy-3-methylbutan-2-yl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-hydroxy-3-methylbutan-2-yl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-hydroxy-3-methylbutan-2-yl)-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-benzyl-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(4-methoxybenzyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-isopropyl-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-cyclohexyl-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   5-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-isobutyl-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(2-hydroxyethyl)-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(5-isopropyl-2-methoxyphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one;-   (S)-1-(1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one;-   3-(1-phenylethyl)-5-(quinolin-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;-   (R)-3-(1-phenylethyl)-5-(quinolin-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;-   (R)-6-(5-isopropyl-2-methoxyphenyl)-1-(3-methylbutan-2-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-6-(5-isopropyl-2-methoxyphenyl)-1-(tetrahydrofuran-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-6-(5-isopropyl-2-methoxyphenyl)-1-(3-methylbutan-2-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-cyclopentyl-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-6-(5-isopropyl-2-methoxyphenyl)-1-(tetrahydrofuran-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(cyclopropylmethyl)-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(cyclopentylmethyl)-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(cyclohexylmethyl)-6-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(5-isopropyl-2-methoxyphenyl)-1-neopentyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-isopropyl-6-(3-isopropylphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-isopropyl-6-(2-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-3-(1-hydroxy-3-methylbutan-2-yl)-5-(5-isopropyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;-   (R)-1-(2-hydroxy-1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-1-(2-hydroxy-1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-benzhydryl-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-1-(1-phenylpropyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-phenylpropyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(5-isopropyl-2-methoxyphenyl)-1-(tetrahydro-2H-pyran-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(3-methoxybenzyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-methyl-3-(1-phenylethyl)-5-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-1-methyl-3-(1-phenylethyl)-5-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(cyclopentylmethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(2-fluorophenyl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(4-fluorophenyl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-cyclopentyl-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(3-fluorophenyl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(3-methoxyphenyl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(4-methoxyphenyl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(quinolin-5-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(quinolin-5-yl)-1-(tetrahydro-2H-pyran-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-((1s,4s)-4-hydroxycyclohexyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-((1r,4r)-4-hydroxycyclohexyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(isoquinolin-5-yl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-1-(1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;-   1-(1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;-   1-isopropyl-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(4-chlorophenyl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(4-(methylsulfonyl)phenyl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(pyridin-4-yl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   5-methyl-1-((S)-1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   5-methyl-1-((R)-1-phenylethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-phenylethyl)-6-(quinolin-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-fluorophenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(2-fluorophenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-phenylethyl)-6-(quinolin-6-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(piperidin-4-ylmethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(pyridin-2-yl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-(pyridin-3-yl)ethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-((1s,4s)-4-(hydroxymethyl)cyclohexyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   N-(4-(2-oxo-3-(1-phenylethyl)-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)phenyl)methanesulfonamide;-   6-(3-(methylsulfonyl)phenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-aminophenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-(dimethylamino)phenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-phenyl-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(1-phenylethyl)-6-(4-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   N-(3-(2-oxo-3-(1-phenylethyl)-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)phenyl)methanesulfonamide;-   6-(4-(methylsulfonyl)phenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   3-(1-phenylethyl)-5-(quinolin-5-yl)oxazolo[5,4-b]pyrazin-2(3H)-one;-   1-(cyclopentylmethyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one-   6-(4-hydroxyphenyl)-1-isopropyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-hydroxyphenyl)-1-isobutyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-hydroxyphenyl)-1-((tetrahydro-2H-pyran-3-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(cyclohexylmethyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   5-(3-Hydroxyphenyl)-3-(2-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;-   4-(3-(3-Methoxybenzyl)-2-oxo-2,3-dihydrooxazolo[5,4-b]pyrazin-5-yl)-N-methyl    benzamide;-   1-Cyclopentyl-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-Cyclohexyl-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzamide;-   Methyl    4-(3-(cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzoate;-   1-(Cyclohexylmethyl)-6-(pyridin-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)-N-methylbenzamide;-   1-(Cyclohexylmethyl)-6-(4-(hydroxymethyl)phenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(pyridin-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzonitrile;-   1-(Cyclohexylmethyl)-6-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)-N-isopropylbenzamide;-   1-(2-Hydroxyethyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(1H-indol-6-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   3-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzamide;-   6-(4-(Aminomethyl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-((1-methylpiperidin-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzonitrile;-   1-((1s,4s)-4-Hydroxycyclohexyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)-N-ethylbenzamide;-   1-(Cyclohexylmethyl)-6-(4-(2-hydroxypropan-2-yl)phenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(4-hydroxy-2-methylphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzoic    acid;-   6-(4-Hydroxyphenyl)-1-(2-methoxyethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-(3-methoxypropyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-4-(3-methoxybenzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-Hydroxyphenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-phenethyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-((1r,4r)-4-Hydroxycyclohexyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-phenyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(1H-pyrazol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(1-oxoisoindolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-(1H-Tetrazol-5-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(2-oxoindolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(1H-indazol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(6-methoxypyridin-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-(piperidin-4-ylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(((1r,4r)-4-Aminocyclohexyl)methyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(6-hydroxypyridin-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(2-methoxypyridin-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-((1r,4r)-4-Hydroxycyclohexyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzamide;-   2-(4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)phenyl)acetic    acid;-   2-(4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)phenyl)acetamide;-   1-(Cyclohexylmethyl)-6-(2-oxoindolin-6-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(3-(Cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)-3-methyl    benzoic acid;-   N-Methyl-4-(2-oxo-3-((tetrahydro-2H-pyran-4-yl)methyl)-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzamide;-   4-(2-oxo-3-((Tetrahydro-2H-pyran-4-yl)methyl)-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzamide;-   7-(4-Hydroxyphenyl)-1-(3-methoxybenzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(2-Hydroxypropan-2-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1H-Indol-5-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-Triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1H-Benzo[d]imidazol-5-yl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(2-oxo-3-(2-(Tetrahydro-2H-pyran-4-yl)ethyl)-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)benzamide;-   6-(3-(2H-1,2,3-Triazol-4-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Imidazol-1-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-((1r,4r)-4-hydroxycyclohexyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(2H-tetrazol-5-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(2-hydroxypyridin-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Imidazol-2-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-1,2,3-Triazol-1-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(2-Hydroxypropan-2-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(4-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Pyrazol-3-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Pyrazol-4-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-(Aminomethyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   1-(Cyclohexylmethyl)-6-(4-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)phenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-((1r,4r)-4-methoxycyclohexyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-(1H-1,2,4-Triazol-3-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-((1r,4r)-4-(Hydroxymethyl)cyclohexyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-((1s,4s)-4-methoxycyclohexyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-((1r,4r)-4-(methoxymethyl)cyclohexyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1-Methyl-1H-pyrazol-4-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(((1r,4r)-4-Hydroxycyclohexyl)methyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(((1s,4s)-4-Hydroxycyclohexyl)methyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1H-Benzo[d]imidazol-5-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   6-(4-(5-(Morpholinomethyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-(3-(2-oxopyrrolidin-1-yl)propyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-(2-morpholinoethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   1-(Cyclohexylmethyl)-6-(4-(oxazol-5-yl)phenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(2-Methyl-1H-benzo[d]imidazol-5-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrocholoride;-   6-(4-(5-(Methoxymethyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-((1s,4s)-4-(Hydroxymethyl)cyclohexyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-Methyl-1H-pyrazol-4-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1H-Pyrazol-4-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(2-Amino-1H-benzo[d]imidazol-5-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    dihydrochloride;-   6-(4-(5-(2-Hydroxypropan-2-yl)-1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-Isopropyl-1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   4-(2-Methoxy-1-(2-morpholinoethyl)-1H-imidazo[4,5-b]pyrazin-6-yl)benzamide    hydrochloride;-   4-(1-((1s,4s)-4-Hydroxycyclohexyl)-2-methoxy-1H-imidazo[4,5-b]pyrazin-6-yl)benzamide;-   6-(4-Hydroxyphenyl)-1-((1s,4s)-4-(methoxymethyl)cyclohexyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3H-imidazo[4,5-b]pyridin-6-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(2-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)ethyl)-6-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Pyrazol-1-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-Triazol-3-yl)phenyl)-1-(2-morpholinoethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Benzo[d]imidazol-2-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Imidazol-2-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   6-(4-(5-(Hydroxymethyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-Imidazol-5-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   6-(4-Hydroxyphenyl)-1-((5-oxopyrrolidin-2-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4,5-Dimethyl-1H-imidazol-2-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-1,2,4-Triazol-5-yl)phenyl)-1-(((1s,4s)-4-methoxycyclohexyl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-1,2,4-Triazol-5-yl)phenyl)-1-(((1r,4r)-4-methoxycyclohexyl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-(1H-1,2,4-Triazol-3-yl)pyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-((dimethylamino)methyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-(pyrrolidin-2-ylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   6-(2-Aminobenzimidazol-5-yl)-1-(cyclohexylmethyl)-4-imidazolino[4,5-b]pyrazin-2-one    dihydrochloride;-   6-(2-(Dimethylamino)-1H-benzo[d]imidazol-5-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-(piperidin-3-ylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-1-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   1-(Cyclohexylmethyl)-6-(2-(methylamino)pyrimidin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(2-(2-methoxyethylamino)pyrimidin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-((methylamino)methyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-Oxopyrrolidin-2-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(1H-imidazol-2-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-1-(2-methyl-2-morpholinopropyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-Triazol-3-yl)phenyl)-1-(1-morpholinopropan-2-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(Pyrrolidin-2-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-(aminomethyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(5-(Hydroxymethyl)thiophen-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (1r,4r)-4-(6-(4-Hydroxyphenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-1-yl)cyclo-hexanecarboxamide;-   (1s,4s)-4-(6-(4-Hydroxyphenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-1-yl)cyclohexanecarboxamide;-   6-(4-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl)-1-(2-morpholinoethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-Oxopyrrolidin-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(Pyrrolidin-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1H-benzo[d]imidazol-5-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(3-(Hydroxymethyl)thiophen-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(5-(2-Hydroxyethyl)thiophen-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(pyrimidin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-Fluoropyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-Aminopyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-methyl-1H-imidazol-2-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-Methyl-1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-(Methylamino)pyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(2-aminopyrimidin-5-yl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(2-hydroxypropan-2-yl)phenyl)-1-(((1r,4r)-4-methoxycyclohexyl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-hydroxyphenyl)-1-((1-methylpiperidin-3-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   1-(cyclohexylmethyl)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(hydroxymethyl)thiophen-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1H-benzo[d]imidazol-6-yl)-1-(((1r,4r)-4-methoxycyclohexyl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4,5-dimethyl-1H-imidazol-2-yl)phenyl)-1-(2-morpholinoethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-1-(2-morpholino-2-oxoethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-3-(cyclohexylmethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;-   (R)-6-(4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (S)-6-(4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (1r,4r)-4-(6-(4-(2-hydroxypropan-2-yl)phenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-1-yl)cyclohexanecarboxamide;-   6-(3-Methyl-4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-B]pyrazin-2(3H)-one;-   6-(4-(1H-imidazol-2-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(5-(Aminomethyl)-1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(1H-benzo[d]imidazol-5-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(2-Aminopyrimidin-5-yl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-Hydroxyphenyl)-1-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one    hydrochloride;-   6-(3-Methyl-4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-B]pyrazin-2(3H)-one;-   1-(Cyclohexylmethyl)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-(2-Hydroxypropan-2-yl)pyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(6-(2-Hydroxypropan-2-yl)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   6-(4-(4H-1,2,4-Triazol-3-yl)phenyl)-1-(2-morpholino-2-oxoethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (R)-6-(4-(4H-1,2,4-Triazol-3-yl)phenyl)-3-(cyclohexylmethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (R)-6-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-B]pyrazin-2(3H)-one;-   (S)-6-(4-(4H-1,2,4-Triazol-3-yl)phenyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one;-   (1r,4r)-4-(6-(4-(2-Hydroxypropan-2-yl)phenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-1-yl)cyclohexanecarboxamide;    and-   6-(4-(5-Methyl-1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one,    and pharmaceutically acceptable salts, clathrates, solvates,    stereoisomers, tautomers, and prodrugs thereof.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (II):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

R¹ is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl;

—X-A-B—Y— taken together form —N(R²)CH₂C(O)NH—, —N(R²)C(O)CH₂NH—,—N(R²)C(O)NH—, —N(R²)C═N—, or —C(R²)═CHNH—;

L is a direct bond, NH or O;

R² is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl; and

R³ and R⁴ are independently H or C₁₋₈alkyl.

In one embodiment, the TOR kinase inhibitors of formula (II) are thosewherein —X-A-B—Y— taken together form —N(R²)CH₂C(O)NH—.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)CH₂NH—.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C═N—.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —C(R²)═CHNH—.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein L is a direct bond.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted pyridine, substituted or unsubstitutedindole or substituted or unsubstituted quinoline.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R¹ is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclopentyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH— and R¹ issubstituted aryl, such as phenyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH— and R¹ issubstituted or unsubstituted heteroaryl, such as substituted orunsubstituted pyridine, substituted or unsubstituted indole orsubstituted or unsubstituted quinoline.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH— and R¹ issubstituted or unsubstituted cycloalkyl, such as substituted orunsubstituted cyclopentyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R² is substituted C₁₋₈alkyl, such as —CH₂C₆H₅.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R² is unsubstituted C₁₋₈alkyl, such as unsubstitutedmethyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R² is substituted aryl, such as halo, haloalkyl or alkoxysubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R² is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclohexyl or substituted or unsubstitutedcycloheptyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R² is substituted heterocyclylalkyl, such as substitutedpiperidine.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein R³ and R⁴ are H.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH— and R² isunsubstituted aryl, such as unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, R¹ issubstituted or unsubstituted heteroaryl, such as substituted orunsubstituted pyridine, and R² is substituted or unsubstituted aryl,such as substituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, R¹ issubstituted or unsubstituted heteroaryl, such as substituted orunsubstituted pyridine, R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl, and R³ and R⁴ are H.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, L is a directbond, R¹ is substituted or unsubstituted heteroaryl, such as substitutedor unsubstituted pyridine, R² is substituted or unsubstituted aryl, suchas substituted or unsubstituted phenyl, and R³ and R⁴ are H.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, R¹ issubstituted or unsubstituted aryl, such as substituted or unsubstitutedphenyl, and R² is substituted or unsubstituted aryl, such as substitutedor unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, R¹ issubstituted or unsubstituted aryl, such as substituted or unsubstitutedphenyl, R² is substituted or unsubstituted aryl, such as substituted orunsubstituted phenyl, and R³ and R⁴ are H.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, L is a directbond, R¹ is substituted or unsubstituted aryl, such as substituted orunsubstituted phenyl, R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl, and R³ and R⁴ are H.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, R¹ issubstituted or unsubstituted heteroaryl, L is a direct bond and R² issubstituted or unsubstituted C₁₋₈alkyl or substituted or unsubstitutedcycloalkyl.

In another embodiment, the TOR kinase inhibitors of formula (II) arethose wherein —X-A-B—Y— taken together form —N(R²)C(O)NH—, R¹ issubstituted or unsubstituted aryl, L is a direct bond and R² issubstituted or unsubstituted C₁₋₈alkyl or substituted or unsubstitutedcycloalkyl.

In another embodiment, the TOR kinase inhibitors of formula (II) do notinclude8,9-dihydro-8-oxo-9-phenyl-2-(3-pyridinyl)-7H-purine-6-carboxamide,8,9-dihydro-8-oxo-9-phenyl-2-(3-pyridinyl)-7H-purine-6-carboxamide,8,9-dihydro-8-oxo-9-phenyl-2-(3-pyridinyl)-7H-purine-6-carboxamide,2-(4-cyanophenyl)-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide,2-(4-nitrophenyl)-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide,9-benzyl-2-(4-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide,2-methyl-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide,9-benzyl-9H-purine-2,6-dicarboxamide,9-[2,3-bis[(benzoyloxy)methyl]cyclobutyl]-2-methyl-9H-Purine-6-carboxamide,9-benzyl-2-methyl-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-methyl-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-(trifluoromethyl)-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-(prop-1-enyl)-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-phenyl-9H-purine-6-carboxamide,9-(3-hydroxypropyl)-2-methyl-9H-purine-6-carboxamide,9-(3-hydroxypropyl)-2-(trifluoromethyl)-9H-purine-6-carboxamide,2-methyl-9-phenylmethyl-9H-purine-6-carboxamide or2-methyl-9-β-D-ribofuranosyl-9H-purine-6-carboxamide.

In another embodiment, the TOR kinase inhibitors of formula (II) do notinclude compounds wherein R² is a substituted furanoside.

In another embodiment, the TOR kinase inhibitors of formula (II) do notinclude compounds wherein R² is a substituted or unsubstitutedfuranoside.

In another embodiment, the TOR kinase inhibitors of formula (II) do notinclude (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (IIa):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

R¹ is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl;

R² is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl; and

R³ and R⁴ are independently H or C₁₋₈alkyl.

In one embodiment, the TOR kinase inhibitors of formula (IIa) are thosewherein R¹ is substituted aryl, substituted or unsubstituted heteroaryl,such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted pyridine, substituted or unsubstitutedindole or substituted or unsubstituted quinoline.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R¹ is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclopentyl.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R² is substituted C₁₋₈alkyl, such as —CH₂C₆H₅.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R² is unsubstituted C₁₋₈alkyl, such as unsubstitutedmethyl.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R² is substituted aryl, such as halo, haloalkyl or alkoxysubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R² is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclohexyl or substituted or unsubstitutedcycloheptyl.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R² is substituted heterocyclylalkyl, such as substitutedpiperidine.

In another embodiment, the TOR kinase inhibitors of formula (IIa) arethose wherein R³ and R⁴ are H.

In another embodiment, the TOR kinase inhibitors of formula (IIa) do notinclude8,9-dihydro-8-oxo-9-phenyl-2-(3-pyridinyl)-7H-Purine-6-carboxamide,8,9-dihydro-8-oxo-9-phenyl-2-(3-pyridinyl)-7H-Purine-6-carboxamide,8,9-dihydro-8-oxo-9-phenyl-2-(3-pyridinyl)-7H-Purine-6-carboxamide,2-(4-cyanophenyl)-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide,2-(4-nitrophenyl)-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide,9-benzyl-2-(4-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide,9-phenylmethyl-9H-purine-2,6-dicarboxamide, or2-methyl-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide.

In another embodiment, the TOR kinase inhibitors of formula (IIa) do notinclude compounds wherein R² is a substituted furanoside.

In another embodiment, the TOR kinase inhibitors of formula (IIa) do notinclude compounds wherein R² is a substituted or unsubstitutedfuranoside.

In another embodiment, the TOR kinase inhibitors of formula (IIa) do notinclude (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (IIb):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

is —C(R²)═CH—NH— or —N(R²)—CH═N—;

R¹ is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl;

R² is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl; and

R³ and R⁴ are independently H or C₁₋₈alkyl.

In one embodiment, the TOR kinase inhibitors of formula (IIb) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted pyridine, substituted or unsubstitutedindole or substituted or unsubstituted quinoline.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R¹ is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclopentyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R² is substituted C₁₋₈alkyl, such as —CH₂C₆H₅.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R² is unsubstituted C₁₋₈alkyl, such as unsubstitutedmethyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R² is substituted aryl, such as halo, haloalkyl or alkoxysubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R² is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclohexyl or substituted or unsubstitutedcycloheptyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R² is substituted heterocyclylalkyl, such as substitutedpiperidine.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R³ and R⁴ are H.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose

wherein is —C(R²)═CH—NH— and R² is substituted aryl, such as substitutedphenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose

wherein is —N(R²)—CH═N— and R² is substituted aryl, such as substitutedphenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) arethose wherein R¹ is substituted aryl, such as phenyl, and R² issubstituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIb) do notinclude 9-benzyl-9H-purine-2,6-dicarboxamide,9-[2,3-bis[(benzoyloxy)methyl]cyclobutyl]-2-methyl-9H-Purine-6-carboxamide,9-benzyl-2-methyl-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-methyl-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-(trifluoromethyl)-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-(prop-1-enyl)-9H-purine-6-carboxamide,9-(2-hydroxyethyl)-2-phenyl-9H-purine-6-carboxamide,9-(3-hydroxypropyl)-2-methyl-9H-purine-6-carboxamide,9-(3-hydroxypropyl)-2-(trifluoromethyl)-9H-purine-6-carboxamide,9-phenylmethyl-9H-purine-2,6-dicarboxamide,2-methyl-9-phenylmethyl-9H-purine-6-carboxamide or2-methyl-9-β-D-ribofuranosyl-9H-purine-6-carboxamide.

In another embodiment, the TOR kinase inhibitors of formula (IIb) do notinclude compounds wherein R² is substituted cyclobutyl when

is —N(R²)—CH═N—.

In another embodiment, the TOR kinase inhibitors of formula (IIb) do notinclude compounds wherein R² is a substituted furanoside when

is —N(R²)—CH═N—.

In another embodiment, the TOR kinase inhibitors of formula (IIb) do notinclude compounds wherein R² is substituted pyrimidine when

is —C(R²)═CH—NH—.

In another embodiment, the TOR kinase inhibitors of formula (IIb) do notinclude compounds wherein R² is substituted oxetane when

is —N(R²)—CH═N—.

In another embodiment, the TOR kinase inhibitors of formula (IIb) do notinclude compounds wherein R² is substituted cyclopentyl or aheterocyclopentyl when

is —N(R²)—CH═N—.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (IIc):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

R¹ is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl;

R² is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl; and

R³ and R⁴ are independently H or C₁₋₈alkyl.

In one embodiment, the TOR kinase inhibitors of formula (IIc) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted pyridine, substituted or unsubstitutedindole or substituted or unsubstituted quinoline.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R¹ is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclopentyl.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R² is substituted C₁₋₈alkyl, such as —CH₂C₆H₅.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R² is unsubstituted C₁₋₈alkyl, such as unsubstitutedmethyl.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R² is substituted aryl, such as halo, haloalkyl or alkoxysubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R² is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclohexyl or substituted or unsubstitutedcycloheptyl.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R² is substituted heterocyclylalkyl, such as substitutedpiperidine.

In another embodiment, the TOR kinase inhibitors of formula (IIc) arethose wherein R³ and R⁴ are H.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (IId):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

R¹ is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl;

R² is substituted or unsubstituted C₁₋₈alkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, or substituted or unsubstitutedheterocyclylalkyl; and

R³ and R⁴ are independently H or C₁₋₈alkyl.

In one embodiment, the TOR kinase inhibitors of formula (IId) are thosewherein R¹ is substituted aryl, such as substituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R¹ is substituted or unsubstituted heteroaryl, such assubstituted or unsubstituted pyridine, substituted or unsubstitutedindole or substituted or unsubstituted quinoline.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R¹ is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclopentyl.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R² is substituted C₁₋₈alkyl, such as —CH₂C₆H₅.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R² is unsubstituted C₁₋₈alkyl, such as unsubstitutedmethyl.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R² is substituted or unsubstituted aryl, such assubstituted or unsubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R² is substituted aryl, such as halo, haloalkyl or alkoxysubstituted phenyl.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R² is substituted or unsubstituted cycloalkyl, such assubstituted or unsubstituted cyclohexyl or substituted or unsubstitutedcycloheptyl.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R² is substituted heterocyclylalkyl, such as substitutedpiperidine.

In another embodiment, the TOR kinase inhibitors of formula (IId) arethose wherein R³ and R⁴ are H.

Representative TOR kinase inhibitors of formula (II) include compoundsfrom Table B.

Table B.

-   9-benzyl-8-oxo-2-(pyridin-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   N-methyl-8-oxo-9-phenyl-2-(pyridin-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   8-oxo-9-phenyl-2-(pyridin-2-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(2-chloropyridin-3-yl)-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide;-   2-(2-methoxypyridin-3-yl)-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide;-   N,N-dimethyl-8-oxo-9-phenyl-2-(pyridin-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-methyl-8-oxo-2-(pyridin-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-hydroxyphenyl)-8-oxo-9-o-tolyl-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-indol-4-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-indol-6-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-hydroxyphenyl)-9-(4-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(2-hydroxypyridin-4-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-chlorophenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-fluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2,6-difluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-cycloheptyl-8-oxo-2-(pyridin-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-methoxyphenyl)-8-oxo-2-(quinolin-5-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-cyclopentyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-methoxyphenyl)-8-oxo-2-(3-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-methoxyphenyl)-2-(6-methoxypyridin-3-yl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-hydroxyphenyl)-8-oxo-9-(4-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-benzyl-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-hydroxyphenyl)-8-oxo-9-(2-(trifluoromethoxy)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2,4-dichlorophenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-methoxyphenyl)-2-(3-nitrophenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-cyanophenyl)-8-oxo-9-phenyl-8,9-dihydro-7H-purine-6-carboxamide;-   9-(3-fluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-methoxyphenyl)-8-oxo-2-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(5-fluoropyridin-3-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1-benzylpiperidin-4-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   benzyl    4-(6-carbamoyl-8-oxo-2-(pyridin-3-yl)-7H-purin-9(8H)-yl)piperidine-1-carboxylate;-   9-cyclohexyl-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-methoxyphenyl)-8-oxo-2-(3-(trifluoromethoxy)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-phenyl-2-(pyridin-3-yl)-9H-purine-6-carboxamide;-   6-oxo-8-phenyl-2-(pyridin-3-yl)-5,6,7,8-tetrahydropteridine-4-carboxamide;-   6-oxo-8-phenyl-2-(pyridin-4-yl)-5,6,7,8-tetrahydropteridine-4-carboxamide;-   2-(3-aminophenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-hydroxyphenyl)-9-(2-methoxyphenyl)-9H-purine-6-carboxamide;-   9-Cyclopentyl-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-tert-Butyl-2-(3-hydroxy-phenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   [2-(3-Hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo(7-hydropurin-6-yl)]-N-methylcarboxamide;-   2-phenyl-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide;-   [2-(3-Hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo(7-hydropurin-6-yl)]-N,N-dimethyl    carboxamide;-   2-(3-Hydroxyphenylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-Hydroxyphenylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(trans-4-Hydroxycyclohexyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(trans-4-Hydroxycyclohexyl)-8-oxo-2-(pyridin-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-(trans-4-Hydroxycyclohexyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(trans-4-Hydroxycyclohexyl)-8-oxo-2-(pyridin-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenylamino)-9-(2-methoxyphenyl)-9H-purine-6-carboxamide;-   9-Isopropyl-2-(3-hydroxy-phenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   Methyl    4-(6-carbamoyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)benzoate;-   2-(2-Chloro-3-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(3-Cyanophenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(2-Hydroxyphenylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-9-(4-methoxy-2-methylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-8-oxo-9-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-Cyano-phenyl)-9-(2-methoxy-phenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   4-[6-Carbamoyl-9-(2-methoxy-phenyl)-8-oxo-8,9-dihydro-7H-purin-2-yl]-benzoic    acid;-   Methyl    3-(6-carbamoyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)benzoate;-   3-(6-Carbamoyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)benzoic    acid;-   2-(3-Hydroxyphenyl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Indazol-6-yl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(4-Carbamoylphenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Ethylphenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2,5-Dichlorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(3-Carbamoylphenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2,6-Dichlorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(2-Hydroxyphenyl)-9-(2-methoxyphenyl)purine-6-carboxamide;-   2-(1H-Indazol-5-yl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2,3-Dichlorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-[4-(Hydroxymethyl)phenyl]-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carbox-amide;-   2-[3-(Hydroxymethyl)phenyl]-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carbox-amide;-   9-(2-Methoxyphenyl)-8-oxo-2-(pyridin-4-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-Fluoro-3-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carbox-amide;-   2-(2-Fluoro-3-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carbox-amide;-   2-[4-(1-Hydroxy-isopropyl)phenyl]-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-[3-(1-Hydroxy-isopropyl)phenyl]-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2-Methoxyphenyl)-2-(2-nitrophenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2-Methoxyphenyl)-2-(4-nitrophenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2-Methoxyphenyl)-2-(2-nitrophenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2,4-Difluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2-Methoxyphenyl)-2-{3-[(methylsulfonyl)amino]phenyl}-8-oxo-7-hydropurine-6-carboxamide;-   9-(4-Chloro-2-fluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2-Chlorophenyl)-8-oxo-2-(3-pyridyl)-7-hydropurine-6-carboxamide;-   8-oxo-2-(3-pyridyl)-9-[2-(trifluoromethyl)phenyl]-7-hydropurine-6-carboxamide;-   9-(3-Chloro-2-fluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2-Fluoro-3-trifluoromethylphenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(2,3,4-Trifluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(1H-Benzo[d]imidazol-6-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-[3-(Acetylamino)phenyl]-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(3-hydroxyphenyl)-8-(2-methoxyphenyl)-6-oxo-5,6,7,8-tetrahydropteridine-4-carbox-amide;-   9-(2-Methoxyphenyl)-8-oxo-2-pyrazol-4-yl-7-hydropurine-6-carboxamide;-   9-(2-Methoxyphenyl)-8-oxo-2-pyrazol-3-yl-7-hydropurine-6-carboxamide;-   9-(4-Aminocyclohexyl)-2-(3-hydroxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-[3-(Difluoromethyl)phenyl]-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carbox-amide;-   2-[5-(Difluoromethyl)-2-fluorophenyl]-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(1H-benzo[d]imidazol-4-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(6-Hydroxypyridin-3-yl)-8-oxo-9-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-benzo[d]imidazol-6-yl)-9-(2-fluorophenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-Benzimidazol-6-yl-8-oxo-9-[2-(trifluoromethyl)phenyl]-7-hydropurine-6-carboxamide;-   2-(5-Chloropyridin-3-yl)-8-oxo-9-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   trans-4-(6-Carbamoyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purin-2-ylamino)cyclohexyl    carbamate;-   (R)-9-(2-Methoxyphenyl)-8-oxo-2-(pyrrolidin-3-ylamino)-8,9-dihydro-7H-purine-6-carboxamide;-   (S)-9-(2-Methoxyphenyl)-8-oxo-2-(pyrrolidin-3-ylamino)-8,9-dihydro-7H-purine-6-carboxamide;-   (cis)-4-(6-Carbamoyl-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purin-2-ylamino)cyclohexyl    carbamate;-   2-(trans-4-Hydroxycyclohexylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-Chloropyridin-3-yl)-8-oxo-9-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(cis-4-Hydroxycyclohexylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-((1H-Imidazol-1-yl)methyl)phenylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-Hydroxypyridin-3-yl)-8-oxo-9-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   (R)-9-(2-Methoxyphenyl)-8-oxo-2-(pyrrolidin-2-ylmethylamino)-8,9-dihydro-7H-purine-6-carboxamide;-   (S)-9-(2-Methoxyphenyl)-8-oxo-2-(pyrrolidin-2-ylmethylamino)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(2-Hydroxyethylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Methoxyphenyl)-8-oxo-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-6-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-(1H-1,2,4-Triazol-3-yl)phenyl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide;-   9-(Biphenyl-2-yl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-9-(2-fluorophenyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Methoxyphenyl)-2-(2-methyl-1H-benzo[d]imidazol-6-yl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-(Hydroxymethyl)phenylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(2-(Hydroxymethyl)phenylamino)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-tert-Butylphenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-8-oxo-9-(2-phenoxyphenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Benzo[d]imidazol-6-yl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Indazol-4-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(2-Hydroxypyridin-3-yl)-8-oxo-9-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Imidazo[4,5-b]pyridin-6-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-(1H-Imidazol-1-yl)phenyl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Cyclohexylphenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-(1H-Imidazol-2-yl)phenyl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Benzo[d]imidazol-1-yl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Imidazo[4,5-b]pyridin-6-yl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Isopropylphenyl)-8-oxo-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Imidazo[4,5-b]pyridin-6-yl)-8-oxo-9-(2-(trifluoromethyl)phenyl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Methoxyphenyl)-2-(2-(methylthio)-1H-benzo[d]imidazol-5-yl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Indol-5-yl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(Cyclohexylmethyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2,3-Dihydro-1H-inden-1-yl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-9-isobutyl-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(trans-4-Methoxycyclohexyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(cis-4-Methoxycyclohexyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-8-oxo-9-(5,6,7,8-tetrahydronaphthalen-1-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-9-cyclohexyl-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-9-(1H-indol-4-yl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Fluoro-3-methoxyphenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Fluoro-5-methoxyphenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-Cyclohexyl-2-(1H-imidazo[4,5-b]pyridin-6-yl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-8-oxo-9-(tetrahydro-2H-pyran-4-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-8-oxo-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Cyclopentylphenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-8-oxo-9-(piperidin-4-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   9-(2-Fluoro-4-methoxyphenyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-benzo[d]imidazol-6-yl)-9-cyclohexyl-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-Benzimidazol-6-yl-9-(trans-4-methoxycyclohexyl)-8-oxo-7-hydropurine-6-carboxamide;-   2-(4-(Aminomethyl)phenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-9-(cis-4-(methoxymethyl)cyclohexyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   9-(trans-4-Aminocyclohexyl)-2-(3-hydroxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-9-(2-isobutylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   (R)-2-(3-Hydroxyphenyl)-8-oxo-9-(tetrahydrofuran-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   (S)-2-(3-Hydroxyphenyl)-8-oxo-9-(tetrahydrofuran-3-yl)-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-(Aminomethyl)phenyl)-9-(2-methoxyphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-(1H-1,2,3-Triazol-5-yl)phenyl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-9-(cis-4-methoxycyclohexyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Benzo[d]imidazol-6-yl)-9-(cis-4-methoxycyclohexyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(1H-Imidazo[4,5-b]pyridin-6-yl)-9-(cis-4-methoxycyclohexyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;-   2-(3-Hydroxyphenyl)-9-((1r,4r)-4-(methoxymethyl)cyclohexyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide;    and-   9-(2-Isopropylphenyl)-2-(4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide,    and pharmaceutically acceptable salts, clathrates, solvates,    stereoisomers, tautomers, and prodrugs thereof.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (III):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

R¹ is substituted or unsubstituted C₁₋₈ alkyl, substituted orunsubstituted aryl, substituted or unsubstituted cycloalkyl, substitutedor unsubstituted heterocyclyl, or substituted or unsubstitutedheterocyclylalkyl;

R² is H, substituted or unsubstituted C₁₋₈ alkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted heterocyclylalkyl, substituted orunsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;

R³ and R⁴ are each independently H, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted aryl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocyclyl, substituted orunsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl,substituted or unsubstituted cycloalkylalkyl, or R³ and R⁴, togetherwith the atoms to which they are attached, form a substituted orunsubstituted cycloalkyl or substituted or unsubstituted heterocyclyl;

or R² and one of R³ and R⁴, together with the atoms to which they areattached, form a substituted or unsubstituted heterocyclyl,

wherein in certain embodiments, the TOR kinase inhibitors do not includethe compounds depicted below, namely:

-   6-(4-hydroxyphenyl)-4-(3-methoxybenzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;

-   6-(4-(1H-1,2,4-triazol-5-yl)phenyl)-3-(cyclohexylmethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;    or

-   (R)-6-(4-(1H-1,2,4-triazol-5-yl)phenyl)-3-(cyclohexylmethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

In some embodiments of compounds of formula (III), R¹ is substituted orunsubstituted aryl or substituted or unsubstituted heteroaryl. In oneembodiment, R¹ is phenyl, pyridyl, pyrimidyl, benzimidazolyl, indolyl,indazolyl, 1H-pyrrolo[2,3-b]pyridyl, 1H-imidazo[4,5-b]pyridyl,1H-imidazo[4,5-b]pyridin-2(3H)-onyl, 3H-imidazo[4,5-b]pyridyl, orpyrazolyl, each optionally substituted. In some embodiments, R¹ isphenyl substituted with one or more substituents independently selectedfrom the group consisting of substituted or unsubstituted C₁₋₈ alkyl(for example, methyl), substituted or unsubstituted heterocyclyl (forexample, substituted or unsubstituted triazolyl or pyrazolyl), halogen(for example, fluorine), aminocarbonyl, cyano, hydroxyalkyl (forexample, hydroxypropyl), and hydroxy. In other embodiments, R¹ ispyridyl substituted with one or more substituents independently selectedfrom the group consisting of substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted heterocyclyl (for example, substituted orunsubstituted triazolyl), halogen, aminocarbonyl, cyano, hydroxyalkyl,—OR, and —NR₂, wherein each R is independently H, or a substituted orunsubstituted C₁₋₄ alkyl. In yet other embodiments, R¹ is1H-pyrrolo[2,3-b]pyridyl or benzimidazolyl, each optionally substitutedwith one or more substituents independently selected from the groupconsisting of substituted or unsubstituted C₁₋₈ alkyl, and —NR₂, whereineach R is independently H, or a substituted or unsubstituted C₁₋₄ alkyl.

In some embodiments of compounds of formula (III), R¹ is

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₄ alkyl (for example, methyl); R′ is at each occurrenceindependently a substituted or unsubstituted C₁₋₄ alkyl, halogen (forexample, fluorine), cyano, —OR, or —NR₂; m is 0-3; and n is 0-3. It willbe understood by those skilled in the art that any of the substitutentsR′ may be attached to any suitable atom of any of the rings in the fusedring systems. It will also be understood by those skilled in the artthat the connecting bond of R¹ (designated by the bisecting wavy line)may be attached to any of the atoms in any of the rings in the fusedring systems.

In some embodiments of compounds of formula (III), R¹ is

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₄ alkyl; R′ is at each occurrence independently asubstituted or unsubstituted C₁₋₄ alkyl, halogen, cyano, —OR, or —NR₂; mis 0-3; and n is 0-3.

In some embodiments of compounds of formula (III), R² is H, substitutedor unsubstituted C₁₋₈ alkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedC₁₋₄ alkyl-heterocyclyl, substituted or unsubstituted C₁₋₄ alkyl-aryl,or substituted or unsubstituted C₁₋₄ alkyl-cycloalkyl. For example, R²is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,tert-butyl, n-pentyl, isopentyl, cyclopentyl, cyclohexyl,tetrahydrofuranyl, tetrahydropyranyl, (C₁₋₄ alkyl)-phenyl, (C₁₋₄alkyl)-cyclopropyl, (C₁₋₄ alkyl)-cyclobutyl, (C₁₋₄ alkyl)-cyclopentyl,(C₁₋₄ alkyl)-cyclohexyl, (C₁₋₄ alkyl)-pyrrolidyl, (C₁₋₄alkyl)-piperidyl, (C₁₋₄ alkyl)-piperazinyl, (C₁₋₄ alkyl)-morpholinyl,(C₁₋₄ alkyl)-tetrahydrofuranyl, or (C₁₋₄ alkyl)-tetrahydropyranyl, eachoptionally substituted.

In other embodiments, R² is H, C₁₋₄ alkyl, (C₁₋₄alkyl)(OR),

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₄ alkyl (for example, methyl); R′ is at each occurrenceindependently H, —OR, cyano, or a substituted or unsubstituted C₁₋₄alkyl (for example, methyl); and p is 0-3.

In some such embodiments, R² is H, C₁₋₄ alkyl, (C₁₋₄alkyl)(OR),

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₂ alkyl; R′ is at each occurrence independently H, —OR,cyano, or a substituted or unsubstituted C₁₋₂ alkyl; and p is 0-1.

In some other embodiments of compounds of formula (III), R² and one ofR³ and R⁴ together with the atoms to which they are attached form asubstituted or unsubstituted heterocyclyl. For example, in someembodiments, the compound of formula (III) is

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₄ alkyl; R″ is H, OR, or a substituted or unsubstitutedC₁₋₄ alkyl; and R¹ is as defined herein.

In some embodiments of compounds of formula (III), R³ and R⁴ are both H.In others, one of R³ and R⁴ is H and the other is other than H. In stillothers, one of R³ and R⁴ is C₁₋₄ alkyl (for example, methyl) and theother is H. In still others, both of R³ and R⁴ are C₁₋₄ alkyl (forexample, methyl).

In some such embodiments described above, R¹ is substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Forexample, R¹ is phenyl, pyridyl, pyrimidyl, benzimidazolyl, indolyl,indazolyl, 1H-pyrrolo[2,3-b]pyridyl, 1H-imidazo[4,5-b]pyridyl,1H-imidazo[4,5-b]pyridin-2(3H)-onyl, 3H-imidazo[4,5-b]pyridyl, orpyrazolyl, each optionally substituted. In some embodiments, R¹ isphenyl substituted with one or more substituents independently selectedfrom the group consisting of substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted heterocyclyl, halogen, aminocarbonyl,cyano, hydroxyalkyl and hydroxy. In others, R¹ is pyridyl substitutedwith one or more substituents independently selected from the groupconsisting of cyano, substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted heterocyclyl, hydroxyalkyl, halogen,aminocarbonyl, —OR, and —NR₂, wherein each R is independently H, or asubstituted or unsubstituted C₁₋₄ alkyl. In others, R¹ is1H-pyrrolo[2,3-b]pyridyl or benzimidazolyl, optionally substituted withone or more substituents independently selected from the groupconsisting of substituted or unsubstituted C₁₋₈ alkyl, and —NR₂, whereinR is independently H, or a substituted or unsubstituted C₁₋₄ alkyl

In certain embodiments, the compounds of formula (III) have an R¹ groupset forth herein and an R² group set forth herein.

In some embodiments of compounds of formula (III), the compound at aconcentration of 10 μM inhibits mTOR, DNA-PK, or PI3K or a combinationthereof, by at least about 50%. Compounds of formula (III) may be shownto be inhibitors of the kinases above in any suitable assay system.

Representative TOR kinase inhibitors of formula (III) include compoundsfrom Table C.

Table C.

-   6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-((trans-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-((cis-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((trans-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-((trans-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((cis-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((trans-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(cis-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((cis-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(trans-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-((cis-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(cis-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-isopropyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(cis-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(cis-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-ethyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(trans-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-isopropyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-ethyl-6-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(cis-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-4-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(2-methoxyethyl)-6-(4-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-(1H-1,2,4-triazol-5-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   5-(8-(2-methoxyethyl)-6-oxo-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)-4-methylpicolinamide;-   3-(6-oxo-8-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)benzamide;-   3-(6-oxo-8-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)benzonitrile;-   5-(8-(trans-4-methoxycyclohexyl)-6-oxo-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)-4-methylpicolinamide;-   6-(1H-imidazo[4,5-b]pyridin-6-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(1H-indazol-6-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-((1R,3S)-3-methoxycyclopentyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-((1S,3R)-3-methoxycyclopentyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-((1R,3R)-3-methoxycyclopentyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-((1S,3    S)-3-methoxycyclopentyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-ethyl-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(1H-indol-6-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(1H-indol-5-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(((1R,3    S)-3-methoxycyclopentyl)methyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(((1S,3R)-3-methoxycyclopentyl)methyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-fluoro-2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-fluoro-2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3,3-dimethyl-6-(4-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((1R,3    S)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((1S,3R)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-4(1S,3    S)-3-methoxycyclopentyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((1R,3R)-3-methoxycyclopentyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((1S,3    S)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((1R,3R)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((1R,3    S)-3-methoxycyclopentyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((1S,3R)-3-methoxycyclopentyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-fluoro-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(3-fluoro-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7′-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-1′-((tetrahydro-2H-pyran-4-yl)methyl)-1′H-spiro[cyclopentane-1,2′-pyrazino[2,3-b]pyrazin]-3′(4′H)-one;-   7′-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-1′-((tetrahydro-2H-pyran-4-yl)methyl)-1′H-spiro[cyclobutane-1,2′-pyrazino[2,3-b]pyrazin]-3′(4′H)-one;-   4-(cyclopropylmethyl)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7′-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-1′H-spiro[cyclopentane-1,2′-pyrazino[2,3-b]pyrazin]-3′(4′H)-one;-   7′-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-1′H-spiro[cyclobutane-1,2′-pyrazino[2,3-b]pyrazin]-3′(4′H)-one;-   7′-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-1′H-spiro[cyclopropane-1,2′-pyrazino[2,3-b]pyrazin]-3′(4′H)-one;-   (R)-6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-((tetrahydrofuran-2-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (S)-6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-((tetrahydrofuran-2-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(1H-indazol-5-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(6-oxo-8-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)benzamide;-   4-(2-methoxyethyl)-3,3-dimethyl-6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-ethyl-3,3-dimethyl-6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3,3-dimethyl-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (R)-6-(6-(1-hydroxyethyl)pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3,3-dimethyl-6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)-4-methylpyridin-3-yl)-4-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)-4-methylpyridin-3-yl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3,3-dimethyl-6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3,3-dimethyl-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)-2-methylpyridin-3-yl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)-2-methylpyridin-3-yl)-4-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (S)-6-(6-(1-hydroxyethyl)pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3,3-dimethyl-6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,3-dimethyl-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(2-hydroxypropan-2-yl)phenyl)-4-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(2-hydroxypropan-2-yl)phenyl)-4-((trans-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(cis-4-methoxycyclohexyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(trans-4-methoxycyclohexyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(2-hydroxypropan-2-yl)phenyl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(2-methoxyethyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   9-(6-(4H-1,2,4-triazol-3-yl)-3-pyridyl)-6,11,4a-trihydromorpholino[4,3-e]pyrazino[2,3-b]pyrazin-5-one;-   6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   5-(8-(cis-4-methoxycyclohexyl)-6-oxo-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)-6-methylpicolinonitrile;-   6-(6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   9-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)-3-(2-methoxyacetyl)-6,11,4a-trihydropiperazino[1,2-e]pyrazino[2,3-b]pyrazin-5-one;-   9-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)-6,11,4a-trihydropiperazino[1,2-e]pyrazino[2,3-b]pyrazin-5-one;-   9-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)-3-(2-methoxyethyl)-6,11,4a-trihydropiperazino[1,2-e]pyrazino[2,3-b]pyrazin-5-one;-   4-(cyclopentylmethyl)-6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   9-(6-(4H-1,2,4-triazol-3-yl)-2-methyl-3-pyridyl)-6,11,4a-trihydromorpholino[4,3-e]pyrazino[2,3-b]pyrazin-5-one;-   4-(trans-4-hydroxycyclohexyl)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(cis-4-hydroxycyclohexyl)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((tetrahydrofuran-3-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(cyclopentylmethyl)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-neopentyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-isobutyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3-methyl-6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(piperidin-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-3-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   8-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)(3    aS,2R)-2-methoxy-5,10,3a-trihydropyrazino[2,3-b]pyrrolidino[1,2-e]pyrazin-4-one;-   8-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)(2R,3    aR)-2-methoxy-5,10,3a-trihydropyrazino[2,3-b]pyrrolidino[1,2-e]pyrazin-4-one;-   8-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)(2S,3    aR)-2-methoxy-5,10,3a-trihydropyrazino[2,3-b]pyrrolidino[1,2-e]pyrazin-4-one;-   8-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)(2S,3    aS)-2-methoxy-5,10,3a-trihydropyrazino[2,3-b]pyrrolidino[1,2-e]pyrazin-4-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(3-methoxypropyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (S)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((tetrahydrofuran-2-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (R)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((tetrahydrofuran-2-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   9-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)-3-methyl-6,11,4a-trihydropiperazino[1,2-e]pyrazino[2,3-b]pyrazin-5-one;-   9-(4-(4H-1,2,4-triazol-3-yl)phenyl)-6,11,4a-trihydromorpholino[4,3-e]pyrazino[2,3-b]pyrazin-5-one;-   9-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)-6,11,4a-trihydropiperidino[1,2-e]pyrazino[2,3-b]pyrazin-5-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(cis-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(2-morpholinoethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-phenethyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(cyclohexylmethyl)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((trans-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((cis-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (R)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(tetrahydrofuran-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (S)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(tetrahydrofuran-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-phenyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (S)-6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3-methyl-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   9-[6-(1-hydroxy-isopropyl)-3-pyridyl]-6,11,4a-trihydromorpholino[4,3-e]pyrazino[2,3-b]pyrazin-5-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(2-amino-7-methyl-1H-benzo[d]imidazol-5-yl)-4-(3-(trifluoromethyl)benzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(3-(trifluoromethyl)benzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   9-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)-6,11,4a-trihydromorpholino[4,3-e]pyrazino[2,3-b]pyrazin-5-one;-   6-(4-methyl-2-(methylamino)-1H-benzo[d]imidazol-6-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   8-(4-(4H-1,2,4-triazol-3-yl)-2-methylphenyl)-5,10,3a-trihydropyrazino[2,3-b]pyrrolidino[1,2-e]pyrazin-4-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-ethyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(3-(trifluoromethyl)benzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-methyl-1H-benzo[d]imidazol-6-yl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   6-(4-(2-hydroxypropan-2-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;    and-   6-(4-(1H-1,2,4-triazol-5-yl)phenyl)-4-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one,    and pharmaceutically acceptable salts, clathrates, solvates,    stereoisomers, tautomers, and prodrugs thereof.

In one embodiment, the TOR kinase inhibitors include compounds havingthe following formula (IV):

and pharmaceutically acceptable salts, clathrates, solvates,stereoisomers, tautomers, and prodrugs thereof, wherein:

R¹ is substituted or unsubstituted C₁₋₈ alkyl, substituted orunsubstituted aryl, substituted or unsubstituted cycloalkyl, substitutedor unsubstituted heterocyclyl, or substituted or unsubstitutedheterocyclylalkyl;

R² is H, substituted or unsubstituted C₁₋₈ alkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted heterocyclylalkyl, substituted orunsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;

R³ is H, or a substituted or unsubstituted C₁₋₈ alkyl,

wherein in certain embodiments, the TOR kinase inhibitors do not include7-(4-hydroxyphenyl)-1-(3-methoxybenzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one,

In some embodiments of compounds of formula (IV), R¹ is substituted orunsubstituted aryl or substituted or unsubstituted heteroaryl. Forexample, R¹ is phenyl, pyridyl, pyrimidyl, benzimidazolyl,1H-pyrrolo[2,3-b]pyridyl, indazolyl, indolyl, 1H-imidazo[4,5-b]pyridyl,1H-imidazo[4,5-b]pyridin-2(3H)-onyl, 3H-imidazo[4,5-b]pyridyl, orpyrazolyl, each optionally substituted. In some embodiments, R¹ isphenyl substituted with one or more substituents independently selectedfrom the group consisting of substituted or unsubstituted C₁₋₈ alkyl(for example, methyl), substituted or unsubstituted heterocyclyl (forexample, a substituted or unsubstituted triazolyl or pyrazolyl),aminocarbonyl, halogen (for example, fluorine), cyano, hydroxyalkyl andhydroxy. In other embodiments, R¹ is pyridyl substituted with one ormore substituents independently selected from the group consisting ofsubstituted or unsubstituted C₁₋₈ alkyl (for example, methyl),substituted or unsubstituted heterocyclyl (for example, a substituted orunsubstituted triazolyl), halogen, aminocarbonyl, cyano, hydroxyalkyl(for example, hydroxypropyl), —OR, and —NR₂, wherein each R isindependently H, or a substituted or unsubstituted C₁₋₄ alkyl. In someembodiments, R¹ is 1H-pyrrolo[2,3-b]pyridyl or benzimidazolyl,optionally substituted with one or more substituents independentlyselected from the group consisting of substituted or unsubstituted C₁₋₈alkyl, and —NR₂, wherein R is independently H, or a substituted orunsubstituted C₁₋₄ alkyl.

In some embodiments, R¹ is

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₄ alkyl (for example, methyl); R′ is at each occurrenceindependently a substituted or unsubstituted C₁₋₄ alkyl (for example,methyl), halogen (for example, fluoro), cyano, —OR, or —NR₂; m is 0-3;and n is 0-3. It will be understood by those skilled in the art that anyof the substitutents R′ may be attached to any suitable atom of any ofthe rings in the fused ring systems.

In some embodiments of compounds of formula (IV), R¹ is

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₄ alkyl; R′ is at each occurrence independently asubstituted or unsubstituted C₁₋₄ alkyl, halogen, cyano, —OR or —NR₂; mis 0-3; and n is 0-3.

In some embodiments of compounds of formula (IV), R² is H, substitutedor unsubstituted C₁₋₈ alkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedC₁₋₄ alkyl-heterocyclyl, substituted or unsubstituted C₁₋₄ alkyl-aryl,or substituted or unsubstituted C₁₋₄ alkyl-cycloalkyl. For example, R²is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,tert-butyl, n-pentyl, isopentyl, cyclopentyl, cyclohexyl,tetrahydrofuranyl, tetrahydropyranyl, (C₁₋₄ alkyl)-phenyl, (C₁₋₄alkyl)-cyclopropyl, (C₁₋₄ alkyl)-cyclobutyl, (C₁₋₄ alkyl)-cyclopentyl,(C₁₋₄ alkyl)-cyclohexyl, (C₁₋₄ alkyl)-pyrrolidyl, (C₁₋₄alkyl)-piperidyl, (C₁₋₄ alkyl)-piperazinyl, (C₁₋₄ alkyl)-morpholinyl,(C₁₋₄ alkyl)-tetrahydrofuranyl, or (C₁₋₄ alkyl)-tetrahydropyranyl, eachoptionally substituted.

In other embodiments, R² is H, C₁₋₄ alkyl, (C₁₋₄alkyl)(OR),

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₄ alkyl (for example, methyl); R′ is at each occurrenceindependently H, —OR, cyano, or a substituted or unsubstituted C₁₋₄alkyl (for example, methyl); and p is 0-3.

In other embodiments of compounds of formula (IV), R² is H, C₁₋₄ alkyl,(C₁₋₄alkyl)(OR),

wherein R is at each occurrence independently H, or a substituted orunsubstituted C₁₋₂ alkyl; R′ is at each occurrence independently H, —OR,cyano, or a substituted or unsubstituted C₁₋₂ alkyl; and p is 0-1.

In other embodiments of compounds of formula (IV), R³ is H.

In some such embodiments described herein, R¹ is substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Forexample, R¹ is phenyl, pyridyl, pyrimidyl, benzimidazolyl,1H-pyrrolo[2,3-b]pyridyl, indazolyl, indolyl, 1H-imidazo[4,5-b]pyridine,pyridyl, 1H-imidazo[4,5-b]pyridin-2(3H)-onyl, 3H-imidazo[4,5-b]pyridyl,or pyrazolyl, each optionally substituted. In some embodiments, R¹ isphenyl substituted with one or more substituents independently selectedfrom the group consisting of substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted heterocyclyl, aminocarbonyl, halogen,cyano, hydroxyalkyl and hydroxy. In others, R¹ is pyridyl substitutedwith one or more substituents independently selected from the groupconsisting of C₁₋₈ alkyl, substituted or unsubstituted heterocyclyl,halogen, aminocarbonyl, cyano, hydroxyalkyl, —OR, and —NR₂, wherein eachR is independently H, or a substituted or unsubstituted C₁₋₄ alkyl. Instill others, R¹ is 1H-pyrrolo[2,3-b]pyridyl or benzimidazolyl,optionally substituted with one or more substituents independentlyselected from the group consisting of substituted or unsubstituted C₁₋₈alkyl, and —NR₂, wherein R is independently H, or a substituted orunsubstituted C₁₋₄ alkyl.

In certain embodiments, the compounds of formula (IV) have an R¹ groupset forth herein and an R² group set forth herein.

In some embodiments of compounds of formula (IV), the compound at aconcentration of 10 μM inhibits mTOR, DNA-PK, PI3K, or a combinationthereof by at least about 50%. Compounds of formula (IV) may be shown tobe inhibitors of the kinases above in any suitable assay system.

Representative TOR kinase inhibitors of formula (IV) include compoundsfrom Table D.

Table D.

-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-((trans-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(cis-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-((cis-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-ethyl-7-(1H-pyrrolo[3,2-b]pyridin-5-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-((cis-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-benzo[d]imidazol-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-((trans-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-((trans-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(cis-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(cis-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-ethyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-((cis-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-indol-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-((trans-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-((cis-4-hydroxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(trans-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-isopropyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(trans-4-hydroxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-isopropyl-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-ethyl-7-(5-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-hydroxypyridin-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-isopropyl-7-(4-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   5-(8-isopropyl-7-oxo-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)-4-methylpicolinamide;-   7-(1H-indazol-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-aminopyrimidin-5-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-aminopyridin-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(methylamino)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-hydroxypyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(4-(1H-pyrazol-3-yl)phenyl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-indazol-4-yl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-indazol-6-yl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(pyrimidin-5-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-methoxypyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(2-methoxyethyl)-7-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-ethyl-7-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-ethyl-7-(1H-indazol-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(pyridin-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-aminopyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-methyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   2-(2-hydroxypropan-2-yl)-5-(8-(trans-4-methoxycyclohexyl)-7-oxo-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)pyridine    1-oxide;-   4-methyl-5-(7-oxo-8-((tetrahydro-2H-pyran-4-yl)methyl)-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)picolinamide;-   5-(8-((cis-4-methoxycyclohexyl)methyl)-7-oxo-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)-4-methylpicolinamide;-   7-(1H-pyrazol-4-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(trans-4-methoxycyclohexyl)-7-(4-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3-((7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-2-oxo-3,4-dihydropyrazino[2,3-b]pyrazin-1(2H)-yl)methyl)benzonitrile;-   1-((trans-4-methoxycyclohexyl)methyl)-7-(4-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   3-(7-oxo-8-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)benzamide;-   5-(8-((trans-4-methoxycyclohexyl)methyl)-7-oxo-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)-4-methylpicolinamide;-   3-((7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-oxo-3,4-dihydropyrazino[2,3-b]pyrazin-1    (2H)-yl)methyl)benzonitrile;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1R,3R)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1S,3R)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1S,3    S)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1R,3    S)-3-methoxycyclopentyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-indazol-6-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(2-morpholinoethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(trans-4-hydroxycyclohexyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(cis-4-hydroxycyclohexyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-morpholinoethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-isopropyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-imidazo[4,5-b]pyridin-6-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-((cis-4-methoxycyclohexyl)methyl)-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(trans-4-hydroxycyclohexyl)-7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(cis-4-hydroxycyclohexyl)-7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   4-(7-oxo-8-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-5,6,7,8-tetrahydropyrazino[2,3-b]pyrazin-2-yl)benzamide;-   7-(1H-indazol-5-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-((1S,3R)-3-methoxycyclopentyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-((1R,3R)-3-methoxycyclopentyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-((1R,3S)-3-methoxycyclopentyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-((1S,3S)-3-methoxycyclopentyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-indol-5-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(1H-indol-6-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(4-(2-hydroxypropan-2-yl)phenyl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-((trans-4-methoxycyclohexyl)methyl)-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((cis-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(2-methoxyethyl)-7-(4-methyl-2-(methylamino)-1H-benzo[d]imidazol-6-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(7-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(2-methoxyethyl)-7-(4-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-benzyl-7-(2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(3-fluoro-4-(4H-1,2,4-triazol-3-yl)phenyl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(3-fluoro-4-(4H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(3-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(trans-4-methoxycyclohexyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(5-fluoro-2-methyl-4-(4H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(3-fluoro-2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(2-methoxyethyl)-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans-4-methoxycyclohexyl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(cyclopentylmethyl)-7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(4-(2-hydroxypropan-2-yl)phenyl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (S)-7-(6-(1-hydroxyethyl)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (R)-7-(6-(1-hydroxyethyl)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(4-(2-hydroxypropan-2-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(4-(trifluoromethyl)benzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(3-(trifluoromethyl)benzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(3-methoxypropyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(4-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(4-methyl-2-(methylamino)-1H-benzo[d]imidazol-6-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-amino-4-methyl-1H-benzo[d]imidazol-6-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (R)-7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3-methyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   (S)-7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3-methyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,3-dimethyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-amino-4-methyl-1H-benzo[d]imidazol-6-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(2-methyl-4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   7-(4-(1H-1,2,4-triazol-5-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;-   1-(1-hydroxypropan-2-yl)-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;    and-   1-(2-hydroxyethyl)-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one,    and pharmaceutically acceptable salts, clathrates, solvates,    stereoisomers, tautomers, and prodrugs thereof.

4.4 Methods for Making TOR Kinase Inhibitors

The TOR kinase inhibitors can be obtained via standard, well-knownsynthetic methodology, see e.g., March, J. Advanced Organic Chemistry;Reactions Mechanisms, and Structure, 4th ed., 1992. Starting materialsuseful for preparing compounds of formula (III) and intermediatestherefore, are commercially available or can be prepared fromcommercially available materials using known synthetic methods andreagents.

Particular methods for preparing compounds of formula (I) are disclosedin U.S. Pat. No. 7,981,893, issued Jul. 19, 2011, incorporated byreference herein in its entirety. Particular methods for preparingcompounds of formula (II) are disclosed in U.S. Pat. No. 7,968,556,issued Jun. 28, 2011, incorporated by reference herein in its entirety.Particular methods for preparing compounds of formula (III) and (IV) aredisclosed in U.S. Publication No. 2010/0216781, filed Oct. 26, 2009, andU.S. Publication No. 2011/0137028, filed Oct. 25, 2010, incorporated byreference herein in its entirety.

4.5 Methods of Use

Provided herein are methods for treating or preventing a solid tumor,non-Hodgkin lymphoma or multiple myeloma, comprising administering aneffective amount of a TOR kinase inhibitor to a patient having a solidtumor, non-Hodgkin lymphoma or multiple myeloma. In one embodiment, thesolid tumor, non-Hodgkin lymphoma or multiple myeloma, is rapamycinresistant.

In one embodiment, the non-Hodgkin lymphoma is diffuse large B-celllymphoma (DLBCL), follicular lymphoma (FL), acute myeloid leukemia(AML), mantle cell lymphoma (MCL), or ALK⁺ anaplastic large celllymphoma. In one embodiment, the non-Hodgkin lymphoma is advanced solidnon-Hodgkin lymphoma.

In one embodiment, the solid tumor is a neuroendocrine tumor. In certainembodiments, the neuroendocrine tumor is a neuroendocrine tumor of gutorigin. In certain embodiments, the neuroendocrine tumor is ofnon-pancreatic origin. In certain embodiments, the neuroendocrine tumoris non-pancreatic of gut origin. In certain embodiments, theneuroendocrine tumor is of unknown primary origin. In certainembodiments, the neuroendocrine tumor is a symptomatic endocrineproducing tumor or a nonfunctional tumor. In certain embodiments, theneuroendocrine tumor is locally unresectable, metastatic moderate, welldifferentiated, low (grade 1) or intermediate (grade 2).

In one embodiment, the solid tumor is non-small cell lung cancer(NSCLC).

In another embodiments the solid tumor is glioblastoma multiforme (GBM).

In another embodiment, the solid tumor is hepatocellular carcinoma(HCC).

In another embodiment, the solid tumor is breast cancer. In oneembodiment, the breast cancer is estrogen receptor positive (ER+,ER+/Her2− or ER+/Her2+). In one embodiment, the breast cancer isestrogen receptor negative (ER−/Her2+). In one embodiment, the breastcancer is triple negative (TN) (breast cancer that does not express thegenes and/or protein corresponding to the estrogen receptor (ER),progesterone receptor (PR), and that does not overexpress the Her2/neuprotein).

In another embodiment, the solid tumor is colorectal cancer (CRC).

In another embodiment, the solid tumor is salivary cancer.

In another embodiment, the solid tumor is pancreatic cancer.

In another embodiment, the solid tumor is adenocystic cancer.

In another embodiment, the solid tumor is adrenal cancer.

In another embodiment, the solid tumor is esophageal cancer, renalcancer, leiomyosarcoma, or paraganglioma.

In one embodiment, the solid tumor is an advanced solid tumor.

In one embodiment, the advanced solid tumor is a neuroendocrine tumor.In certain embodiments, the neuroendocrine tumor is a neuroendocrinetumor of gut origin. In certain embodiments, the neuroendocrine tumor isof non-pancreatic origin. In certain embodiments, the neuroendocrinetumor is non-pancreatic of gut origin. In certain embodiments, theneuroendocrine tumor is of unknown primary origin. In certainembodiments, the neuroendocrine tumor is a symptomatic endocrineproducing tumor or a nonfunctional tumor. In certain embodiments, theneuroendocrine tumor is locally unresectable, metastatic moderate, welldifferentiated, low (grade 1) or intermediate (grade 2).

In one embodiment, the advanced solid tumor is non-small cell lungcancer (NSCLC).

In another embodiments the advanced solid tumor is glioblastomamultiforme (GBM).

In another embodiment, the advanced solid tumor is hepatocellularcarcinoma (HCC).

In another embodiment, the advanced solid tumor is breast cancer. In oneembodiment, the advanced solid tumor is estrogen receptor positive (ER+,ER+/Her2− or ER+/Her2+) breast cancer. In one embodiment, the advancedsolid tumor is ER+/Her2− breast cancer. In one embodiment, the advancedsolid tumor is ER+/Her2+ breast cancer.

In one embodiment, the advanced solid tumor is ER−/Her2+ breast cancer.In one embodiment, the advanced solid tumor is triple negative (TN)breast cancer.

In another embodiment, the advanced solid tumor is colorectal cancer(CRC).

In another embodiment, the advanced solid tumor is salivary cancer.

In another embodiment, the advanced solid tumor is pancreatic cancer.

In another embodiment, the advanced solid tumor is adenocystic cancer.

In another embodiment, the advanced solid tumor is adrenal cancer.

In another embodiment, the advanced solid tumor is esophageal cancer,renal cancer, leiomyosarcoma, or paraganglioma.

In one embodiment, the non-Hodgkin lymphoma is diffuse large B-celllymphoma (DLBCL).

In one embodiment, provided herein are methods for achieving a ResponseEvaluation Criteria in Solid Tumors (RECIST 1.1) of complete response,partial response or stable disease in a patient comprising administeringan effective amount of a TOR kinase inhibitor to a patient having asolid tumor, such as an advanced solid tumor. In another embodiment,provided herein are methods to increase Progression Free Survival rates,as determined by Kaplan-Meier estimates.

In one embodiment, provided herein are methods for preventing ordelaying a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) ofprogressive disease in a patient, comprising administering an effectiveamount of a TOR kinase inhibitor to a patient having a solid tumor, suchas an advanced solid tumor. In one embodiment the prevention or delayingof progressive disease is characterized or achieved by a change inoverall size of the target lesions, of for example, between −30% and+20% compared to pre-treatment. In another embodiment, the change insize of the target lesions is a reduction in overall size of more than30%, for example, more than 50% reduction in target lesion size comparedto pre-treatment. In another, the prevention is characterized orachieved by a reduction in size or a delay in progression of non-targetlesions compared to pre-treatment. In one embodiment, the prevention isachieved or characterized by a reduction in the number of target lesionscompared to pre-treatment. In another, the prevention is achieved orcharacterized by a reduction in the number or quality of non-targetlesions compared to pre-treatment. In one embodiment, the prevention isachieved or characterized by the absence or the disappearance of targetlesions compared to pre-treatment. In another, the prevention isachieved or characterized by the absence or the disappearance ofnon-target lesions compared to pre-treatment. In another embodiment, theprevention is achieved or characterized by the prevention of new lesionscompared to pre-treatment. In yet another embodiment, the prevention isachieved or characterized by the prevention of clinical signs orsymptoms of disease progression compared to pre-treatment, such ascancer-related cachexia or increased pain.

In certain embodiments, provided herein are methods for decreasing thesize of target lesions in a patient compared to pre-treatment,comprising administering an effective amount of a TOR kinase inhibitorto a patient having a solid tumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for decreasing thesize of a non-target lesion in a patient compared to pre-treatment,comprising administering an effective amount of a TOR kinase inhibitorto a patient having a solid tumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for achieving areduction in the number of target lesions in a patient compared topre-treatment, comprising administering an effective amount of a TORkinase inhibitor to a patient having a solid tumor, such as an advancedsolid tumor.

In certain embodiments, provided herein are methods for achieving areduction in the number of non-target lesions in a patient compared topre-treatment, comprising administering an effective amount of a TORkinase inhibitor to a patient having a solid tumor, such as an advancedsolid tumor.

In certain embodiments, provided herein are methods for achieving anabsence of all target lesions in a patient, comprising administering aneffective amount of a TOR kinase inhibitor to a patient having a solidtumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for achieving anabsence of all non-target lesions in a patient, comprising administeringan effective amount of a TOR kinase inhibitor to a patient having asolid tumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for treating a solidtumor, such as an advanced solid tumor, the methods comprisingadministering an effective amount of a TOR kinase inhibitor to a patienthaving a solid tumor, such as an advanced solid tumor, wherein thetreatment results in a complete response, partial response or stabledisease, as determined by Response Evaluation Criteria in Solid Tumors(RECIST 1.1).

In certain embodiments, provided herein are methods for treating a solidtumor, such as an advanced solid tumor, the methods comprisingadministering an effective amount of a TOR kinase inhibitor to a patienthaving a solid tumor, such as an advanced solid tumor, wherein thetreatment results in a reduction in target lesion size, a reduction innon-target lesion size and/or the absence of new target and/ornon-target lesions, compared to pre-treatment.

In certain embodiments, provided herein are methods for treating a solidtumor, such as an advanced solid tumor, the methods comprisingadministering an effective amount of a TOR kinase inhibitor to a patienthaving a solid tumor, such as an advanced solid tumor, wherein thetreatment results in prevention or retarding of clinical progression,such as cancer-related cachexia or increased pain.

In another embodiment, provided herein are methods for inducing atherapeutic response characterized with the International WorkshopCriteria (IWC) for NHL (see Cheson B D, Pfistner B, Juweid, M E, et. al.Revised Response Criteria for Malignant Lymphoma. J. Clin. Oncol: 2007:(25) 579-586) of a patient, comprising administering an effective amountof a TOR kinase inhibitor to a patient having non-Hodgkin lymphoma. Inanother embodiment, provided herein are methods for achieving completeremission, partial remission or stable disease, as determined by theInternational Workshop Criteria (IWC) for NHL in a patient, comprisingadministering an effective amount of a TOR kinase inhibitor to patienthaving non-Hodgkin lymphoma. In another embodiment, provided herein aremethods for achieving an increase in overall survival, progression-freesurvival, event-free survival, time to progression, disease-freesurvival or lymphoma-free survival as determined by the InternationalWorkshop Criteria (IWC) for NHL in a patient, comprising administeringan effective amount of a TOR kinase inhibitor to patient havingnon-Hodgkin lymphoma.

In another embodiment, provided herein are methods for inducing atherapeutic response assessed with the International Uniform ResponseCriteria for Multiple Myeloma (IURC) (see Durie B G M, Harousseau J- L,Miguel J S, et al. International uniform response criteria for multiplemyeloma. Leukemia, 2006; (10) 10:1-7) of a patient, comprisingadministering an effective amount of a TOR kinase inhibitor to a patienthaving multiple myeloma. In another embodiment, provided herein aremethods for achieving a stringent complete response, complete response,or very good partial response, as determined by the InternationalUniform Response Criteria for Multiple Myeloma (IURC) in a patient,comprising administering an effective amount of a TOR kinase inhibitorto patient having multiple myeloma. In another embodiment, providedherein are methods for achieving an increase in overall survival,progression-free survival, event-free survival, time to progression, ordisease-free survival in a patient, comprising administering aneffective amount of a TOR kinase inhibitor to patient having multiplemyeloma.

In another embodiment, provided herein are methods for inducing atherapeutic response assessed with the Response Assessment forNeuro-Oncology (RANO) Working Group for GBM (see Wen P., Macdonald, DR., Reardon, D A., et al. Updated response assessment criteria forhighgrade gliomas: Response assessment in neuro-oncology working group.J. Clin. Oncol. 2010; 28: 1963-1972) of a patient, comprisingadministering an effective amount of a TOR kinase inhibitor to a patienthaving glioblastoma multiforme.

In one embodiment, RANO will be used to establish the proportion ofsubjects progression-free at 6 months from Day 1 relative to efficacyevaluable subjects in the GBM type.

In another embodiment, provided herein are methods for improving theEastern Cooperative Oncology Group Performance Status (ECOG) of apatient, comprising administering an effective amount of a TOR kinaseinhibitor to a patient having a tumor, such as an advanced solid tumor.

In another embodiment, provided herein are methods for inducing atherapeutic response assessed by Positron Emission Tomography (PET)outcome of a patient, comprising administering an effective amount of aTOR kinase inhibitor to a patient having a tumor, such as an advancedsolid tumor. In certain embodiments, provided herein are methods fortreating a solid tumor, such as an advanced solid tumor, the methodscomprising administering an effective amount of a TOR kinase inhibitorto a patient having a solid tumor, such as an advanced solid tumor,wherein the treatment results in a reduction in tumor metabolicactivity, for example, as measured by PET imaging.

In another embodiment, provided herein are methods for inducing atherapeutic response assessed by a reduction in carcinoidsyndrome-related symptoms, such as diarrhea and/or flushing, and/or areduction in endocrine hormone markers, such as chromogranin, gastrin,serotonin, and/or glucagon.

In one embodiment, provided herein are methods for inhibitingphosphorylation of S6RP, 4E-BP1 and/or AKT in a patient having a solidtumor (for example, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer), non-Hodgkin lymphoma or multiple myeloma,comprising administering an effective amount of a TOR kinase inhibitorto said patient. In another embodiment, the solid tumor is esophagealcancer, renal cancer, leiomyosarcoma, or paraganglioma. In some suchembodiments, the inhibition of phosphorylation is assessed in abiological sample of the patient, such as in circulating blood and/ortumor cells, skin biopsies and/or tumor biopsies or aspirate. In suchembodiments, the amount of inhibition of phosphorylation is assessed bycomparison of the amount of phospho-S6RP, 4E-BP1 and/or AKT before andafter administration of the TOR kinase inhibitor. In certainembodiments, provided herein are methods for measuring inhibition ofphosphorylation of S6RP, 4E-BP1 or AKT in a patient having a solid tumor(for example, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer), non-Hodgkin lymphoma or multiple myeloma,comprising administering an effective amount of a TOR kinase inhibitorto said patient, measuring the amount of phosphorylated S6RP, 4E-BP1and/or AKT in said patient, and comparing said amount of phosphorylatedS6RP, 4E-BP1 and/or AKT to that of said patient prior to administrationof an effective amount of a TOR kinase inhibitor. In another embodiment,the solid tumor is esophageal cancer, renal cancer, leiomyosarcoma, orparaganglioma. In some embodiments, the inhibition of phosphorylation ofS6RP, 4E-BP1 and/or AKT is assessed in B-cells, T-cells and/ormonocytes.

In certain embodiments, provided herein are methods for inhibitingphosphorylation of S6RP, 4E-BP1 and/or AKT in a biological sample of apatient having a solid tumor (for example, a neuroendocrine tumor,non-small cell lung cancer, glioblastoma multiforme, hepatocellularcarcinoma, breast cancer, colorectal cancer, salivary cancer, pancreaticcancer, adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma ormultiple myeloma, comprising administering an effective amount of a TORkinase inhibitor to said patient and comparing the amount ofphosphorylated S6RP, 4E-BP1 and/or AKT in a biological sample of apatient obtained prior to and after administration of said TOR kinaseinhibitor, wherein less phosphorylated S6RP, 4E-BP1 and/or AKT in saidbiological sample obtained after administration of said TOR kinaseinhibitor relative to the amount of phosphorylated S6RP, 4E-BP1 and/orAKT in said biological sample obtained prior to administration of saidTOR kinase inhibitor indicates inhibition. In another embodiment, thesolid tumor is esophageal cancer, renal cancer, leiomyosarcoma, orparaganglioma. In some embodiments, the inhibition of phosphorylation ofS6RP, 4E-BP1 and/or AKT is assessed in B-cells, T-cells and/ormonocytes.

In one embodiment, provided herein are methods for inhibitingDNA-dependent protein kinase (DNA-PK) activity in a patient having asolid tumor (for example, a neuroendocrine tumor, non-small cell lungcancer, glioblastoma multiforme, hepatocellular carcinoma, breastcancer, colorectal cancer, salivary cancer, pancreatic cancer,adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma or multiplemyeloma, comprising administering an effective amount of a TOR kinaseinhibitor to said patient. In another embodiment, the solid tumor isesophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma. Insome embodiments, DNA-PK inhibition is assessed in the skin of thepatient having a solid tumor (for example, a neuroendocrine tumor,non-small cell lung cancer, glioblastoma multiforme, hepatocellularcarcinoma, breast cancer, colorectal cancer, salivary cancer, pancreaticcancer, adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma ormultiple myeloma, in one example in a UV light-irradiated skin sample ofsaid patient. In another embodiment, the solid tumor is esophagealcancer, renal cancer, leiomyosarcoma, or paraganglioma. In anotherembodiment, DNA-PK inhibition is assessed in a tumor biopsy or aspirateof a patient having a solid tumor (for example, a neuroendocrine tumor,non-small cell lung cancer, glioblastoma multiforme, hepatocellularcarcinoma, breast cancer, colorectal cancer, salivary cancer, pancreaticcancer, adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma ormultiple myeloma. In one embodiment, inhibition is assessed by measuringthe amount of phosphorylated DNA-PK S2056 (also known as pDNA-PK S2056)before and after administration of the TOR kinase inhibitor. In anotherembodiment, the solid tumor is esophageal cancer, renal cancer,leiomyosarcoma, or paraganglioma. In certain embodiments, providedherein are methods for measuring inhibition of phosphorylation of DNA-PKS2056 in a skin sample of a patient having a solid tumor (for example, aneuroendocrine tumor, non-small cell lung cancer, glioblastomamultiforme, hepatocellular carcinoma, breast cancer, colorectal cancer,salivary cancer, pancreatic cancer, adenocystic cancer or adrenalcancer), non-Hodgkin lymphoma or multiple myeloma, comprisingadministering an effective amount of a TOR kinase inhibitor to saidpatient, measuring the amount of phosphorylated DNA-PK S2056 present inthe skin sample and comparing said amount of phosphorylated DNA-PK S2056to that in a skin sample from said patient prior to administration of aneffective amount of a TOR kinase inhibitor. In another embodiment, thesolid tumor is esophageal cancer, renal cancer, leiomyosarcoma, orparaganglioma. In one embodiment, the skin sample is irradiated with UVlight.

In certain embodiments, provided herein are methods for inhibitingDNA-dependent protein kinase (DNA-PK) activity in a skin sample of apatient having a solid tumor (for example, a neuroendocrine tumor,non-small cell lung cancer, glioblastoma multiforme, hepatocellularcarcinoma, breast cancer, colorectal cancer, salivary cancer, pancreaticcancer, adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma ormultiple myeloma, comprising administering an effective amount of a TORkinase inhibitor to said patient and comparing the amount ofphosphorylated DNA-PK in a biological sample of a patient obtained priorto and after administration of said TOR kinase inhibitor, wherein lessphosphorylated DNA-PK in said biological sample obtained afteradministration of said TOR kinase inhibitor relative to the amount ofphosphorylated DNA-PK in said biological sample obtained prior toadministration of said TOR kinase inhibitor indicates inhibition. Inanother embodiment, the solid tumor is esophageal cancer, renal cancer,leiomyosarcoma, or paraganglioma.

In some embodiments, the TOR kinase inhibitor is a compound as describedherein. In one embodiment, the TOR kinase inhibitor is a compound offormula (I), (II), (III), or (IV). In one embodiment, the TOR kinaseinhibitor is a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie),(If), (Ig), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV). In oneembodiment, the TOR kinase inhibitor is a compound from Table A, B, C orD. In one embodiment, the TOR kinase inhibitor is Compound 1 (a TORkinase inhibitor set forth herein having molecular formula C₂₁H₂₇N₅O₃).In one embodiment, the TOR kinase inhibitor is Compound 2 (a TOR kinaseinhibitor set forth herein having molecular formula C₁₆H₁₆N₈O). In oneembodiment, Compound 1 is7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one.In another embodiment, Compound 2 is1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

A TOR kinase inhibitor can be combined with radiation therapy orsurgery. In certain embodiments, a TOR kinase inhibitor is administeredto patient who is undergoing radiation therapy, has previously undergoneradiation therapy or will be undergoing radiation therapy. In certainembodiments, a TOR kinase inhibitor is administered to a patient who hasundergone tumor removal surgery.

Further provided herein are methods for treating patients who have beenpreviously treated for a solid tumor (for example, a neuroendocrinetumor, non-small cell lung cancer, glioblastoma multiforme,hepatocellular carcinoma, breast cancer, colorectal cancer, salivarycancer, pancreatic cancer, adenocystic cancer or adrenal cancer),non-Hodgkin lymphoma or multiple myeloma, but are non-responsive tostandard therapies, as well as those who have not previously beentreated. In another embodiment, the solid tumor is esophageal cancer,renal cancer, leiomyosarcoma, or paraganglioma. Further provided hereinare methods for treating patients who have undergone surgery in anattempt to treat the condition at issue, as well as those who have not.Because patients with a solid tumor (for example, a neuroendocrinetumor, non-small cell lung cancer, glioblastoma multiforme,hepatocellular carcinoma, breast cancer, colorectal cancer, salivarycancer, pancreatic cancer, adenocystic cancer or adrenal cancer),non-Hodgkin lymphoma or multiple myeloma have heterogenous clinicalmanifestations and varying clinical outcomes, the treatment given to apatient may vary, depending on his/her prognosis. The skilled clinicianwill be able to readily determine without undue experimentation specificsecondary agents, types of surgery, and types of non-drug based standardtherapy that can be effectively used to treat an individual patient witha solid tumor (for example, a neuroendocrine tumor, non-small cell lungcancer, glioblastoma multiforme, hepatocellular carcinoma, breastcancer, colorectal cancer, salivary cancer, pancreatic cancer,adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma or multiplemyeloma. In another embodiment, the solid tumor is esophageal cancer,renal cancer, leiomyosarcoma, or paraganglioma.

In certain embodiments, the methods provided herein comprise the use ofa kit comprising a TOR kinase inhibitor provided herein.

In certain embodiments, provided herein are methods for treating orpreventing a solid tumor (for example, a neuroendocrine tumor, non-smallcell lung cancer, glioblastoma multiforme, hepatocellular carcinoma,breast cancer, colorectal cancer, salivary cancer, pancreatic cancer,adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma or multiplemyeloma, comprising administering an effective amount of a TOR kinaseinhibitor to a patient having a solid tumor (for example, aneuroendocrine tumor, non-small cell lung cancer, glioblastomamultiforme, hepatocellular carcinoma, breast cancer, colorectal cancer,salivary cancer, pancreatic cancer, adenocystic cancer or adrenalcancer), non-Hodgkin lymphoma or multiple myeloma, wherein said TORkinase inhibitor is a component of a kit provided herein. In anotherembodiment, the solid tumor is esophageal cancer, renal cancer,leiomyosarcoma, or paraganglioma.

In certain embodiments, provided herein are methods for monitoring theresponse to TOR kinase inhibitor treatment of a patient having a solidtumor (for example, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer), non-Hodgkin lymphoma or multiple myeloma,comprising administering an effective amount of a TOR kinase inhibitorto a patient having a solid tumor (for example, a neuroendocrine tumor,non-small cell lung cancer, glioblastoma multiforme, hepatocellularcarcinoma, breast cancer, colorectal cancer, salivary cancer, pancreaticcancer, adenocystic cancer or adrenal cancer), non-Hodgkin lymphoma ormultiple myeloma and assessing inhibition of disease progression,inhibition of tumor growth, reduction of primary and/or secondarytumor(s), relief of tumor-related symptoms, improvement in quality oflife, inhibition of tumor secreted factors (including tumor secretedhormones, such as those that contribute to carcinoid syndrome), delayedappearance of primary and/or secondary tumor(s), slowed development ofprimary and/or secondary tumor(s), decreased occurrence of primaryand/or secondary tumor(s), slowed or decreased severity of secondaryeffects of disease, arrested tumor growth and/or regression of tumors,inhibition of phosphorylation of S6RP, 4E-BP1 and/or AKT, or inhibitionof DNA-dependent protein kinase (DNA-PK) activity, wherein said TORkinase inhibitor and means for assessing treatment response arecomponents of a kit provided herein. In another embodiment, the solidtumor is esophageal cancer, renal cancer, leiomyosarcoma, orparaganglioma. Inhibition of phosphorylation of S6RP, 4E-BP1, and/or AKTcan be measured in blood, skin, tumor, and/or circulating tumor cells(CTCs) in blood by various methodology including flow cytometry, ELISA,immunohistochemistry (IHC), immunofluorescence (IF) usingphosphoraltion-specific antibodies Inhibition of DNA-PK activity can bemeasured in blood, skin, and/or circulating tumor cells (CTCs) in bloodby monitoring phosphorylation of substrates of DNA-PK, such as DNA-PKitself and XRCC4. Inhibition of DNA-PK activity can also be measured bymonitoring accumulation of double strand DNA damage in tissues and/orcells such as those mentioned above.

In further embodiments, the solid tumor (for example, a neuroendocrinetumor, non-small cell lung cancer, glioblastoma multiforme,hepatocellular carcinoma, breast cancer, colorectal cancer, salivarycancer, pancreatic cancer, adenocystic cancer or adrenal cancer),non-Hodgkin lymphoma or multiple myeloma is that in which the PI3K/mTORpathway is activated. In another embodiment, the solid tumor (esophagealcancer, renal cancer, leiomyosarcoma, or paraganglioma) is that in whichthe PI3K/mTOR pathway is activated. In certain embodiments, the solidtumor (for example, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer), non-Hodgkin lymphoma or multiple myeloma isthat in which the PI3K/mTOR pathway is activated due to PTEN loss, aPIK3CA mutation or EGFR overexpression, or a combination thereof. Inanother embodiment, the solid tumor (for example, esophageal cancer,renal cancer, leiomyosarcoma, or paraganglioma) is that in which thePI3K/mTOR pathway is activated due to PTEN loss, a PIK3CA mutation orEGFR overexpression, or a combination thereof.

4.6 Pharmaceutical Compositions and Routes of Administration

Provided herein are compositions comprising an effective amount of a TORkinase inhibitor and compositions comprising an effective amount of aTOR kinase inhibitor and a pharmaceutically acceptable carrier orvehicle. In some embodiments, the pharmaceutical composition describedherein are suitable for oral, parenteral, mucosal, transdermal ortopical administration.

The TOR kinase inhibitors can be administered to a patient orally orparenterally in the conventional form of preparations, such as capsules,microcapsules, tablets, granules, powder, troches, pills, suppositories,injections, suspensions and syrups. Suitable formulations can beprepared by methods commonly employed using conventional, organic orinorganic additives, such as an excipient (e.g., sucrose, starch,mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphateor calcium carbonate), a binder (e.g., cellulose, methylcellulose,hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone,gelatin, gum arabic, polyethyleneglycol, sucrose or starch), adisintegrator (e.g., starch, carboxymethylcellulose,hydroxypropylstarch, low substituted hydroxypropylcellulose, sodiumbicarbonate, calcium phosphate or calcium citrate), a lubricant (e.g.,magnesium stearate, light anhydrous silicic acid, talc or sodium laurylsulfate), a flavoring agent (e.g., citric acid, menthol, glycine ororange powder), a preservative (e.g, sodium benzoate, sodium bisulfite,methylparaben or propylparaben), a stabilizer (e.g., citric acid, sodiumcitrate or acetic acid), a suspending agent (e.g., methylcellulose,polyvinyl pyrroliclone or aluminum stearate), a dispersing agent (e.g.,hydroxypropylmethylcellulose), a diluent (e.g., water), and base wax(e.g., cocoa butter, white petrolatum or polyethylene glycol). Theeffective amount of the TOR kinase inhibitor in the pharmaceuticalcomposition may be at a level that will exercise the desired effect; forexample, about 0.005 mg/kg of a patient's body weight to about 10 mg/kgof a patient's body weight in unit dosage for both oral and parenteraladministration.

The dose of a TOR kinase inhibitor to be administered to a patient israther widely variable and can be patient to the judgment of ahealth-care practitioner. In general, the TOR kinase inhibitors can beadministered one to four times a day in a dose of about 0.005 mg/kg of apatient's body weight to about 10 mg/kg of a patient's body weight in apatient, but the above dosage may be properly varied depending on theage, body weight and medical condition of the patient and the type ofadministration. In one embodiment, the dose is about 0.01 mg/kg of apatient's body weight to about 5 mg/kg of a patient's body weight, about0.05 mg/kg of a patient's body weight to about 1 mg/kg of a patient'sbody weight, about 0.1 mg/kg of a patient's body weight to about 0.75mg/kg of a patient's body weight or about 0.25 mg/kg of a patient's bodyweight to about 0.5 mg/kg of a patient's body weight. In one embodiment,one dose is given per day In another embodiment, two doses are given perday. In any given case, the amount of the TOR kinase inhibitoradministered will depend on such factors as the solubility of the activecomponent, the formulation used and the route of administration.

In another embodiment, provided herein are methods for the treatment orprevention of a disease or disorder comprising the administration ofabout 0.375 mg/day to about 750 mg/day, about 0.75 mg/day to about 375mg/day, about 3.75 mg/day to about 75 mg/day, about 7.5 mg/day to about55 mg/day or about 18 mg/day to about 37 mg/day of a TOR kinaseinhibitor to a patient in need thereof. In a particular embodiment, themethods disclosed herein comprise the administration of 15 mg/day, 30mg/day, 45 mg/day or 60 mg/day of a TOR kinase inhibitor to a patient inneed thereof. In another, the methods disclosed herein compriseadministration of 0.5 mg/day, 1 mg/day, 2 mg/day, 4 mg/day, 8 mg/day, 16mg/day, 20 mg/day, 25 mg/day, 30 mg/day or 40 mg/day of a TOR kinaseinhibitor to a patient in need thereof.

In another embodiment, provided herein are methods for the treatment orprevention of a disease or disorder comprising the administration ofabout 0.1 mg/day to about 1200 mg/day, about 1 mg/day to about 100mg/day, about 10 mg/day to about 1200 mg/day, about 10 mg/day to about100 mg/day, about 100 mg/day to about 1200 mg/day, about 400 mg/day toabout 1200 mg/day, about 600 mg/day to about 1200 mg/day, about 400mg/day to about 800 mg/day or about 600 mg/day to about 800 mg/day of aTOR kinase inhibitor to a patient in need thereof. In a particularembodiment, the methods disclosed herein comprise the administration of0.1 mg/day, 0.5 mg/day, 1 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, 30mg/day, 40 mg/day, 45 mg/day, 50 mg/day, 60 mg/day, 75 mg/day, 100mg/day, 125 mg/day, 150 mg/day, 200 mg/day, 250 mg/day, 300 mg/day, 400mg/day, 600 mg/day or 800 mg/day of a TOR kinase inhibitor to a patientin need thereof.

In another embodiment, provided herein are unit dosage formulations thatcomprise between about 0.1 mg and about 2000 mg, about 1 mg and 200 mg,about 35 mg and about 1400 mg, about 125 mg and about 1000 mg, about 250mg and about 1000 mg, or about 500 mg and about 1000 mg of a TOR kinaseinhibitor.

In a particular embodiment, provided herein are unit dosage formulationcomprising about 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20mg, 30 mg, 45 mg, 50 mg, 60 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg,250 mg, 300 mg, 400 mg, 600 mg or 800 mg of a TOR kinase inhibitor.

In another embodiment, provided herein are unit dosage formulations thatcomprise 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg,250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, 1000 mg or 1400mg of a TOR kinase inhibitor. In a particular embodiment, providedherein are unit dosage formulations that comprise 10 mg, 15 mg, 20 mg,30 mg, 45 mg or 60 mg of a TOR kinase inhibitor.

A TOR kinase inhibitor can be administered once, twice, three, four ormore times daily.

A TOR kinase inhibitor can be administered orally for reasons ofconvenience. In one embodiment, when administered orally, a TOR kinaseinhibitor is administered with a meal and water. In another embodiment,the TOR kinase inhibitor is dispersed in water or juice (e.g., applejuice or orange juice) and administered orally as a suspension. Inanother embodiment, when administered orally, a TOR kinase inhibitor isadministered in a fasted state.

The TOR kinase inhibitor can also be administered intradermally,intramuscularly, intraperitoneally, percutaneously, intravenously,subcutaneously, intranasally, epidurally, sublingually, intracerebrally,intravaginally, transdermally, rectally, mucosally, by inhalation, ortopically to the ears, nose, eyes, or skin. The mode of administrationis left to the discretion of the health-care practitioner, and candepend in-part upon the site of the medical condition.

In one embodiment, provided herein are capsules containing a TOR kinaseinhibitor without an additional carrier, excipient or vehicle.

In another embodiment, provided herein are compositions comprising aneffective amount of a TOR kinase inhibitor and a pharmaceuticallyacceptable carrier or vehicle, wherein a pharmaceutically acceptablecarrier or vehicle can comprise an excipient, diluent, or a mixturethereof. In one embodiment, the composition is a pharmaceuticalcomposition.

The compositions can be in the form of tablets, chewable tablets,capsules, solutions, parenteral solutions, troches, suppositories andsuspensions and the like. Compositions can be formulated to contain adaily dose, or a convenient fraction of a daily dose, in a dosage unit,which may be a single tablet or capsule or convenient volume of aliquid. In one embodiment, the solutions are prepared from water-solublesalts, such as the hydrochloride salt. In general, all of thecompositions are prepared according to known methods in pharmaceuticalchemistry. Capsules can be prepared by mixing a TOR kinase inhibitorwith a suitable carrier or diluent and filling the proper amount of themixture in capsules. The usual carriers and diluents include, but arenot limited to, inert powdered substances such as starch of manydifferent kinds, powdered cellulose, especially crystalline andmicrocrystalline cellulose, sugars such as fructose, mannitol andsucrose, grain flours and similar edible powders.

Tablets can be prepared by direct compression, by wet granulation, or bydry granulation. Their formulations usually incorporate diluents,binders, lubricants and disintegrators as well as the compound. Typicaldiluents include, for example, various types of starch, lactose,mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such assodium chloride and powdered sugar. Powdered cellulose derivatives arealso useful. In one embodiment, the pharmaceutical composition islactose-free. Typical tablet binders are substances such as starch,gelatin and sugars such as lactose, fructose, glucose and the like.Natural and synthetic gums are also convenient, including acacia,alginates, methylcellulose, polyvinylpyrrolidine and the like.Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

A lubricant might be necessary in a tablet formulation to prevent thetablet and punches from sticking in the die. The lubricant can be chosenfrom such slippery solids as talc, magnesium and calcium stearate,stearic acid and hydrogenated vegetable oils. Tablet disintegrators aresubstances that swell when wetted to break up the tablet and release thecompound. They include starches, clays, celluloses, algins and gums.More particularly, corn and potato starches, methylcellulose, agar,bentonite, wood cellulose, powdered natural sponge, cation-exchangeresins, alginic acid, guar gum, citrus pulp and carboxymethyl cellulose,for example, can be used as well as sodium lauryl sulfate. Tablets canbe coated with sugar as a flavor and sealant, or with film-formingprotecting agents to modify the dissolution properties of the tablet.The compositions can also be formulated as chewable tablets, forexample, by using substances such as mannitol in the formulation.

When it is desired to administer a TOR kinase inhibitor as asuppository, typical bases can be used. Cocoa butter is a traditionalsuppository base, which can be modified by addition of waxes to raiseits melting point slightly. Water-miscible suppository bases comprising,particularly, polyethylene glycols of various molecular weights are inwide use.

The effect of the TOR kinase inhibitor can be delayed or prolonged byproper formulation. For example, a slowly soluble pellet of the TORkinase inhibitor can be prepared and incorporated in a tablet orcapsule, or as a slow-release implantable device. The technique alsoincludes making pellets of several different dissolution rates andfilling capsules with a mixture of the pellets. Tablets or capsules canbe coated with a film that resists dissolution for a predictable periodof time. Even the parenteral preparations can be made long-acting, bydissolving or suspending the TOR kinase inhibitor in oily or emulsifiedvehicles that allow it to disperse slowly in the serum.

4.7. Kits

In certain embodiments, provided herein are kits comprising a TOR kinaseinhibitor. In particular embodiments, provided herein are kitscomprising a unit dosage form comprising a TOR kinase inhibitor in asealed container, wherein the unit dosage form comprises about 1 mg toabout 100 mg of a TOR kinase inhibitor. In particular embodiments,provided herein are kits comprising a unit dosage form comprising a TORkinase inhibitor in a sealed container, wherein the unit dosage formcomprises about 5 mg, about 20 mg or about 50 mg of a TOR kinaseinhibitor.

In other embodiments, provide herein are kits comprising a TOR kinaseinhibitor and means for monitoring patient response to administration ofsaid TOR kinase inhibitor. In certain embodiments, the patient has asolid tumor, non-Hodgkin lymphoma or multiple myeloma. In particularembodiments, the patient response measured is inhibition of diseaseprogression, inhibition of tumor growth, reduction of primary and/orsecondary tumor(s), relief of tumor-related symptoms, improvement inquality of life, inhibition of tumor secreted factors (including tumorsecreted hormones, such as those that contribute to carcinoid syndrome),delayed appearance of primary and/or secondary tumor(s), sloweddevelopment of primary and/or secondary tumor(s), decreased occurrenceof primary and/or secondary tumor(s), slowed or decreased severity ofsecondary effects of disease, arrested tumor growth and/or regression oftumors.

In other embodiments, provide herein are kits comprising a TOR kinaseinhibitor and means for monitoring patient response to administration ofsaid TOR kinase inhibitor, wherein said response is Response EvaluationCriteria in Solid Tumors (RECIST 1.1), International Workshop Criteria(IWC) for NHL, International Uniform Response Criteria for MultipleMyeloma (IURC), Eastern Cooperative Oncology Group Performance Status(ECOG) or Response Assessment for Neuro-Oncology (RANO) Working Groupfor GBM.

In other embodiments, provided herein are kits comprising a TOR kinaseinhibitor and means for measuring the amount of inhibition ofphosphorylation of S6RP, 4E-BP1 and/or AKT in a patient. In certainembodiments, the kits comprise means for measuring inhibition ofphosphorylation of S6RP, 4E-BP1 and/or AKT in circulating blood or tumorcells and/or skin biopsies or tumor biopsies/aspirates of a patient. Incertain embodiments, provided herein are kits comprising a TOR kinaseinhibitor and means for measuring the amount of inhibition ofphosphorylation as assessed by comparison of the amount of phospho-S6RP,4E-BP1 and/or AKT before, during and/or after administration of the TORkinase inhibitor. In certain embodiments, the patient has a solid tumor(for example, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer), non-Hodgkin lymphoma or multiple myeloma. Inanother embodiment, the solid tumor is esophageal cancer, renal cancer,leiomyosarcoma, or paraganglioma.

In other embodiments, provided herein are kits comprising a TOR kinaseinhibitor and means for measuring the amount of inhibition ofDNA-dependent protein kinase (DNA-PK) activity in a patient. In certainembodiments, the kits comprise means for measuring the amount ofinhibition of DNA-dependent protein kinase (DNA-PK) activity in a skinsample and/or a tumor biopsy/aspirate of a patient. In one embodiment,the kits comprise a means for measuring the amount of pDNA-PK S2056 in askin sample and/or a tumor biopsy/aspirate of a patient. In oneembodiment, the skin sample is irradiated by UV light. In certainembodiments, provided herein are kits comprising a TOR kinase inhibitorand means for measuring the amount of inhibition of DNA-dependentprotein kinase (DNA-PK) activity before, during and/or afteradministration of the TOR kinase inhibitor. In certain embodiments,provided herein are kits comprising a TOR kinase inhibitor and means formeasuring the amount of phosphorylated DNA-PK S2056 before, duringand/or after administration of the TOR kinase inhibitor. In certainembodiments, the patient has a solid tumor (for example, aneuroendocrine tumor, non-small cell lung cancer, glioblastomamultiforme, hepatocellular carcinoma, breast cancer, colorectal cancer,salivary cancer, pancreatic cancer, adenocystic cancer or adrenalcancer), non-Hodgkin lymphoma or multiple myeloma. In anotherembodiment, the solid tumor is esophageal cancer, renal cancer,leiomyosarcoma, or paraganglioma.

Inhibition of phosphorylation of S6RP, 4E-BP1, and/or AKT can bemeasured in blood, skin, tumor, and/or circulating tumor cells (CTCs) inblood by various methodology including flow cytometry, ELISA,immunohistochemistry (IHC) using phosphorylation-specific antibodies.Inhibition of DNA-PK activity can be measured in blood, skin, and/orcirculating tumor cells (CTCs) in blood by monitoring phosphorylation ofsubstrates of DNA-PK, such as DNA-PK itself and XRCC4. Inhibition ofDNA-PK activity can also be measured by monitoring accumulation ofdouble strand DNA damage in tissues and/or cells such as those mentionedabove.

In certain embodiments, the kits provided herein comprise an amount of aTOR kinase inhibitor effective for treating or preventing a solid tumor(for example, a neuroendocrine tumor, non-small cell lung cancer,glioblastoma multiforme, hepatocellular carcinoma, breast cancer,colorectal cancer, salivary cancer, pancreatic cancer, adenocysticcancer or adrenal cancer), non-Hodgkin lymphoma or multiple myeloma. Inanother embodiment, the solid tumor is esophageal cancer, renal cancer,leiomyosarcoma, or paraganglioma. In certain embodiments, the kitsprovided herein comprise a TOR kinase inhibitor having the molecularformula C₁₆H₁₆N₈O. In certain embodiments, the kits provided hereincomprise Compound 1.

In certain embodiments, the kits provided herein further compriseinstructions for use, such as for administering a TOR kinase inhibitorand/or monitoring patient response to administration of a TOR kinaseinhibitor.

5. EXAMPLES 5.1 Biological Examples 5.1.1 Biochemical Assays

mTOR HTR-FRET Assay.

The following is an example of an assay that can be used to determinethe TOR kinase inhibitory activity of a test compound. TOR kinaseinhibitors were dissolved in DMSO and prepared as 10 mM stocks anddiluted appropriately for the experiments. Reagents were prepared asfollows:

“Simple TOR buffer” (used to dilute high glycerol TOR fraction): 10 mMTris pH 7.4, 100 mM NaCl, 0.1% Tween-20, 1 mM DTT. Invitrogen mTOR(cat#PV4753) was diluted in this buffer to an assay concentration of0.200 μg/mL.

ATP/Substrate solution: 0.075 mM ATP, 12.5 mM MnCl₂, 50 mM Hepes, pH7.4, 50 mM β-GOP, 250 nM Microcystin LR, 0.25 mM EDTA, 5 mM DTT, and 3.5μg/mL GST-p70S6.

Detection reagent solution: 50 mM HEPES, pH 7.4, 0.01% Triton X-100,0.01% BSA, 0.1 mM EDTA, 12.7 μg/mL Cy5-αGST Amersham (Cat#PA92002V), 9ng/mL α-phospho p70S6 (Thr389) (Cell Signaling Mouse Monoclonal #9206L),627 ng/mL α-mouse Lance Eu (Perkin Elmer Cat#AD0077).

To 20 μL of the Simple mTor buffer is added 0.5 μL of test compound inDMSO. To initiate the reaction 5 μL of ATP/Substrate solution was addedto 20 μL of the Simple TOR buffer solution (control) and to the compoundsolution prepared above. The assay was stopped after 60 min by adding 5μL of a 60 mM EDTA solution; 10 μL of detection reagent solution wasthen added and the mixture was allowed to sit for at least 2 hoursbefore reading on a Perkin-Elmer Envision Microplate Reader set todetect LANCE Eu TR-FRET (excitation at 320 nm and emission at 495/520nm).

TOR kinase inhibitors were tested in the mTor HTR-FRET assay and werefound to have activity therein, with certain compounds having an IC₅₀below 10 μM in the assay, with some compounds having an IC₅₀ between and0.005 nM and 250 nM, others having an IC₅₀ between and 250 nM and 500nM, others having an IC₅₀ between 500 nM and 1 μM, and others having anIC₅₀ between 1 μM and 10 μM.

DNA-PK Assay.

DNA-PK assays were performed using the procedures supplied in thePromega DNA-PK assay kit (catalog #V7870). DNA-PK enzyme was purchasedfrom Promega (Promega cat#V5811).

Selected TORKi have, or are expected to have, an IC₅₀ below 10 μM inthis assay, with some TORKi having an IC₅₀ below 1 μM, and others havingan IC₅₀ below 0.10 μM.

5.1.2 Cell Based Assays

Materials and Methods.

Cell lines and cell culture: Human glioblastoma and lung cancer celllines are purchased from American Type Culture Collection (ATCC) andmaintained in RPMI 1640 plus 10% bovine calf serum (FCS) or recommendedspecial culture medium. The non-small cell lung cancer cells can includethe following cell lines NCI-H460, NCI-H838, NCI-H1792, NCI-H520,NCI-H1993, NCI-H1944, NCI-H1975, NCI-H1395, A549, NCI-H2122, NCI-H1703,NCI-H1299, NCI-H647, NCI-H358, SK-LU-1, NCI-H1734, NCI-H1693, NCI-H226,NCI-H23, NCI-H2030, NCI-H1755, Calu-6, Calu-1, SW1573, NCI-H2009,NCI-H441, HOP92, NCI-H2110, NCI-H727, NCI-H1568, Calu-3, NCI-H2228,NCI-H2444, NCI-H1563, NCI-H1650, NCI-H1437, NCI-H650, NCI-H1838,NCI-H2291, NCI-H28 and NCI-H596. Additional cell lines that TOR kinaseinhibitors can be tested against include HT-3, HeLaSF, Hela S3,SKG-IIIa, SiHa, MS751, BOKU, C-33-A, C-4-II, Ca-Ski, DoTc2-4510, ME-180,OMC-1, SW756, and TC-YIK.

Glioblastoma cell lines obtained from, for example, ATCC (for exampleA-172, T98G, DBTRG-05MG, M059K, M059J, LN18, LN-229, TIME, G44, and U87MG, U-118 MG, U-138 MG cells) can be engineered to express the EGFRvIIImutation or overexpress EGFR by methods known in the art. The cell linescan also been engineered to express EGFRvIII or overexpress EGFR, andexpress PTEN simultaneously. Additionally, cell lines with EGFRoverexpression and EGFRvIII mutation can be established from humantumors (patient samples). (See for example A. Lal et al, Cancer Res,62:3335 (2002), J. J. Kelly et al, Stem Cells 27(8):1722 (2009), M. Y.Wang et al, Cancer Res. 66:7864 (2006)).

Cell Viability Assay for NSCLC Lines.

Cell viability was assessed using the Cell Titer-Glo Luminescent CellViability from Promega. The assay is a homogenous method of determiningthe number of viable cells in culture based on quantitation of theadenosine triphosphate (ATP) present, an indicator of metabolicallyactive cells. The homogenous assay procedure involves adding the singlereagent (CellTiter-Glo Reagent) directly to cells cultured inserum-supplemented medium. Cells were plated into a 96-well flat bottomplate (Costar Catalog Number 33595) at densities that were previouslyoptimized for each cell line. The cells were incubated overnight in 5%CO₂ at 37° C. The following day, compound dilutions were prepared andall concentrations were assayed in triplicate. The cells were incubatedwith Compound 1 (0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM and 30 μMfor NSCLC cells) in 5% CO₂ at 37° C. for 3 days. After a 3-dayincubation period, 100 μL of CellTiter-Glo reagent was added to eachwell for 2 minutes with shaking and further incubated for 10 minutes (noshaking) at room temperature to stabilize the signal. The luminescencewas measured on the VICTOR X2 multilabel plate reader. The percentgrowth inhibition was calculated using the DMSO control in the sameplate (no compound) response as 100% cell growth. The average valuesfrom triplicates were plotted to obtain IC₅₀ values using software XLfitfrom IDBS. The formula used for determining IC₅₀ in XLfit was modelnumber 205, which utilizes a 4 Parameter Logistic Model or SigmoidalDose-Response Model to calculate the IC₅₀ values. All IC₅₀ values arereported as an average from either two independent experiments or asingle experiment. Results for Compound 1 for selected NSCLC cells linesare set forth in Table 1.

TABLE 1 NSCLC Cell Line IC₅₀ μM NCI-H1568 0.226 NCI-H2228 0.264 NCI-H7270.288 Calu-3 0.302 NCI-H460 0.37 NCI-H838 0.39 NCI-H2110 0.456 NCI-H5200.499 NCI-H520 0.50 NCI-H1993 0.50 NCI-H1792 0.54 NCI-H1944 0.55NCI-H1395 0.60 NCI-H549 0.77 NCI-H2444 0.778 NCI-H2122 0.90 NCI-H17030.92 NCI-H1975 0.96 NCI-H1437 0.975 NCI-H1299 1.23 NCI-H647 1.36NCI-H358 1.42 SK-LU-1 1.44 NCI-H1734 1.55 NCI-H1693 1.58 NCI-H226 1.75HOP62 2.007 NCI-H596 2.196 NCI-H23 2.21 NCI-H2030 2.23 NCI-H1755 3.03Calu-6 4.52 Calu-1 4.74 SW1573 7.21 NCI-H2009 26.01 NCI-H441 >30HOP92 >30 NCI-H1563 >30 NCI-H1650 >30 NCI-H1838 >30 NCI-H2291 >30NCI-H28 >30 NCI-H650 >30

Growth Inhibition Assay for HCC and NHL Lines.

All HCC and NHL cell lines were maintained and tested in the culturemedia indicated in Table 2 and 3. The seeding density for each cell linewas optimized to ensure assay linearity in 384-well plates.

Compound 1 was dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 mMstock solution. A serial titration was performed to produce a workingconcentration range of 1.5 μM to 10 mM. Aliquots to produce finalconcentrations of 1.5 nM to 10 μM were spotted via an acoustic dispenser(EDC ATS-100) into an empty 384-well plate. Compound 1 was spotted in a10-point serial dilution fashion (3-fold dilution) in duplicate withinthe plate. The DMSO concentration was kept constant for a final assayconcentration of 0.1% DMSO. Plates were replicated for use withdifferent cell lines and testing periods. After compound platereplication, all plates were sealed (Agilent ThermoLoc) and stored at−20° C. for up to 1 month. Repeat testing of Compound 1 in the controlcell line (A549) resulted in consistent GI₅₀ and IC₅₀ values regardlessof plate replication sequence or storage time at −20° C., suggestingCompound 1 is stable under the storage conditions used in the currentstudy for at least 1 month. When ready for testing, plates were removedfrom the freezer, thawed, and unsealed just prior to the addition of thetest cells. Prior to testing, cells were grown and expanded in cultureflasks to provide sufficient amounts of starting material. Cells werethen diluted to the appropriate densities and added directly to thecompound-spotted 384-well plates. Cells were allowed to grow for 96hours at 37° C./5% CO₂. At the time when compound was added (t₀),initial cell number was assessed via a viability assay (Cell Titer-Glo)by quantifying the level of luminescence generated by ATP present inviable cells. After 96 hours, cell viability of compound-treated cellswas assessed via Cell Titer-Glo and luminescence measurement. Cell lineswere assayed for growth inhibition by Compound 1 in at least 3independent tests. A control cell line (the lung tumor cell line, A549)was included in each of the assays. The compound response against thiscontrol cell line was monitored closely to enable comparison of the datagenerated through the assay period. All data were normalized andpresented as a percentage of the DMSO-treated cells. Results were thenexpressed as a GI₅₀ value. The GI₅₀ value corrects for the cell count attime zero. In addition, the IC₅₀ value of Compound 1 for each cell linewas calculated. Results for Compound 1 for selected HCC cell lines areset forth in Table 2.

TABLE 2 HCC Cell Line GI₅₀ μM IC₅₀ μM Growth Medium Hep3B 0.26 ± 0.070.34 ± 0.11 DMEM + 10% FBS HepG2 0.24 ± 0.06 0.32 ± 0.13 DMEM + 10% FBSHuH-7 0.07 ± 0.03 0.10 ± 0.04 DMEM + 10% FBS PLC-PRF-5 0.31 ± 0.07 0.43± 0.07 DMEM + 10% FBS SK-HEP-1 0.27 ± 0.04 0.33 ± 0.07 DMEM + 10% FBSSNU-182 0.08 ± 0.03 0.26 ± 0.1  RPMI 1640 + 10% FBS SNU-387 1.26 ± 0.472.47 ± 0.93 RPMI 1640 + 10% FBS SNU-398 0.28 ± 0.06 0.29 ± 0.05 RPMI1640 + 10% FBS SNU-423 0.30 ± 0.05 0.48 ± 0.06 RPMI 1640 + 10% FBSSNU-449 0.37 ± 0.07 0.48 ± 0.11 RPMI 1640 + 10% FBS SNU-475 0.46 ± 0.090.69 ± 0.14 RPMI 1640 + 10% FBS DMEM = Dulbecco's Modified Eagle'sMedium; FBS = fetal bovine serum.

Apoptosis Assay for NHL Lines.

Prior to testing, cells were grown and expanded in culture flasks toprovide sufficient amounts of starting material. Cells were then dilutedto their desired densities and added directly to compound-spotted384-well plates. Cells were allowed to grow for 24 hours in 5% CO₂ at37° C. The apoptotic response was assessed by quantifying the activitiesof caspase 3 and caspase 7 (Caspase 3/7-Glo) in treated cells andcontrol cells at the 24-hour time point. All data was normalized andrepresented as a value relative to the DMSO-treated cells. Results werethen expressed as CalX, which is the minimum compound concentrationrequired to double the levels of caspase 3/7 relative to those of theDMSO-treated cells during their treatment period.

Results for Compound 1 for inhibition of proliferation of selected NHLcell lines are set forth in Table 3 and for Compound 1 and Compound 2 inFIG. 1A and FIG. 1B, and results for Compound 1 and Compound 2 forapoptosis of selected NHL cell lines are set forth in FIG. 2. As can beseen, Compound 1 and Compound 2 induce apoptosis in multiple NHL celllines in vitro.

TABLE 3 Proliferation (n ≧ 3) Apoptosis (n = 1) Cell Line DiseaseSubtype GI₅₀ IC₅₀ CalX Apoptotic KARPAS-422 NHL DLBCL 0.02 ± 0.01 0.02 ±0.01 5.16 N/Y RIVA NHL DLBCL 0.02 ± 0.01  0.1 ± 0.05 3.84 N/Y KASUMI-1Leukemia M-AML 0.04 ± 0.02 0.12 ± 0.03 6.52 N/Y WSU-NHL NHL FL 0.05 ±0   0.07 ± 0   0.16 Y KG-1 Leukemia M-AML 0.06 ± 0.02 0.37 ± 0.04 10 NJEKO-1 NHL MCL 0.07 ± 0.04  0.1 ± 0.05 0.56 Y Toledo NHL DLBCL 0.07 ±0.02 0.44 ± 0.02 3.48 N/Y KARPAS-1106P NHL DLBCL 0.07 ± 0.03 0.07 ± 0.030.25 Y NU-DHL-1 NHL DLBCL 0.08 ± 0.03 0.11 ± 0.05 0.41 Y RC-K8 NHL DLBCL0.08 ± 0.01 0.15 ± 0.03 6.51 N/Y SU-DHL-8 NHL DLBCL 0.08 ± 0.04  0.1 ±0.04 0.07 Y Pfeiffer NHL DLBCL 0.09 ± 0.04 0.19 ± 0.07 10 N WSU-DLCL2NHL DLBCL 0.09 ± 0.02 0.09 ± 0.02 0.19 Y MOLM-13 Leukemia M-AML 0.11 ±0.02 0.14 ± 0.02 7.24 N/Y SU-DHL-16 NHL DLBCL 0.11 ± 0.02 0.11 ± 0.020.11 Y HT NHL DLBCL 0.11 ± 0.04 0.17 ± 0.05 5.62 N/Y U-2940 NHL DLBCL0.11 ± 0.07 0.18 ± 0.1  0.43 Y SU-DHL-4 NHL DLBCL 0.11 ± 0.04 0.12 ±0.05 5.15 N/Y DOHH-2 NHL FL 0.13 ± 0.02 0.16 ± 0.03 0.14 Y OCI-LY-10 NHLDLBCL 0.14 ± 0.04 0.19 ± 0.04 0.7 Y DB NHL DLBCL 0.15 ± 0.1  0.17 ± 0.095.44 N/Y WSU-FSCCL NHL FL 0.16 ± 0.04 0.19 ± 0.04 0.16 Y SU-DHL-6 NHLDLBCL 0.16 ± 0.04  0.2 ± 0.06 10 N SC-1 NHL FL 0.18 ± 0.01  0.2 ± 0.0110 N OCI-LY-7 NHL DLBCL 0.19 ± 0.03 0.25 ± 0.03 0.07 Y SU-DHL-10 NHLDLBCL  0.2 ± 0.02  0.2 ± 0.03 0.54 Y REC-1 NHL MCL  0.2 ± 0.04 0.26 ±0.05 0.79 Y OCI-LY-3 NHL DLBCL 0.21 ± 0.06 0.29 ± 0.07 0.67 Y OCI-LY-19NHL DLBCL 0.22 ± 0.06 0.35 ± 0.08 1.13 Y THP-1 Leukemia M-AML 0.23 ±0.11 0.57 ± 0.16 7.57 N/Y SU-DHL-5 NHL DLBCL 0.23 ± 0.13 0.26 ± 0.140.59 Y HL-60 Leukemia M-AML 0.24 ± 0.06 0.38 ± 0.13 10 N JVM-2 NHL MCL0.26 ± 0.05 0.44 ± 0.18 3.2 N/Y Farage NHL DLBCL 0.27 ± 0.03 0.28 ± 0.040.47 Y U-2932 NHL DLBCL  0.3 ± 0.03 0.45 ± 0.01 2.04 Y SU-DHL-1 ALCLT-cell 0.32 ± 0.02 0.39 ± 0.03 10 N KARPAS-299 ALCL T-cell 0.33 ± 0.120.47 ± 0.22 9.61 N/Y Mino NHL MCL 0.37 ± 0.13 0.48 ± 0.1  0.53 YGranta-519 NHL MCL 0.38 ± 0.08 0.96 ± 0.1  10 N JVM-13 NHL MCL 1.77 ±1.61 3.49 ± 2.48 4.27 N/Y

Cell Proliferation and Viability Assay for MM Lines.

Prior to use, cells were washed and maintained in medium for 5 days.Cells were seeded out at a density of 0.3×10⁶ cells/mL in a 12-wellplate and treated with Compound 1 or Compound 2 for 5 days. 7AADdetection fluorescence-activated cell sorting (FACS) flow cytometry wasused in the analysis. Results are shown in FIGS. 3-6 and Tables 4-5.

TABLE 4 Proliferation Cell Line IC₅₀ μM Compound 1 IC₅₀ μM Compound 2H929 0.19 0.13 KMS34 0.1 0.07 DF15 0.1 0.05 LP-1 0.22 0.16 RPMI 0.170.15 MM1.S 0.44 0.0.37 CAG 0.8 0.41 Anbl 6 0.37 U266 0.56 0.32 OPM2 0.330.37

TABLE 5 Viability Cell Line IC₅₀ μM Compound 1 IC₅₀ μM Compound 2 H9290.73 μM 0.40 μM KMS34 0.42 0.12 DF15 0.85 0.57 LP-1 0.83 RPMI 1.1 0.45MM1.S 1.01 0.85 CAG 2.6 1.5 Anbl 6 0.78 U266 4.29 OPM2 0.6 0.51

Growth Inhibition Assay for Breast Cancer (BC) (Compound 1).

All breast cancer cell lines were maintained and tested in appropriateculture media. The seeding density for each cell line was optimized toensure assay linearity in 384-well plates.

Increasing concentrations of Compound 1 were spotted via an acousticdispenser (EDC ATS-100) into an empty 384-well plate. Compound 1 wasspotted in a 10-point serial dilution fashion (3-fold dilution) induplicate within the plate. The dimethyl sulfoxide (DMSO) concentrationwas kept constant for a final assay concentration of 0.1% DMSO. Plateswere replicated for use against different cell lines and testingperiods. After compound plate replication, all plates were sealed(Agilent ThermoLoc) and stored at −20° C. for up to 1 month. When readyfor testing, plates were removed from the freezer, thawed, and unsealedjust prior to the addition of the test cell.

Prior to testing, cells were grown and expanded in culture flasks toprovide sufficient amounts of starting material. Cells were then dilutedto their desired densities and added directly to the Compound 1-spotted384-well plates. Cells were allowed to grow for 96 hours at 37° C./5%CO₂. At the time of setup (t₀), initial cell number was assessed via aviability assay (Cell Titer-Glo) and read for luminescence. After 96hours, cell viability of Compound 1-treated cells was assessed via CellTiter-Glo and read for luminescence.

Cell lines were assayed for growth inhibition by Compound 1 for at leasttwo independent tests. All data was normalized and represented as apercentage of the DMSO-treated control cells. Results were thenexpressed as a GI₅₀, which is the compound concentration required toinhibit cell growth in treated cells to 50% of the growth of theuntreated control cells during the 96 hours of treatment (Table 6). Thepotency of Compound 1 in different subtypes of breast cancer cell linesis shown in FIG. 7A, while the correlation of Compound 1 sensitivity toER, HER, PIK3CA, and TP53 status is shown in FIG. 7B. As can be seenfrom the data, the potency of Compound 1 strongly correlates withluminal cell type in breast cancer.

TABLE 6 Breast Cancer Molec. Tumor GI₅₀ Cell Line ER Her2 SubtypeSubtype PTEN PIK3CA TP53 (uM) SD BT-483 + − Luminal ER+ + E542K M246I or0.0217 mut HCC1500 + − Luminal ER+ + WT WT 0.0248 0.0045 ZR-75-1 + −Luminal ER+ − WT WT 0.0321 0.0098 MDA-MB- + − Luminal ER+ + WT WT 0.04080.0332 175-VII T47D + − Luminal ER+ + H1047R L194F 0.0553 0.0196EFM-19 + − Luminal ER+ + H1047L H193R 0.0572 0.0171 KPL-1 + − LuminalER+ + E545K WT 0.0973 0.0071 HCC1428 + − Luminal ER+ + WT WT 0.09840.0095 MDA-MB- + − Luminal ER+ + WT E285K or 0.101 0.0423 134-VI WTCAMA-1 + − Luminal ER+ + WT R280T 0.1458 0.0899 MDA-MB- + − Luminal ER+− WT Y236C 0.1691 0.0192 415 MCF7 + − Luminal ER+ + E545K WT 0.18070.0909 HCC202 − + Luminal Her2+ + E545K 283 > FS 0.0201 0.0196UACC-812 + + Luminal Her2+ + WT WT 0.0478 0.016 ZR-75-30 + + LuminalHer2+ + WT WT 0.0634 0.0098 MDA-MB- + + Luminal Her2+ + E545K, E56X or0.0657 0.0345 361 K567R S166* or WT SK-BR-3 − + Luminal Her2+ + WT R175H0.1212 0.0553 MDA-MB- − + Luminal Her2+ + H1047R H368del or 0.14320.0295 453 WT EFM-192A + + Luminal Her2+ + C420R 270fs 0.1922 0.0375HCC1954 − + Basal Her2+ + H1047R Y163C 0.1972 0.0899 AU565 − + LuminalHer2+ + WT R175H or 0.213 WT BT-474 + + Luminal Her2+ + K111N or E285K0.2261 WT HCC1569 − + Basal Her2+ − WT E294* and 0.3557 0.3023 227fsMCF12A − − Basal TN + WT unk 0.0444 0.0221 CAL-51 − − Basal TN − E542KWT 0.119 0.0224 MCF10A − − Basal TN + WT WT 0.1471 0.172 BT-549 − −Basal TN − WT R249S 0.1492 0.104 HCC70 − − Basal TN − WT R248Q or 0.17160.1492 WT MDA-MB- − − Basal TN − WT G266E 0.222 0.1168 435 CAL-85-1 − −Basal TN + WT K132E 0.253 0.0027 BT-20 − − Basal TN − H1047R K132Q or0.33 and WT P539R HCC1143 − − Basal TN + WT R248Q or 0.3427 0.2513 WTHS578T − − Basal TN + WT V157F 0.3429 0.0046 HCC2157 − − Basal TN − WTR248W or 0.3992 0.322 WT HCC1187 − − Basal TN + WT G108del 0.5674 0.2614HCC1937 − − Basal TN − WT R306* 0.697 0.3973 CAL-120 − − Basal TN + WTmut or WT 0.7002 0.0835 MDA-MB- − − Basal TN + WT R280K 0.7105 0.0544231 NCI/ADR- − − Basal TN + WT unk 0.9441 0.2325 RES DU4475 − − Basal TN− WT WT 1.2392 0.5476 MDA-MB- − − Basal TN − WT R273H 1.8556 0.038 468HCC38 − − Basal TN − WT R273L 2.9544 0.0419 MDA-MB- − − Basal TN − WTR273H or 2.9873 0.018 436 202fs MDA-MB- − − Basal TN + WT A88fs*52 4.3411.1704 157 or S261del ER = estrogen receptor Her2 = human epidermalgrowth factor receptor 2 TN = triple negative (estrogen receptornegative, progesterone receptor negative, human epidermal growth factorrector 2 negative) WT = wild type status Mut = mutant Unk = unknown SD =Standard deviation.

Growth Inhibition Assay for Cell Lines with Varying Sensitivity toRapamycin (Compound 1).

Cells were plated in 96-well plates at densities determined for eachcell line and the following day were treated with a range of Compound 1concentrations. The cells were incubated for 3 days at 37° C. and then20 ml of WST-1 (Roche) for PC-3, A549, HCT 116, U87-MG, MDA-MB-231, andNCI-H23) or 100 ml CellTiter-Glo reagent (Promega) for NCI-H460, T47D)was added to each well and the assay was completed according tomanufacturer protocols. The percentage inhibition at each concentrationof compound was normalized to the DMSO control values. The percentageinhibition was determined for each replicate and then the 3 values wereaveraged for each set of triplicate wells. All data were analyzed usingXLfit from IDBS. The formula used for determining IC₅₀ in Xlfit wasmodel number 205, which utilizes a 4-parameter logistic model orsigmoidal dose-response model to calculate IC₅₀ values. IC₅₀ values arereported as an average.

Rapamycin effects on proliferation tend to plateau in most cell lines.The sensitivity to Rapamycin was determined by the level of inhibitionwhere this plateau occurs and assigned as follows: sensitive 100-55%inhibition; partially sensitive 54-31% inhibition and insensitive 0-30%.As can be seen in FIG. 8 Compound 1 shows potent cell growth inhibition,including in cell types that are partially sensitive, or insensitive toRapamycin.

5.1.3 In Vivo Assays

NCI-H441 NSCLC In Vivo Tumor Growth Model.

A xenograft study was conducted with NCI-H441 tumor-bearing mice. SCIDmice were inoculated subcutaneously with NCI-H441 cells in the flankregion above the right hind leg. Following inoculation of the animals,the tumors were allowed to grow to about 100 mm³ prior to randomization.On Day 14 following tumor cell inoculation, the mice bearing NCI-H441tumors ranging between 87 and 136 mm³ were pooled together andrandomized into various treatment groups. Compound 1 was formulated in0.5% CMC and 0.25% Tween 80 in water (as a suspension). The animals wereorally administered vehicle (CMC-Tween) or Compound 1 twice daily (BID)for up to 26 days. Doses of Compound 1 ranged between 1 and 10 mg/kg.The positive control rapamycin (4 mg/kg, Q3D) was administered via theintraperitoneal (IP) route. Rapamycin was prepared as solution in 2%ethanol, 45% polyethyleneglycol 400, and 53% saline. Tumors weremeasured twice a week using calipers and tumor volumes were calculatedusing the formula of W²×L/2. Statistical analysis was performed using aone-way analysis of variance (ANOVA) followed by Dunnett's post-hoccomparison with the vehicle-treated control group. Results are set forthin FIG. 9, wherein it is shown that Compound 1 significantly inhibitedNCI-H441 NSCLC tumor growth in vivo.

In Vivo Evaluation of Compound 1 in Low Passage Tumorgraft Models ofNon-Small Cell Lung Cancer (NSCLC).

The objective of the study was to evaluate the single agent efficacy ofCompound 1 in non-small cell lung cancer (NCSLC) models. The antitumoractivity of Compound 1 was evaluated in low passage non-small cell lungcancer (NSCLC) tumorgraft models. The tumorgrafts were developed bydirectly implanting the human tumor fragments into immunocompromisedmice and then subsequently passaged in vivo. The tumors from theseprimary tumorgrafts have preserved biological and morphologicalcharacteristics of the original human tumors. The antitumor activity ofCompound 1 was evaluated at three dose levels (1, 5 and 10 mg/kg) withonce daily dosing for 28 days. During the course of the study antitumoractivity was evaluated by measuring the tumors. Compound 1 significantlyinhibited the growth of NSCLC primary tumor grafts in vivo.

U87MG Human Glioblastoma Xenograft Model (Compound 1).

Efficacy Studies: Groups of female SCID mice bearing U87MG tumors(n=8-10/group) were dosed orally with vehicle or Compound 1 throughoutthe study, starting when tumor volumes reached approximately 200 mm³.The twice daily (BID) dose groups were dosed with a 10-hour separationbetween morning and evening doses. In the positive control group,rapamycin was administered Q3D via intraperitoneal (IP) route. At theend of each study, plasma and/or tumor samples were collected.

TABLE 7A Design of Efficacy Study with twice daily dosing for 18 daysDosing Dosing Dose Group Schedule Duration Vehicle (n = 9) BID 18 daysRapamycin 4 mg/kg (n = 7) Q3D 18 days Compound 1 5 mg/kg (n = 9) BID 18days Compound 1 10 mg/kg (n = 9) BID 18 days Compound 1 25 mg/kg (n = 9)Q2D 18 days

TABLE 7B Design of Efficacy Study with once daily dosing for 3 weeksDosing Dosing Dose Group Schedule Duration Vehicle (n = 10) QD 3 weeksRapamycin 4 mg/kg (n = 6) Q3D 3 weeks Compound 1 0.5 mg/kg (n = 10) QD 3weeks Compound 1 1 mg/kg (n = 10) QD 3 weeks Compound 1 3 mg/kg (n = 10)QD 3 weeks Compound 1 5 mg/kg (n = 10) QD 3 weeks

Cell Line and Culture. U87MG cell line was obtained from American TissueCulture Collection (ATCC) (Gaithersberg, Md.) and grown in growth mediumcontaining MEM, 2 mM L-glutamine, 0.1 mM non-essential amino acids and 1mM sodium pyruvate and 10% fetal bovine serum (FBS). The cells weredetached from tissue culture flasks using trypsin-EDTA. Aftercentrifugation, the cell pellets were suspended in phosphate bufferedsaline (PBS) and counted using a hemocytometer. The final volume wasadjusted to 5×10⁶ cells/0.1 mL of PBS.

Tumor Cell Inoculation. Mice were anesthetized with inhaled isofluraneand then inoculated with U87MG tumor cells subcutaneously on the righthind leg with 0.1 mL of a single cell suspension in PBS using a sterile1 mL syringe fitted with a 26 gauge needle. Following inoculation, themice were returned to microisolator cages

Randomization of Animals. Following inoculation, tumors were allowed togrow to about 200 mm³ prior to randomization. The typical number of daysrequired for tumors to reach 200 mm³ was 14-15 days. The tumor of eachanimal was measured and animals with tumors ranging between 175-250 mm³were included in the study. Animals from the pool were then distributedrandomly into various cages and the cages were randomly assigned tovehicle, positive control, or test article groups. All of the mice weretagged with metal ear tags on the right ear.

Test Article Preparation and Administration. Suspensions of Compound 1were prepared in aqueous 0.5% CMC and 0.25% Tween-80. The formulationswere homogenized using a Teflon™ pestle and mortar (Potter-Elvehjemtissue grinder). Between the doses, the formulated compound was storedunder constant stirring using a magnetic stirrer at 4° C. in the dark.The test article and vehicle were administered by oral gavage. Thepositive control, rapamycin, was prepared as solution in 2% ethanol, 45%polyethyleneglycol 400, and 53% saline and administered by IP injection.Sterile syringes and gavage needles were used for compoundadministration. All of the procedures including injections were done inbiosafety cabinets disinfected with 70% ethanol prior to use.

Tumor Measurements. Tumor volumes were determined prior to theinitiation of treatment and were considered as the starting volumes.Thereafter, tumors were measured twice a week for the duration of thestudy. The long and short axes of each tumor were measured using adigital caliper in millimeters. Tumor volumes were calculated using theformula: width²×length/2. The tumor volumes were expressed in cubicmillimeters (mm³).

Tumor Growth Delay (TGD) Calculations. Tumor growth delay is thedifference in days for treated versus control tumors to reach a volumeof 1000 mm³. The TGD was calculated from the data plotted in a graphformat.

Body Weight Measurements. Initial body weights were recorded prior tothe initiation of treatment using a digital scale. The percent bodyweight change during the course of the study was calculated usinginitial body weight measurements. Body weights of each animal weremeasured twice a week at the same time as the tumor measurements. Bodyweights were measured more frequently if significant decreases werenoted during the course of the study.

Mechanism of action studies. To determine the mechanism of action ofCompound 1, mice bearing U87MG tumors of approximately 500 mm³ weredosed orally with vehicle or Compound 1 at 5 mg/kg BID for 4 days. Thepositive control, rapamycin, was dosed at 4 mg/kg Q3D for 4 days. Twohours after the 7^(th) dose of Compound 1 on day 4, animals wereeuthanized and tumors were dissected out and snap frozen in liquidnitrogen. In the rapamycin-treated group tumors were collected at 2 hourafter the 2^(nd) dose on day 4. The tumors were processed forimmunohistochemistry (IHC) or TUNEL.

Immunohistochemistry. Five to ten micron (5-10 μm) thick cryostatsections were used for IHC. The expression of the cell proliferationmarker Ki67 was evaluated by IHC using anti-Ki67 antibody. Anti-CD31antibody was used to determine blood vessel density and is a measurementof tumor angiogenesis. Frozen sections were fixed in 4% paraformaldehydefor 10 minutes at room temperature, washed in PBS, blocked andpermeabilized with normal goat serum and triton X-100. Sections werethen incubated with primary antibody (overnight) followed by incubationwith secondary antibody (60 minutes). The sections were washed,counterstained with Hoechst stain and mounted with antifade reagent. Fordouble labeling methods (Ki67 and CD31), cocktails of primary andsecondary antibodies were used for incubation. Positive and negativecontrols were included in each assay. Positive controls included thesections that were known to be reactive with the antibody. Negativecontrols included omission of primary or secondary antibody. Thesections were visualized with a Nikon E800 microscope equipped withfluorescence detection equipment and a digital camera attached to acomputer.

Apoptosis TUNEL Assay. To detect apoptotic cells, fluorescence in situcell death detection kit (Roche Biosciences) was used. Five to tenmicron (5-10 μm) thick cryostat sections were fixed in 4%paraformaldehyde for 15 minutes at room temperature, washed,permeabilized with 0.3% triton X-100 and 0.1% sodium citrate in PBS for10 minutes. Sections were then washed in PBS and incubated with alabeling solution containing TdT enzyme for 1 hour at 37° C. in thedark. The sections were washed in PBS, counterstained with Hoechst dye(0.4 μg/mL) at room temperature for 10 minutes and mounted in ProlongGold antifade reagent.

Quantitation of Immunohistochemistry. The tissues sections processed forapoptosis or immunostained for proliferating cells (Ki67) or bloodvessels were quantitated using Metamorph software. Using 20× objective,5 different fields from each section, 2-4 sections from each tumor, and3-4 tumors from each treatment group or control were used forquantitation. The area of interest was expressed as the percentthreshold area of the total area.

Results. The antitumor activity of Compound 1 was initially tested at 5and 10 mg/kg BID and 25 mg/kg Q2D (FIG. 10A). Dosing started on Day 14when tumor volumes ranged between 230-250 mm³ and continued until Day31. By Day 31, the vehicle-treated group measured 2404±185.6 mm³. Allanimals in the positive control group that received rapamycin (4 mg/kg,Q3D) had significantly (p<0.001) smaller tumors when compared with thevehicle group on Day 31. At the beginning of the dosing period, all ofthe Compound 1-treated groups showed tumor regression, and thispersisted until the end of the dosing period on Day 31. The averagetumor volumes of Compound 1-treated groups on Day 24 were smaller thantheir respective starting volumes on Day 14 (149±9, 96±4 and 101±8 mm³Day 24 versus 231±4, 235±4 and 238±5 mm³ on Day 14 for 5 and 10 mg/kgBID, and 25 mg/kg Q2D respectively). The average tumor volumes ofCompound 1-treated groups on Day 31 were smaller than their respectivestarting volumes on Day 14 (208±31, 96±13 and 116±15 mm³ Day 31 versus231±4, 235±4 and 238±5 mm³ on Day 14 for 5 and 10 mg/kg BID and 25 mg/kgQ2D, respectively). The tumor volumes from the 5 and 10 mg/kg BID and 25mg/kg Q2D Compound 1-treated animals were reduced by 91, 96, and 95%,respectively, compared with the vehicle control group. On Day 31 thevehicle control animals were euthanized. The animals in the Compound 1and rapamycin treated groups were allowed to survive without any furtherdosing to observe the kinetics of tumor re-growth following cessation oftest article administration. Immediately following cessation of dosing,tumor growth resumed. The animals in each group were euthanized whentumor volumes reached about 2000 mm³. Tumor growth delay (TGD) was 11,20, and 17 days for the 5 mg/kg BID, 10 mg/kg BID, and 25 mg/kg Q2Dgroups, respectively. No significant change in body weight was observedin the groups dosed with vehicle, Compound 1 at 5 mg/kg BID, or thepositive control. Compound 1-treated mice (10 mg/kg BID and 25 mg/kgQ2D) lost about 10% of their initial body mass by the end of the firstcycle (p<0.01). As soon as dosing ceased, the animals immediately gainedweight (FIG. 11). Conclusion: Treatment with Compound 1 significantlyinhibited U87MG glioblastoma tumor growth in vivo.

A second study was designed to determine the lowest efficacious dose ofCompound 1 with QD dosing and the corresponding plasma exposure(expressed as AUC) in the U87MG tumor xenograft model (FIG. 10B). Dosingwas initiated on Day 14 when average tumor volumes ranged between 171mm³ and 179 mm³. By the end of the 3-week dosing period on Day 34,vehicle-treated tumors reached an average volume of 2308±240 mm³.Rapamycin significantly inhibited tumor growth (p<0.001) on day 34.Following Compound 1 treatment, dose-dependent antitumor activity wasobserved. Significant (p<0.001) tumor volume reduction was achieved atall dose levels tested. The lowest efficacious dose as determined by 65%tumor volume inhibition was 1 mg/kg QD. No statistically significantchange in body weight was observed in any of the groups in the study.

Apoptotic Activity of Compound 1. To determine if Compound 1 inducesapoptosis in U87MG tumors, vehicle, Compound 1 and rapamycin-treatedtumor sections were processed for TUNEL which labels apoptotic cells. Inthis assay, terminal deoxunucleotidyl transferase (TdT) incorporates theFITC-labeled nucleotides to the ends of DNA strand breaks in situ(Gavrieli Y et. al., J Cell Biol 119:493-501 (1992)). FITC-labelednucleotides (representing the cells with DNA strand breaks, a hallmarkof apoptosis) can be detected using a microscope equipped with afluorescence attachment. Relatively very few (<0.1%) TUNEL-positivecells were observed in vehicle-treated U87MG tumors (FIG. 10C). Thenumber of TUNEL-positive cells in the tumors treated with Compound 1 andrapamycin were comparable (FIG. 10C). There was more than a four-foldincrease in TUNEL-positive cells in Compound 1-treated tumors comparedwith vehicle control-treated tumors. These data suggest that apoptosiscontributes to the observed antitumor activity of Compound 1 in vivo.

Antiproliferative and Antiangiogenic Activity of Compound 1.Immunohistochemistry with anti-Ki67 antibody was utilized to determineif Compound 1 inhibited tumor growth by blocking the proliferation oftumor cells in vivo. Ki67 is a nuclear antigen expressed inproliferating cells. A strong correlation between the fraction of cellsin S phase and the Ki67 index has been demonstrated (Vielh P et. al., AmJ Clin Pathol 94:681-686 (1990); Gasparini G et al., Int J Cancer57:822-829 (1994)). Tumor sections were co-stained with anti-CD31antibody to determine the antiangiogenic activity of the compound. CD31(also called PECAM-1) antibody recognizes a CD31 molecule expressed onthe endothelial cell membranes and is involved in their adhesiveinteractions (DeLisser H M, et al., Am J Pathol 151(3):671-677 (1997)).Nuclei were counter-stained with Hoechst dye. The proliferating cellsand microvessels were quantitated using Metamorph software and expressedas a percent of the threshold area. In vehicle-treated U87MG tumors,there was a significant number of cells (about 20%, expressed asKi67-positive threshold area) were proliferating (FIG. 10D). There was a59% reduction (p<0.001) in the number of proliferating cells in theCompound 1-treated tumors compared with vehicle-treated tumors. About11% of the threshold area comprised of CD31-positive vessels in thevehicle control U87MG tumor sections as determined by CD31immunohistochemistry. CD31-positive blood vessels in Compound 1-treatedU87MG tumors were significantly reduced (50%, p<0.001) when comparedwith vehicle-treated tumors (FIG. 10E). These data suggest that Compound1 inhibited proliferation of U87MG tumor cells and angiogenesis in thetumors.

U87MG Human Glioblastoma Xenograft Model (Compound 2).

Efficacy Studies: Groups of female SCID mice bearing U87MG tumors(n=8-10/group) were dosed orally with vehicle or Compound 2 (dosesranged between 0.05 and 1 mg/kg) throughout the study, starting whentumor volumes reached approximately 170-180 mm³. The twice daily (BID)dose groups were dosed with a 10-hour separation between morning andevening doses. In the positive control group, rapamycin was administeredevery third day (Q3D) via intraperitoneal (IP) route. At the end of eachstudy, plasma and/or tumor samples were collected.

TABLE 8 Design of Efficacy Study Dosing Dosing Study Dose Group (n)Schedule Duration A Vehicle (n = 9) QD 3 weeks Rapamycin 4 mg/kg (n = 6)Q3D 3 weeks Compound 2 0.1 mg/kg (n = 9) QD 3 weeks Compound 2 0.5 mg/kg(n = 9) QD 3 weeks Compound 2 1 mg/kg (n = 9) QD 3 weeks B Vehicle (n =9) BID 3 weeks Rapamycin 4 mg/kg (n = 6) Q3D 3 weeks Compound 2 0.05mg/kg (n = 9) BID 3 weeks Compound 2 0.1 mg/kg (n = 9) BID 3 weeksCompound 2 0.3 mg/kg (n = 9) BID 3 weeks BID = twice daily; Q3D = oncein 3 days; QD = once daily.

Cell Line and Culture. U87MG cell line was obtained from American TissueCulture Collection (ATCC) (Gaithersburg, Md.) and grown in growth mediumcontaining MEM, 2 mM L-glutamine, 0.1 mM non-essential amino acids, and1 mM sodium pyruvate plus 10% FBS. The cells were detached from tissueculture flasks using trypsin-EDTA. After centrifugation, the cellpellets were suspended in PBS and cells counted using a hemocytometer.The final volume was adjusted to 5×10⁶ cells/0.1 mL of PBS.

Tumor Cell Inoculation. Mice were anesthetized with inhaled isofluraneand then inoculated with U87MG tumor cells subcutaneously above theright hind leg with 0.1 mL of a single cell suspension in PBS using asterile 1 mL syringe fitted with a 26-gauge needle. Followinginoculation, the mice were returned to microisolator cages

Randomization of Animals. Following inoculation of animals, tumors wereallowed to grow to approximately 200 mm³ prior to randomization of mice.The typical number of days required for tumors to reach 200 mm³ was14-15 days. The tumor of each animal was measured and animals withtumors ranging between 170 and 180 mm³ were included in the study.Animals from the study pool were then distributed randomly into variouscages and the cages were randomly assigned to vehicle, positive control,or test article groups. All of the mice were tagged with metal ear tagson the right ear. A typical group consisted of 9-10 animals.

Test Article Preparation and Administration. Suspensions of Compound 2were prepared in aqueous 0.5% CMC and 0.25% Tween-80. The formulationswere homogenized using a Teflon™ pestle and mortar (Potter-Elvehjemtissue grinder). For different dose levels, the formulated compound wasdiluted from highest dose level to lowest. Between the doses, theformulated compound was stored under constant stirring using a magneticstirrer at 4° C. in the dark. The test article and vehicle wereadministered by oral gavage. The positive control, rapamycin, wasprepared as a solution in 2% ethanol, 45% polyethyleneglycol 400, and53% saline and administered by IP injection. Sterile syringes and gavageneedles were used for compound administration. All of the proceduresincluding injections were done in biosafety cabinets disinfected with70% ethanol prior to use.

Tumor Measurements. Tumor volumes were determined prior to theinitiation of treatment and were considered as the starting volumes.Thereafter, tumors were measured twice a week for the duration of thestudy. The long and short axes of each tumor were measured using adigital caliper in millimeters. Tumor volumes were calculated using theformula: width²×length/2. The tumor volumes were expressed in mm³.

Body Weight Measurements. Initial body weights were recorded prior tothe initiation of treatment using a digital scale. The percentage bodyweight change during the course of the study was calculated usinginitial body weight measurements. Body weights of each animal weremeasured twice a week at the same time as the tumor measurements. Bodyweights were measured more frequently if significant decreases werenoted during the course of the study.

Results. The antitumor activity of Compound 2 was tested with QD dosingat 0.1, 0.5, and 1 mg/kg (FIG. 12). Dosing started on Day 14 when tumorvolumes ranged between 170 and 180 mm³ and continued until Day 34. ByDay 34, the vehicle-treated group measured 2309±240 mm³. All animals inthe positive control group that received rapamycin (4 mg/kg, Q3D) hadsignificantly (p<0.001) smaller tumors when compared with the vehiclegroup on Day 34. Tumor inhibition for each treatment group is shown inFIG. 10 as a percentage and represents the difference in average tumorvolume between Compound 2-treated mice and vehicle-treated mice on Day34. Dose-dependent tumor inhibition was achieved with Compound 2. Theaverage tumor volumes of all Compound 2-treated groups weresignificantly smaller (p<0.001) than in vehicle-treated control mice onDay 34. The lowest efficacious dose as determined by approximately 65%tumor volume inhibition was observed at the 0.5 mg/kg dose level.

The antitumor activity of Compound 2 was tested with BID dosing at 0.05,0.1, and 0.3 mg/kg (FIG. 13). Dosing was initiated on Day 15 whenaverage tumor volumes ranged between 170 and 180 mm³. By the end of the3-week dosing period on Day 35, vehicle-treated tumors reached anaverage volume of 2155±245 mm³. The positive control rapamycinsignificantly inhibited tumors (p<0.001) on Day 35 when compared to thevehicle control. Dose-dependent tumor inhibition was achieved withCompound 2 (FIG. 13). The average tumor volumes of all of Compound2-treated groups were significantly smaller (p<0.001) than vehiclecontrol on Day 35. The tumor inhibition presented in FIG. 13 for eachtreatment group represents the percentage difference in average tumorvolumes between the Compound 2-treated and vehicle-treated control miceon Day 35. The lowest efficacious dose that achieved approximately 65%tumor volume inhibition was observed between the 0.1 and 0.3 mg/kg doselevel.

U87MG Intracranial Glioblastoma Model (Compound 1).

An intracranial glioblastoma study was conducted with U87MG cellstransfected with luciferase (U87-MG-Luc). Nude mice were inoculatedintracranially with U87MG-Luc cells into the brain. Followinginoculation of animals, the tumors were allowed to grow for 7 days. Onday 7 following tumor cell inoculation, the mice were imaged usingXenogen imaging system. The mice having tumors with an average fluxranging between 6.29×10⁷ and 1.59×10⁸ photons/sec were pooled togetherand randomized into various treatment groups. Compound 1 was formulatedin 0.5% CMC and 0.25% Tween 80 in water (as a suspension). The animalswere orally administered vehicle (CMC-Tween) or Compound 1 once daily(QD) for up to 6 weeks. Doses of Compound 1 ranged between 2.5 and 20mg/kg. The positive control Temozolomide (10 mg/kg, QD) was administeredvia intra peritoneal (IP) route. Temozolomide was formulated in 5%N-methylpyrrolidone, 45% PEG400 and 50% saline. The animals were imagedfor bioluminescence once a week using Xenogen imaging system andmonitored for survival. Statistical analysis was performed using alog-rank test between Compound-treated and vehicle-treated controlgroups. Compound 1 significantly prolonged the life of mice withintracranial glioblastoma (See FIG. 14).

G144 Cancer Stem Cell Derived Intracranial Glioblastoma Model (Compound1).

An intracranial glioblastoma study was conducted with G144 glioblastomacells transfected with luciferase (G144-Luc). Nude mice were inoculatedintracranially with G144-Luc cells into the brain. Following inoculationof animals, the tumors were allowed to grow for 5 weeks. At the end of 5weeks following tumor cell inoculation, the mice were imaged usingXenogen imaging system. The mice having tumors with an average fluxranging between 3.71×10⁶ and 3.87×10⁷ photons/sec were pooled togetherand randomized into various treatment groups. Compound 1 was formulatedin 0.5% CMC and 0.25% Tween 80 in water (as a suspension). The animalswere orally administered vehicle (CMC-Tween) or Compound 1 once daily(QD) for up to 6 weeks. Doses of 10 mg/kg and 20 mg/kg Compound 1 wereused. The positive control Temozolomide (TMZ) (10 mg/kg, QD) wasadministered via intra peritoneal (IP) route. Temozolomide wasformulated in 5% N-methylpyrrolidone, 45% PEG400 and 50% saline. Theanimals were monitored for tumor growth by imaging for bioluminescenceonce a week using Xenogen imaging system. Statistical analysis wasperformed using a one-way analysis of variance (ANOVA) followed byDunnett's post-hoc comparison with the vehicle-treated control groups.Compound 1 significantly inhibited the intracranial tumor growth (seeFIG. 15).

U87MG Intracranial Glioblastoma Model (Compound 2).

An intracranial glioblastoma study was conducted with U87MG cellstransfected with luciferase (U87-MG-Luc). Nude mice were inoculatedintracranially with U87MG-Luc cells into the brain. Followinginoculation of animals, the tumors were allowed to grow for 7 days. Onday 7 following tumor cell inoculation, the mice were imaged usingXenogen imaging system. The mice having tumors with an average fluxranging between 2.94×10⁷ and 1.89×10⁸ photons/sec were pooled togetherand randomized into various treatment groups. Compound 2 was formulatedin 0.5% CMC and 0.25% Tween 80 in water (as a suspension). The animalswere orally administered vehicle (CMC-Tween) or. Compound 2 once daily(QD) for up to 6 weeks. Doses of Compound 2 ranged between 0.5 and 5mg/kg. The positive control Temozolomide (10 mg/kg, QD) was administeredvia intra peritoneal (IP) route. Temozolomide was formulated in 5%N-methylpyrrolidone, 45% PEG400 and 50% saline. The animals were imagedfor bioluminescence once a week using Xenogen imaging system andmonitored for survival. Statistical analysis was performed using alog-rank test between. Compound 2-treated and vehicle-treated controlgroups. Compound 2 significantly prolonged the life of mice withintracranial glioblastoma (see FIG. 16).

Hepatocellular Carcinoma (Hep3B2.1-7) Orthotopic Study.

Hep3B2.1-7 human liver tumor cells were cultured in RPMI 1640 cellculture medium, supplemented with 10% FBS, 1% Glutamax and 1%penicillin-streptomycin. The cells were harvested by trypsinization,washed twice in HBSS and counted. The cells were then resuspended inHBSS:Matrigel™ (1:1, v/v) to a final concentration of 2×10⁸ cells/mL.Prior to inoculation (while the animal was anesthetized via injectableKetamil (10 mg/mL)/Xylazil (0.9 mg/mL) anesthetic), the skin on theincision site was swabbed with alcohol and an incision was made into theskin directly over the liver to expose the main lobe of the liver. Theneedle was introduced into the main lobe of the liver, where 2×10⁶Hep3B2.1-7 cells (in 10 μL with 50% Matrigel™) were discharged. Fourteendays post-inoculation, a satellite group of mice were culled to assessthe presence of tumors in the liver.

Compound 1 powder was suspended in 0.5% CMC/0.25% Tween80 to achieve astock concentration of 2 mg/mL. Briefly, Compound 1 was weighed and avolume of 0.5% CMC/0.25% Tween80 was added to achieve a 2 mg/mL stocksolution. The mixture was then vortexed, followed by homogenization witha mortar and pestle to achieve a fine suspension. The stock was preparedfreshly for each dose and diluted with 0.5% CMC/0.25% Tween80 to achievethe required concentration for dosing.

The mice in each group received daily oral (p.o.) treatment with eitherVehicle Control (0.5% CMC/0.25% Tween80; Group 1) or Compound 1 (1, 5 or10 mg/kg; Groups 4, 5 and 6, respectively). Treatments began on Day 0and continued for three weeks.

The Vehicle Control and Test Articles were administered in a dosingvolume of 5 mL/kg. Each animal's body weight was measured immediatelyprior to dosing. The volume of dosing solution administered to eachanimal was calculated and adjusted based on individual body weight.

Samples were collected at termination of the study or earlier if micewere culled due to ethical reasons. One hour post-final dose, all micereceiving Vehicle Control (Group 1) and Compound 1 (Groups 4-6,inclusive) were bled via terminal cardiac bleed into Lithium Heparincollection tubes. The samples were centrifuged (2000 rcf) for 15 minutesat 4° C. The plasma component was collected into fresh cryovials andstored at −80° C. The intact liver and tumor was excised and weighed.The tumor was removed from the liver and weighed separately. Each tumorwas cut into three portions, one portion being preserved in 10% neutralbuffered formalin for paraffin embedding, and the remaining two portionssnap frozen in liquid nitrogen and stored at −80° C. Compound 1exhibited significant tumor growth inhibition at 10 mg/kg (see FIGS.17-18).

Human Plasma Cell Myeloma (NCI-H929) Study.

Female SCID mice (Fox Chase SCID®, CB17/Icr-Prkce^(scid), Charles River)were 8 weeks old at the beginning of the study. The animals were fed adlibitum water (reverse osmosis, 1 ppm Cl) and NIH 31 Modified andIrradiated Lab Diet® consisting of 18.0% crude protein, 5.0% crude fat,and 5.0% crude fiber.

NCI-H929 plasma cell myeloma cells were obtained from the American TypeCulture Collection, and were maintained at Piedmont as exponentiallygrowing suspension cultures in RPMI 1640 medium supplemented with 20%fetal bovine serum, 2 mM glutamine, 100 units/mL penicillin G sodium,100 μg/mL streptomycin sulfate, 25 μg/mL gentamicin, and 50 μMβ-mercaptoethanol. The tumor cells were grown in tissue culture flasksin a humidified incubator at 37° C., in an atmosphere of 5% CO₂ and 95%air.

The NCI-H929 tumor cells used for implantation were harvested during logphase growth and resuspended at a concentration of 5×10⁷ cells/mL in 50%Matrigel (BD Biosciences). Each SCID mouse was injected subcutaneouslyin the right flank with 1×10⁷ NCI-H929 tumor cells (0.2 mL cellsuspension). Tumors were calipered in two dimensions to monitor growthas their mean volume approached 100-150 mm³. Tumor size, in mm³,

${{Tumor}\mspace{14mu} {Volume}} = \frac{w^{2} \times l}{2}$

where w=width and l=length, in mm, of the tumor. Tumor weight wasestimated with the assumption that 1 mg is equivalent to 1 mm³ of tumorvolume.

Fourteen days after tumor cell implantation, on Day 1 (D1) of the study,mice were sorted into treatment groups. Tumors were calipered twiceweekly during the study.

Compound 1 was a powder that was stored desiccated at room temperature,protected from light. It was suspended in 0.5% carboxymethyl cellulose:0.25% Tween®80 in deionized water (Vehicle) for dosing. Compound 1suspensions were prepared every other day; between treatments, thecompound was maintained in suspension at 4° C. by continuous magneticstirring, protected from light.

Compound 1 was administered via oral gavage (p.o.) once daily fortwenty-eight days (qd×28). Treatment efficacy was determined from thecalculated tumor volumes on Day 12. MTV(n), the median tumor volume forthe number of animals, n, evaluable on the day of analysis, wasdetermined for each group. Percent tumor growth inhibition (% TGI) wasdefined as the difference between the MTV of the control group and theMTV of the drug-treated group, expressed as a percentage of the MTV ofthe control group:

${\% \mspace{14mu} {TGI}} = {{\left( \frac{{MTV}_{control} - {MTV}_{{drug}\text{-}{treated}}}{{MTV}_{control}} \right) \times 100} = {\left\lbrack {1 - \left( {{MTV}_{{drug}\text{-}{treated}}/{MTV}_{control}} \right)} \right\rbrack \times 100}}$

Each animal was to be euthanized when its neoplasm reached the endpointvolume (2000 mm³). For each animal whose tumor reached the endpointvolume, the time to endpoint (TTE) was calculated by the followingequation:

${TTE} = \frac{{\log_{10}\left( {{endpoint}\mspace{14mu} {volume}} \right)} - b}{m}$

where TTE is expressed in days, endpoint volume is in mm³, b is theintercept, and m is the slope of the line obtained by linear regressionof a log-transformed tumor growth data set.

Animals were weighed daily on Day 1-5, then twice weekly until thecompletion of the study. On Day 14, at 1 hour before the 14^(th) dose,mice in each group were sampled for 0.25 mL blood from the mandibularvein, without anesthesia, and with sodium heparin as anti-coagulant. Thesame mice were euthanized 1 hour after the 14^(th) dose, and full volumeblood was to be collected by cardiac puncture under CO₂ anesthesia. Theblood was processed for plasma, which was stored at −80° C. The tumorwas excised from each euthanized animal, trisected, and the three partswere snap frozen in liquid N₂ in separate containers. Significant tumorgrowth inhibition was observed with 10 mg/kg Compound 1 (see FIG. 19).Significant tumor growth delay was observed at 3 mg/kg and 10 mg/kgCompound 1 (see FIG. 19).

HCT-116 Human Colorectal Cancer Xenograft Model.

The HCT-116 cell line was obtained from American Tissue CultureCollection (ATCC) (Gaithersberg, Md.) and grown in growth mediumcontaining McCoy's 5A medium with 2 mM L-glutamine adjusted to contain90% and 10% of fetal bovine serum. The cells were detached from tissueculture flasks using trypsin-EDTA. After centrifugation, the cellpellets were suspended in phosphate buffered saline (PBS) and countedusing a hemocytometer. Matrigel was added to the cell suspension toadjust the final volume to 2×10⁶ cells/0.1 mL of 1:1 mixture ofMatrigel: PBS.

Female 6-8 weeks old CB17 SCID mice were obtained from Charles RiverLaboratories at a body weight of 17-20 g. Mice were anesthetized withinhaled isoflurane and then inoculated with HCT-116 tumor cellssubcutaneously on the right hind leg with 0.1 mL of a single cellsuspension using a sterile 1 mL syringe fitted with a 26 gauge needle.Following inoculation, the mice were returned to microisolator cages.The tumors were allowed to grow to about 100 mm³ prior to randomization.The typical number of days required for tumors to reach 100 mm³ was 7 to8 days. The tumor of each animal was measured and animals with tumorsranging between 100 and 150 mm³ were included in the study. The animalswere distributed randomly into various cages and the cages were randomlyassigned to vehicle, positive control, or test article groups. All ofthe mice were tagged with metal ear tags on the right ear. A typicalgroup consisted of 8 to 10 animals.

Compound 1 was formulated in 0.5% CMC and 0.25% Tween 80 in water (as asuspension). The formulations were homogenized using a Teflon pestle andmortar (Potter-Elvehjem tissue grinder). Between the doses, theformulated compound was stored under constant stirring using a magneticstirrer at 4° C. in the dark. The test article and vehicle wereadministered by oral gavage. The positive control (rapamycin) wasprepared as solution in 2% ethanol, 45% polyethyleneglycol 400, and 53%saline and administered by IP injection. Vehicle and the test articlewere dosed in a volume of 5 mL/kg. The positive control rapamycin wasdosed in a volume of 10 mL/kg. Sterile syringes and gavage needles wereused for compound administration. All the procedures includinginjections were done in biosafety cabinets sprayed with ethanol prior touse.

Groups of female SCID mice bearing HCT-116 tumors (n=9-10/group) weredosed orally with vehicle or Compound 1 (1 mg/kg to 50 mg/kg) twicedaily (BID), once daily (QD), every second day (Q2D), every third day(Q3D) or every 5th day (Q5D) throughout the study starting when thetumor volumes reached approximately 100 mm³. The BID dose groups weredosed with a 10 h separation between the morning and evening doses. Inthe positive control group, rapamycin (n=6/group) was administered viathe intraperitoneal (IP) route Q3D. At the end of each study, plasmaand/or tumor samples were collected.

Tumor volumes were determined prior to the initiation of treatment andwere considered as the starting volumes. Thereafter, tumors weremeasured twice a week for the duration of the study. The long and shortaxes of each tumor were measured using a digital caliper in millimeters.The tumor volumes were calculated using the formula: width²×length/2(using long [L] and short [W] axes of tumors). The tumor volumes wereexpressed in cubic millimeters (mm³). Tumor volume data are expressed asmean±SE. The difference in tumor volume between vehicle and treatmentgroup was expressed in percent volume reduction=100−tumor volume oftreated/tumor volume of control×100. Statistical analysis was done usingGraphpad Prism. Comparison between multiple groups was done usingone-way ANOVA with Newman-Keuls post-test with a 95% significance level.

Initial body weights were recorded prior to the initiation of treatmentusing a digital scale. The percent body weight change during the courseof study was calculated using initial body weight. Body weights of eachanimal were measured twice a week at the same time that tumormeasurements were taken. Body weights were measured more frequently ifsignificant decreases were noted during the course of the study.Statistical analysis for the body weight was performed using one-wayANOVA followed by Dunnett's comparison to the initial body weight ofeach group.

The antitumor activity of Compound 1 was tested at doses of 1 mg/kg, 5mg/kg and 10 mg/kg BID and 25 mg/kg QD and Q2D and is shown in FIG. 20.Dosing was initiated on Day 11 when the tumor volumes ranged between 75and 125 mm³. By the end of the dosing period on Day 25, thevehicle-treated group reached an average volume of 2132±182 mm³. Allanimals in the positive control group that received rapamycin (4 mg/kg,Q3D) showed significantly (p<0.001) smaller tumors when compared withvehicle on the last day. Significant (p<0.001) tumor growth inhibitionwith Compound 1 was observed at 5 mg/kg (BID), 10 mg/kg (BID), and 25mg/kg (QD and Q2D). In the BID dosing paradigm, inhibition of tumorgrowth followed a dose response in that increasing the dose resulted inincreased tumor growth inhibition. The minimum dose required toobtain >65% tumor volume reduction compared to the vehicle control was25 mg/kg QD. Approximately 50% tumor volume reduction was observed atthe 10 mg/kg BID dose level. Body weight loss was observed for the 10mg/kg BID (16.9%) and 25 mg/kg QD (14%) dose groups. No significantchange in body weight was observed in any other group. The studiesdemonstrate that treatment with Compound 1 significantly inhibitsHCT-116 colorectal tumor growth in a dose and schedule-dependent manner.

5.2 Clinical Studies 5.2.1 A Phase 1/2, Multi-Center, Open-Label, DoseFinding Study to Assess the Safety, Tolerability, Pharmacokinetics andPreliminary Efficacy of Compound 1 Administered Orally to Subjects withAdvanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Compound 1 will be administered orally to subjects with solid tumors,non-Hodgkin lymphoma or multiple myeloma. The study is designed as aPhase 1/2 trial consisting of two parts: dose escalation (Part A) anddose expansion (Part B).

Compound 1 will be administered orally to determine safety andtolerability and to define the non-tolerated dose (NTD) and the maximumtolerated dose (MTD).

Evaluations will include the extent of inhibition of phosphorylation ofS6RP (Ser235/236 and/or Ser240/244) and/or 4EB-P1 (Thr37/46) for mTORC1activity and AKT (Ser473) and/or other relevant biomarkers for mTORC2activity in peripheral blood samples and tumor biopsies followingtreatment with Compound 1, and the efficacy of Compound 1.

The study population will consist of men and women, 18 years or older,with advanced NHL, MM, neuroendocrine tumors (the latter also acceptingsubjects aged 12 years or older) or advanced unresectable solid tumors,including subjects who have progressed on (or not been able to tolerate)standard therapy or for whom no standard anticancer therapy exists.

For both the dose escalation and dose expansion parts of this protocol,inclusion criteria are: (1) Understand and voluntarily sign an informedconsent document prior to any study related assessments/procedures areconducted; (2) Men and women, 18 years or older, with histologically orcytologically-confirmed, advanced NHL, MM, or advanced unresectablesolid tumors including subjects who have progressed on (or not been ableto tolerate) standard anticancer therapy or for whom no standardanticancer therapy exists; (3) Eastern Cooperative Oncology GroupPerformance Status (ECOG) PS of 0 or 1 for subjects with solid tumors,and 0-2 for hematologic malignancies; (4) Subjects must have thefollowing laboratory values: Absolute Neutrophil Count (ANC)≧1.5×10⁹/L,Hemoglobin (Hgb)≧9 g/dl, Platelets (plt)≧100×10⁹/L, Potassium withinnormal limits or correctable with supplements, AST/SGOT andALT/SGPT≦2.5×Upper Limit of Normal (ULN) or ≦5.0×ULN if liver tumor ispresent, Serum bilirubin≦1.5×ULN or ≦2×ULN if liver tumor is present,Serum creatinine≦1.5×ULN or 24-hour clearance≧50 mL/min, Negative serumor urine pregnancy test within 48 hours before starting study treatmentin females of childbearing potential; and (5) Able to adhere to thestudy visit schedule and other protocol requirements

For the dose expansion part (Part B) of this protocol, inclusioncriteria are: (1) Retrieval of formalin-fixed, paraffin embedded (FFPE)archival tumor tissue, either in tumor blocks or sectioned/mountedspecimens for gene mutation and/or IHC biomarker assay for all tumorsexcept MM. Only in exceptional circumstances may an exemption waiver begranted by the Sponsor for other tumor types; (2) Satisfactory Screeningbiopsy for gene mutation and/or IHC biomarker assay for accessibletumors for all tumors except NSCLC and NET (optional) and GBM; (3)Histologically-confirmed tumors of the following types, all withmeasurable disease. Type-specific criteria are in addition to, orsupersede, above criteria where applicable: (a) Glioblastoma multiforme(GBM) or gliosarcoma, excluding WHO Grade IV oligoastrocytoma (hasreceived prior treatment including radiation and/or chemotherapy, withradiation completed >12 weeks prior to Day 1; planned salvage surgicaltumor resection on Day 15±7 days, anticipated to yield ≧200 mg tumortissue; no prior or scheduled Gliadel® wafer implant unless area ofassessment and planned resection is outside the region previouslyimplanted; no prior interstitial brachytherapy or stereotacticradiosurgery unless area of assessment and planned resection is outsidethe region previously treated; no enzyme-inducing anti-epileptic drugs(EIAED) such as carbamazepine, phenyloin, phenobarbital, or primidonewithin 14 days before Day 1; able to undergo repeated magnetic resonanceimaging (MRI) scans; Availability of adequate FFPE archival tumormaterial (for PD biomarkers)); (b) Hepatocellular carcinoma (HCC) (Pltcount≧60×10⁹/L if portal hypertension is present; Child-Pugh score ofless than 10 (i.e., class B liver function or better); at least 4 weeksfrom last dose of α-interferon and/or ribivirin; at least 4 weeks fromprior percutaneous ethanol injection, radiofrequency ablation,transarterial embolization, or cryotherapy with documentation ofprogressive or recurrent disease); (c) Gastrointestinal neuroendocrinetumor (NET) of non-pancreatic origin (locally unresectable or metastaticmoderate or well differentiated, low (grade 1) or intermediate (grade2), non-pancreatic NET either of gut origin or of unknown primary;pancreatic, bronchial, and other NET with origins in organs above thediaphragm (e.g., laryngeal, pharyngeal, thyroid), pheochromocytomas,paragangliomas, adenocarcinoid and goblet carcinoid tumors, and poorlydifferentiated, high grade (eg., small cell or large cell) tumors areexcluded; subjects aged 12 years or older; symptomaticendocrine-producing tumors and nonfunctional tumors are both allowed;concurrent therapy with somatostatin analogs is required (the subjectmust be on a stable dose for at least two months with documentedprogressive disease on therapy); evidence of radiologic diseaseprogression within 12 months prior to Cycle 1, Day 1; no receptortargeted radiolabeled therapy within 3 months prior to Cycle 1, Day 1;no liver-directed therapy within 4 weeks prior to Cycle 1, Day 1, unlessa site of measurable disease other than the treated lesion is present;screening and on-study tumor biopsies are optional in this cohort;archival tumor collection should be requested, but is not mandatory inthis cohort); (d) Hormone receptor-positive breast cancer (HRPBC)(unresectable locally advanced or metastatic carcinoma of the breast; ERpositive, and HER2/neu negative (0 or 1+), tumor; measurable diseaseaccording to RECIST v1.1; must have received at least one prior line ofhormonal therapy or at least one year of aromatase therapy in theadjuvant setting, or six months of aromatase inhibitor therapy formetastatic disease; bisphosphonates or denusomab are allowed in stabledoses; cohort may be expanded to enroll a minimum of 5 subjects eachwith tumors containing PIK3CA mutations; (e) Multiple Myeloma (MM)(measurable levels of myeloma paraprotein in serum (>0.5 g/dL) or urine(>0.2 g excreted in a 24-hour collection sample); absolute neutrophilcount (ANC)≧1.0×10⁹/L; platelets (plt)≧60×10⁹/L in subjects in whom <50%of bone marrow mononuclear cells are plasma cells or ≧30×10⁹/L insubjects in whom ≧50% of bone marrow mononuclear cells are plasmacells); (f) Diffuse large B-cell lymphoma (DLBCL) (histologically provendiffuse large B-cell non-Hodgkin's lymphoma; platelets (plt)≧60×10⁹/Lfor subjects in whom <50% of bone marrow mononuclear cells are lymphomacells, or ≧30×10⁹/L for subjects in whom ≧50% of bone marrow mononuclearcells are lymphoma cells; at least 4 weeks from last dose of therapeuticglucocorticosteroids; adrenal replacement doses of glucocorticosteroids(up to the equivalent of 10 mg daily prednisone) are allowed).

For both the dose escalation and dose expansion parts of this protocol,exclusion criteria are: (1) Symptomatic central nervous systemmetastases (excluding GBM; subjects with brain metastases that have beenpreviously treated and are stable for 6 weeks are allowed); (2) Knownacute or chronic pancreatitis; (3) Subjects with any peripheralneuropathy ≧NCI CTCAE grade 2; (4) Subjects with persistent diarrhea ormalabsorption≧NCI CTCAE grade 2, despite medical management; (5)Impaired cardiac function or clinically significant cardiac diseases,including any of the following: LVEF <45% as determined by MUGA scan orECHO, Complete left bundle branch, or bifasicular, block, Congenitallong QT syndrome, Persistent or clinically meaningful ventriculararrhythmias or atrial fibrillation, QTcF>460 msec on screening ECG (meanof triplicate recordings), Unstable angina pectoris or myocardialinfarction ≦3 months prior to starting Compound 1, Other clinicallysignificant heart disease such as congestive heart failure requiringtreatment or uncontrolled hypertension (blood pressure≧160/95 mmHg); (6)Subjects with diabetes on active treatment or subjects with either ofthe following: (a) fasting blood glucose≧126 mg/dL (7.0 mmol/L), or (b)HbAlc≧6.5%; (7) Other concurrent severe and/or uncontrolled concomitantmedical conditions (e.g., active or uncontrolled infection) that couldcause unacceptable safety risks or compromise compliance with theprotocol; (8) Prior systemic cancer-directed treatments orinvestigational modalities ≦5 half lives or 4 weeks, whichever isshorter, prior to starting study drug or who have not recovered fromside effects of such therapy; (9) Subjects who have undergone majorsurgery ≦2 weeks prior to starting study drug or who have not recoveredfrom side effects of such therapy; (10) Women who are pregnant or breastfeeding; Adults of reproductive potential not employing two forms ofbirth control: (a) females of childbearing potential must agree to usetwo adequate forms of contraception methods simultaneously (one must benon-hormonal) from the time of giving informed consent until 28 daysafter the last dose of Compound 1. Females of child-bearing potential,defined as sexually mature women who have not undergone a hysterectomyor bilateral oophorectomy, or who have not been naturally postmenopausal(ie., who have not menstruated at all) for at least 24 consecutivemonths; (b) males (with partners who are female with child-bearingpotential must agree that they or their partners will use at least twoeffective contraceptive methods (including one barrier method) whenengaging in reproductive sexual activity throughout the study, and willavoid conceiving for 28 days after taking the last dose of Compound 1;(11) Subjects with known HIV infection; (12) Known chronic hepatitis Bor C virus (HBV/HCV) infection, unless comorbidity in subjects with HCC;(13) Any significant medical condition, laboratory abnormality, orpsychiatric illness that would prevent the subject from participating inthe study; (14) Any condition including the presence of laboratoryabnormalities, which places the subject at unacceptable risk if he/shewere to participate in the study; (15) Any condition that confounds theability to interpret data from the study.

For the dose expansion part (Part B) of this protocol, exclusioncriteria are: (1) Concurrent active second malignancy for which thepatient is receiving therapy, excluding non-melanomatous skin cancer orcarcinoma in situ of the cervix.

Compound 1 will be supplied in appropriate strengths (e.g., 2.5 mg, 10mg, and 20 mg) containing only the active pharmaceutical ingredient inreddish-brown gelatin capsules for oral administration. No otherexcipients will be used in the product capsules.

Compound 1 will be administered orally, in an uninterrupted once-dailyschedule with no rest period between cycles. A dose of 7.5 mg/day ofCompound 1 will be the starting dose in this protocol. Each dose will betaken in the morning, with the subject having fasted overnight (minimumof 6 hours). Food intake will be delayed until at least one hour afterdosing on the days Compound 1 is taken at home. On clinic visit days,Compound 1 will be administered in the clinic after any predose testshave been completed. Food will be taken after all fasting tests havebeen completed but in no case sooner than 60 minutes after dosing (3hours after dosing on Day 8). In cases where troublesome GI symptoms,fatigue or other symptoms persist beyond the end of Cycle 1, dosing maybe moved to the end of day, providing the subject can maintain at leasta 3-hour separation between the last intake of food and Compound 1administration. Compound 1 may be taken up to 12 hours late if dosinghas been delayed on a single day; otherwise that day's dose should beomitted.

In Part A, subjects will receive single and multiple ascending doselevels of Compound 1 to measure pharmacokinetics (PK) and to identifythe maximum tolerated dose (MTD). A modified accelerated titrationdesign (Simon R, Freidlin B, Rubinstein L, et al. Accelerated TitrationDesigns for Phase I Clinical. Trials in Oncology, Journal of theNational Cancer Institute, (1997) Vol. 89, No. 15.) will be used toestablish initial toxicity. During the accelerated course, initialcohorts of one subject will be given Compound 1 at dose increments of100% until the first instance of first-course grade 2 or highertoxicity, at which point the accelerated part will be terminated, andthis particular cohort will be expanded to 6 subjects. Subsequently, astandard escalation dosing schedule with approximately 50% doseincrements and 6 subjects per cohort will be initiated in order toestablish the non-tolerated dose (NTD) and MTD. Smaller increments andadditional subjects within a dose cohort may also be evaluated.

A dose will be considered to be non-tolerated if 2 evaluable subjects ina dose cohort experience dose-limiting toxicity (DLT). When a NTD isdefined, dose escalation will be stopped. The MTD will be defined as thelast dose tested below the NTD with 0 or 1 out of 6 evaluable subjectsexperiencing DLT during Cycle 1. An intermediate dose (i.e., one betweenthe NTD and the last dose level before the NTD) or additional subjectswithin any dose cohort may be required to determine the MTD moreprecisely.

In Part B, subjects may start Compound 1 at the MTD and/or a lower doselevel based on safety, PK and PD data from Part A. Approximately 150subjects will be treated and evaluated for safety and preliminaryantitumor activity after every two cycles of therapy. Tumor typesinclude non-small cell lung cancer (NSCLC), glioblastoma multiforme(GBM), hepatocellular carcinoma (HCC), gastrointestinal neuroendocrinetumor of non-pancreatic origin (NET), diffuse large B-cell lymphoma(DLBCL), multiple myeloma (MM), and hormone receptor positive breastcancer (HRPBC). Up to 20 subjects will be enrolled in each tumor type.

During the first cycle only in Part A, each subject will be administereda single dose of Compound 1 (Day −1), followed by a 48-hour observationand PK sampling period, followed on Day 1 by daily uninterrupted dosingfor 28 days (Cycle 1=30 days). In subsequent Part A cycles, subjects aretreated in 28-day cycles with continuous dosing from Day 1 to 28. InPart B, subjects will receive continuous dosing for 28 days from thebeginning—there is neither an initial observation period nor a 48-hourPK collection.

Therapy may be discontinued if there is evidence of disease progression,but subjects can continue to receive Compound 1 as long as theInvestigator considers they are deriving benefit from treatment. Therapywill be discontinued if there is unacceptable toxicity or if the subjectdecides to withdraw from the study.

When a dose reduction is indicated, the next lower dose level will beselected. Two dose reductions are allowed. For the starting dose level(7.5 mg) in Part A, reductions will be in 2.5 mg decrements. In Part B,the starting dose level will be 45 mg QD; dose reductions to 30 mg and15 mg QD are permitted. If any subject continues to experienceunacceptable toxicity after 2 dose reductions in Part A, Compound 1 willbe discontinued permanently. In Part B, subjects may dose reduce up to 2levels (i.e., to 15 mg) and increase again if clinically appropriate;subsequent dose reductions are permitted in the event of recurrenttoxicity but, in such circumstances, it is not permitted to reescalatethe dose again.

Subjects will be evaluated for efficacy every 2 cycles through cycle 6and every 3 cycles thereafter. The primary efficacy variable isresponse. Tumor assessments, including imaging (CT, MRI and/or PET) ofthe chest and abdomen and other sites as appropriate, will be performedduring Screening. Subjects with brain lesions will also have brain scansat Screening and during follow-up tumor assessments. After Screening,tumor assessments (for all tumors except multiple myeloma) will beperformed on completion of Cycles 2, 4 and 6 (i.e., on Cycles 3, 5 and7/Day 1±7 days) and then every 3 months thereafter (e.g., Cycle 10 and13/Day 1±7 days). Tumor assessment (for multiple myeloma and onlyNHL/DLBCL with known or suspected marrow involvement) (bone marrowaspiration and biopsy, with PD biomarker analysis, cytogenetic analysisif abnormally present at Screening) will be performed on completion ofCycles 4, 8, 12 and 16 only (i.e., on Cycles 5, 9, 13 and 17/Day 1±7days). Cytogenetics need not be repeated if normal at Screening. Tumorresponse will be based on Response Evaluation Criteria in Solid Tumors(RECIST 1.1), International Workshop Criteria (IWC) for NHL/DLBCL orInternational Uniform Response Criteria (IURC) for Multiple Myeloma, andRANO for GBM, using the post resection MRI scan as the baseline. Giventhe difficulty in assessing tumor response following salvage surgery,the primary efficacy endpoint for GBM will be the proportion of subjectsprogression-free at 6 months from Day 1 relative to efficacy evaluablesubjects in the GBM type. Subjects will be evaluated for tumor responseon completion of Cycle 2, 4, 6, and so on. A descriptive analysis ofevidence of anti-tumor activity will be provided based on clinical andradiographic assessments by the investigator, which includes assessmentof target lesion, non-target lesion, new lesion and overall response.

The efficacy variable of focus for Part A will be best overall response.Other preliminary efficacy variables will be summarized using frequencytabulations for categorical variables or descriptive statistics forcontinuous variables.

For Part B, efficacy variables to be analyzed include tumor response atthe end of treatment, the proportion of subject alive andprogression-free, and duration of response. Efficacy variables willmature when last subject of a treatment arm or cohort have withdrawnfrom the study or completed 6 cycles.

Progression Free Survival rates will be computed using the Kaplan-Meierestimates. Duration of response will also be reported in subjects whorespond, using tumor specific evaluation criteria. Two-sided 90% CIs ofthe response rate, and of the PFS rate at time of each scheduledresponse assessment (ie., Cycles 2, 4, 6, etc.) will be provided bytumor type.

Other preliminary efficacy variables, including ECOG performance status,CTC, and PET outcomes, will be summarized using frequency tabulationsfor categorical variables or descriptive statistics for continuousvariables.

Parameters to be explored include mTOR biomarker inhibition in blood andtumor, histopathologic response, correlations with pharmacogenomicfindings and percentage of inhibition of pAKT (Ser473), phospho-S6RP(Ser235/236 and/or Ser240/244), phospho-4EB-P1 (Thr37/46), and/or otherrelevant biomarkers in peripheral blood samples and tumor, adverseevents and clinical outcome. The pharmacodynamic (PD) measurements areincorporated in this study to evaluate target inhibition of mTORC1 andmTORC2 pathways, the consequences of such inhibition, and PK/PDrelationships. In Parts A and B, biomarker analysis will involvemeasuring pAKT (mTORC2) in protein lysates derived from isolatedplatelets. Levels of p4EB-P1 and pS6RP (mTORC1), and pAKT (mTORC2), willbe measured by flow cytometry using whole blood samples. Likewise, inParts A and B, pAKT, p4EB-P1, p56, Ki67 and/or other relevant markers toassess Compound 1 activity will be measured in serial tumor biopsiesfrom subjects with accessible disease when possible. The changes of eachbiomarker will be determined by comparing the levels of biomarkers inpre- and post-treatment samples and, where possible, correlate thesewith drug exposure in blood, and tissue if available, and tumor responseover time. Full details of all statistical analyses and modeling forthese outcomes will be described in the statistical analysis plan andfinal study report.

The safety variables for this study are adverse events, clinicallaboratory variables, 12-lead ECGs (centrally reviewed), LVEFassessments, physical examinations and vital signs. In Part A, thedecision to either evaluate a higher dose level or declare a MTD will bedetermined by the Safety Review Committee (SRC) each time all clinicaland laboratory safety data for a given cohort is available for review.The SRC will also determine the dose, doses, or schedule appropriate forPart B. During Part B, the SRC will continue to review safety dataregularly and make recommendations about the study continuation, asappropriate.

In certain embodiments, patients undergoing the clinical protocolprovide herein will show a positive tumor response, such as inhibitionof tumor growth or a reduction in tumor size. In certain embodiments,patients undergoing the clinical protocol provide herein will show animprovement in brain lesions, such as a decrease in number or size. Incertain embodiments, patients undergoing the clinical protocol provideherein will achieve a Response Evaluation Criteria in Solid Tumors(RECIST 1.1) of complete response, partial response or stable disease.In certain embodiments, patients undergoing the clinical protocolprovided herein will prevent a Response Evaluation Criteria in SolidTumors (RECIST 1.1) of progressive disease. In certain embodiments,patients undergoing the clinical protocol provide herein will show animprovement in International Workshop Criteria (IWC) or InternationalUniform Response Criteria (IURC). In certain embodiments, patientsundergoing the clinical protocol provide herein will show an improvementin Response Assessment for Neuro-Oncology (RANO) Working Group criteria.In certain embodiments, patients undergoing the clinical protocolprovide herein will show an improvement in ECOG performance status orPET outcomes.

TOR Pathway Biomarker Measurements in Whole Blood.

Blood samples received from clinical sites were aliquoted into a96-deepwell plate and rested for 1 hour at 37° C. The samples werestimulated with anti-IgD and LPS for 15 minutes at 37° C. The red bloodcells were lysed and the white blood cells were fixed with BD Lyse/FixBuffer at a ratio of 15:1 buffer to blood for 10 minutes at 37° C. Theplates were centrifuged, aspirated, and 1 mL of ice-cold methanol wasadded to the wells containing fixed white blood cells to permeabilizethe cells for intracellular staining. The plates were stored overnightat −80° C. The plates were thawed, centrifuged, aspirated and washedtwice with PBS+0.5% BSA. The cells were stained with antibodies specificfor the surface markers CD3, CD14, and CD19, and for mTOR pathwaymarkers, including pS6 (S235/236), p4EBP1 (T37/46), and pAKT (S473). Thecells were washed twice with PBS and fixed with 1.6% PFA.

Sample analysis: The samples were analyzed on an 8 color cytometer.Control wells of 8-peak rainbow beads (Spherotech Libertyville, Ill.)were acquired at multiple points during sample acquisition. The medianfluorescence intensity (MFI) was computed for each marker from thefluorescence intensity levels in T cells, B cells, and monocytes. TheMFI were normalized using the 8-peak rainbow beads and presented as ERF(Equivalent number of Reference Fluorophores). ERFs were calculated fromthe MFIs using a linear regression transformation carried out on alog-log scale using the rainbow calibration particles with 8 intensitieson 8 colors. The percent change from baseline for pS6, p4EBP1, and pAKTin stimulated and non-stimulated T cells, B cells, and monocytes wasdetermined for each patient. The baseline value was an average of twovisits (screening and cycle 1/day −1 at 0 hr pre-dose) when available.

Part A: Accelerated Dose Escalation Results.

28 subjects were treated across 5 dose levels: 7.5 (n=1), 15 (n=2), 30(n=9), 45 (n=7) and 60 mg (n=8). Baseline characteristics were typicalfor phase 1 oncology trials. Although ECOG 2 was allowed, >95% ofsubjects had ECOG 0 or 1. Diverse tumor types were enrolled with themost common being CRC, breast, and pancreas. Half of the patients hadreceived more than 3 prior therapies (see. FIG. 21).

Five dose levels were evaluated. The first grade 2 related toxicity wasobserved at the 3^(rd) dose level (30 mg) and thereafter cohorts wereexpanded to a minimum of 6 subjects with 50% dose escalation increments.Additional subjects were backfilled into all cohorts except doselevel 1. Grade 3 hyperglycemia was reported as a DLT at 30 mg and grade3 rash as a DLT at 45 mg. In response, the protocol DLT criteria weremodified to allow for medical management of rash and hyperglycemia priorto considering these events as DLT in subsequent patients. Fatigue andmucositis were reported as DLT at 60 mg and this dose was considered theNTD; the MTD was determined to be 45 mg once daily and this was the dosetaken forward in Part B. (see FIG. 22)

The most frequent Compound 1-related events (>20%) as well as allrelated grade 3/4 events are shown in FIG. 22). Fatigue, GI toxicity(including mucositis/stomatitis), hyperglycemia, rash and arthralgiawere the most frequent events. One case of grade 3 interstitialpneumonitis requiring hospitalization occurred. Compound 1 dosing washeld and the pneumonitis responded to steroid treatment. The maximumtolerated dose (MTD) was 45 mg QD. (see FIG. 23).

Hyperglycemia was reported frequently with onset often occurring duringcycle 1. Hyperglycemia was associated with elevations of insulin andc-peptide (FIG. 24) and was dose related. Daily fingerstick glucosemonitoring was implemented early in the trial with rapid interventionwith metformin and/or insulin at first occurrence of hyperglycemia.Hyperglycemia was generally manageable and patients were able tocontinue on Compound 1 treatment at the same or a lowered dose.

Dose proportional drug exposure was observed, although there was a highlevel of intersubject variability in exposure. At dose levels of 30 mgand higher, exposures exceeded the levels estimated to provide >50%inhibition of TORC1 (pS6) and TORC2 (pAKT) pathways for at least 8 hourspost dosing based on preclinical xenograft models. There was onlyminimal drug accumulation after 15 days of dosing. Dose proportionalexposure was observed with a terminal half life of 4 to 8 hrs (meansteady state C_(max) 485 ng/mL, AUC₀₋₂₄ 2371 ng^(x)hr/mL at 45 mg) (seeFIG. 25)

TOR pathway biomarker inhibition was monitored in blood samples using astimulated assay (FIG. 26). TORC1 inhibition was monitored bymeasurement of changes in p4EBP1 and pS6 and TORC2 by pAkt. Data wasobtained after the first dose of Compound 1 and sampling timepoints werepre-dose, 1.5, 3, and 5 hours post dose. Biomarker inhibition wasmonitored in B cells, T cells, and monocytes and the cell type with themost consistent findings was selected for presentation. Consistentinhibition of both TORC1 and TORC2 biomarkers was observed for up to 5hours post dose at Compound 1 doses of 30 mg and higher as predicted bypreclinical modeling and human exposures achieved. In general,inhibition of the TORC1 marker, pS6, was more complete and durable thanthe p4EBP1 marker. Inhibition of pAkt confirmed Compound 1 activityagainst the TORC2 pathway and differentiates this agent from rapalogswhich are predominantly TORC1 inhibitors and have been shown to triggerfeedback upregulation of pAkt. PK/PD analysis demonstrated a dosedependent relationship between Compound 1 exposure and mTOR kinaseinhibition.

Fifteen subjects showed target lesion responses in the stable range (seeFIG. 28), of which 1 breast cancer subject showed greater than 30%regression of target lesions (see FIG. 27). The 2 subjects with thegreatest tumor regression both had ER+ breast cancer. One subject withbreast cancer completed more than 11 cycles of study treatment anddemonstrated a confirmed PR, while a second subject with ER+ breastcancer completed nearly 6 cycles of study treatment and demonstrated SDat the time of first restaging scans (after 2 cycles of treatment).

The Dose Level, Treatment Duration and Best Overall Response is shown inFIG. 29. One subject with breast cancer demonstrated complete PR andcompleted more than 11 cycles of study treatment. The subject was doseescalated from 30 to 45 mg. Eight subjects had Stable Disease at thetime of their first restaging scans (after 2 cycles of treatment). Thelongest duration of SD was 24 weeks. Tumors with SD included NSCLC (2),breast, salivary, pancreas, adenocystic, adrenal and colorectal cancer(CRC). SD was observed at doses ranging from 15 to 60 mg.

The ER+/Her2− breast cancer subject achieving Partial Response (see FIG.27) lasting at least 11 months, and completing more than 11 cycles ofstudy treatment, demonstrated a 30% reduction in target lesions at thefirst restaging after 2 cycles of therapy; demonstrated furtherregression at each subsequent restaging with a maximum 50% reductionafter 10 cycles of therapy; and was subsequently removed from the studydue to clinical progression manifest by worsening pulmonary symptomsduring the 12th cycle. The duration of Partial Response from firstrestaging scan to last scan was 220 days (7.2 months or 7.9 cycles) andthe duration of partial response from first restaging scan to last dosewas 271 days (8.9 months or 9.7 cycles). The time to progression fromfirst dose to last scan was 277 days (9.1 months or 9.9 cycles) and thetime to progression from first dose to last dose was 328 days (10.8months or 11.7 cycles).

Compound 1 was well tolerated with toxicities comparable to other drugstargeting this pathway. Evidence of TORC1/TORC2 pathway inhibition wasobserved as well as preliminary signals of anti-tumor activity,including the partial response and stable disease described above.Expansion cohorts in selected hematologic and solid tumors will evaluateCompound 1 at the MTD of 45 mg QD.

Part B: Dose Expansion Findings (Based on Sep. 20, 2012 Findings).

TOR Pathway Biomarker Inhibition:

In all cohorts, TORC1 and TORC2 inhibition was observed in blood, asmeasured by inhibition of pAkt and p4EPB1 formation, when measured atbaseline (average of screening and Cycle 1/Day 1 (t=0 h) and in Cycle1/Day 1 (t=1.5 h after dosing), and in Cycle 1/Day 15 (t=0 h and 1.5 h).The data was analyzed by Paired t test and P values <0.001 were obtainedwhen comparing baseline and Cycle 1/Day 1 (t=1.5 h after dosing), andbetween Cycle 1/Day 15 (t=0 h) and Cycle 1/Day 15 (t=1.5 h).

NSCLC Patients:

TORC1 inhibition (as measured by percent change from baseline forp4EPB1) and TORC2 inhibition (as measured by percent change frombaseline for pAkt/tAkt) were observed in majority of patients. Clearsignals of clinical activity were seen in NSCLC patients. In 17evaluable patients, best target lesions responses up to 35% reductionwere observed, with 11 patients meeting at least Stable Disease and 1patient meeting Partial Response RECIST 1.1 criteria. Four patientscompleted at least 6 cycles of study treatment and one patient remainson study drug after 10 cycles.

HCC Patients:

TORC1 inhibition (as measured by percent change from baseline forp4EPB1) and TORC2 inhibition (as measured by percent change frombaseline for pAkt/tAkt) were observed in majority of patients. Somesignals of clinical activity were seen in HCC patients. In 14 evaluablepatients, best target lesions responses up to 47% reduction wereobserved, with 5 patients meeting at least Stable Disease and 2 patientsmeeting Partial Response RECIST 1.1 criteria. Eight patients completedat least 4 cycles of study treatment.

DLBCL Patients:

TORC1 inhibition (as measured by percent change from baseline forp4EPB1) and TORC2 inhibition (as measured by percent change frombaseline for pAkt) was observed in the first patient analyzed. Somesignals of clinical activity were seen in DLBCL patients. In 11evaluable patients, best target lesions responses up to 75% reductionwere observed, with 1 patient meeting at least Stable Disease and 2patients meeting Partial Response RECIST 1.1 criteria. Restaging tumorassessments are pending in most treated subjects. Nine patients remainon study drug, and are ongoing at up to 6 cycles.

GBM Patients:

TORC1 inhibition (as measured by percent change from baseline forp4EPB1) and TORC2 inhibition (as measured by percent change frombaseline for pAkt) were observed in majority of patients. No signs ofclinical activity, defined as a 6-month Progression-Free Survival, wereobserved in 10 evaluable GBM patients.

MM Patients:

TORC1 inhibition (as measured by percent change from baseline forp4EPB1) and TORC2 inhibition (as measured by percent change frombaseline for pAkt) were observed in 2 patients. No tumor responses wereseen in MM patients. In 11 evaluable patients, none met Partial Responseusing IURCMM criteria, after up to 9 cycles of treatment. Two patientsremain on study drug after 9 cycles.

NET Patients:

Some signals of clinical activity were seen in NET patients. Sixpatients with sufficient follow up met Stable Disease RECIST 1.1criteria. Thirteen patients remain on study drug, and are ongoing at upto 5 cycles. Preliminary signals of activity include improvements incarcinoid syndrome-related symptoms in some patients with refractorybaseline symptoms, reductions in endocrine hormone markers(chromogranin, gastrin, serotonin, glucagon) in some patients, andreductions in tumor metabolic activity, as measured by PET imaging, inthe majority of subjects.

Breast Cancer patients:

Five subjects have initiated study drug in the expansion phase.Biomarker and response information will be collected.

5.2.2 Phase 1A/1B, Multi-Center, Open-Label, Dose Finding Study toAssess the Safety, Tolerability, Pharmacokinetics and PreliminaryEfficacy of Compound 2 Administered Orally to Subjects with GlioblastomaMultiforme or Gliosarcoma

Compound 2 will be administered orally to subjects with glioblastomamultiforme or gliosarcoma. The safety and tolerability of Compound 2 inhumans, as well as the efficacy, will be evaluated in this study. Thestudy will be conducted in two parts: dose escalation (Part A) and doseexpansion (Part B). Subjects will be enrolled sequentially in Part A.Enrollment in Part B will be stratified by tumor type.

The primary objectives of this study are to: A. Determine the safety andtolerability of Compound 2 when administered orally and to define theNTD and the MTD. B. Determine the PK of Compound 2. The secondaryobjectives of this study are to: A. Evaluate the extent of inhibition ofphosphorylation of S6RP and/or 4E-BP1 for mTORC1 activity and AKT and/orother relevant biomarkers for mTORC2 activity, in blood, skin and/ortumor biopsies/aspirates, when available before and during treatmentwith Compound 2. B. Evaluate the inhibition of DNA-PK activity in skinsamples irradiated by UV light and/or tumor biopsies/aspirates usingpDNA-PK S2056 and/or other relevant biomarkers for DNA damage pathwaysbefore and during Compound 2 treatment. C. Provide information on theefficacy of Compound 2.

Compound 2 will be available in four strengths (0.25 mg, 1.0 mg, 5.0 mgand 10 mg) presented in gelatin capsules containing only the activepharmaceutical ingredient. The capsules will be packaged in high densitypolyethylene (HDPE) bottles, fitted with induction seals andchild-resistant polypropylene closures.

The primary endpoints of this study are: a) The following safetyendpoints: DLTs, NTD and MTD, evaluated using the NCI CTCAE criteriaVersion 4; b) PK endpoints: C_(max), AUC, t_(max), t_(1/2), CL/F, Vz/Fand Accumulation Index of Compound 2. The secondary endpoints of thisstudy are: a) Biomarker inhibition, determined by change in the levelsof phosphorylation of S6RP, and/or 4E-BP1, and/or AKT, and/or otherrelevant biomarkers in blood, skin and/or tumor biopsies/aspirates, whenavailable; b) Inhibition of UV-stimulated DNA-PK activity determined bylevels of pDNA-PK and/or other relevant biomarkers in skin and/or tumorbiopsies/aspirates, when available; c) Antitumor efficacy, determined byresponse rates of each tumor type using tumorappropriate responsecriteria.

Between 30 and 60 subjects will be enrolled in Part A, designed toestablish initial toxicity.

Part B will consist of approximately 100 subjects with prespecifiedtypes of advanced solid tumors such as glioblastoma multiforme tofurther assess the safety profile of Compound 2 and provide efficacyinformation. Tumor response rate will be assessed by tumor type and doselevel. The Part B population will be defined by the efficacy seen duringPart A and by data from ongoing preclinical studies.

The overall study design will be comprised of a Screening Period (Day−28 to Day 1), a Treatment and Evaluation Period (28-day QD (and/or BID)cycles until tumor progression, unacceptable toxicity orsubject/physician decision to discontinue administration of Compound 2)and an End of Treatment and Follow-up Period (end of treatmentprocedures within 21 days of last dose; follow-up for 28 days after lastdose for final safety assessment).

Subjects will start Compound 2 QD or BID dosing (or other suitableregimen) on Cycle 1 Day 1 and receive daily treatment in 28-day cycles.Compound 2 may be discontinued when there is evidence of tumorprogression, but subjects can continue to receive study drug as long asthe Investigator considers they are deriving benefit. Compound 2administration will be discontinued when there is unacceptable toxicity,or the subject decides to withdraw from the study.

Compound 2 will be administered orally either once or twice daily (orother suitable dosing regimen) with no rest period between cycles. EachQD dose will be taken in the morning with at least 200 mL of water, withthe subject having fasted overnight (minimum of 6 hours). Food intakewill be delayed until at least 90 minutes after dosing on the daysCompound 2 is taken at home. On clinic visit days, the morning Compound2 dose will be administered in the clinic after any predose tests havebeen completed. Food may be taken after all fasting tests have beencompleted but in no case earlier than 90 minutes after dosing (3 hoursafter dosing on Day 15). For subjects receiving Compound 2 QD wheretroublesome related GI symptoms, fatigue or other symptoms persistbeyond the end of Cycle 1, dosing may be moved to later in the dayproviding the subject can maintain a 3-hour separation between Compound2 administration and the last intake of food and a 90-minute delaybefore ingesting further food. Compound 2 may be taken up to 12 hourslate if dosing has been delayed on a single day; otherwise that doseshould be omitted.

Compound 2 will be administered initially as a QD regimen.

Doses will be administered in an escalating manner followingsatisfactory review of safety data from the lower doses. There will be aminimum of 28 days after the first dose has been administered to thelast subject between dose escalations. Within each cohort, enrollmentwill be staggered so that there is a minimum of 24 hours between Cycle 1Day 1 for each subject in order to evaluate initial toxicity.

Each cycle of Compound 2 lasts 28 days and there is no rest periodbetween cycles. Subjects may be discontinued when there is evidence ofdisease progression but subjects can continue to receive Compound 2 foras long as they derive benefit from treatment, as judged by theInvestigator. Compound 2 administration will be discontinued when thereis unacceptable toxicity or if the subject decides to withdraw from thestudy.

In Part A, cohorts of subjects will initially receive QD ascending dosesof Compound 2 to measure PK and to identify the MTD. In Part A, 0.5 mgQD is the Compound 2 starting dose. A modified accelerated titrationdesign (Simon, R., Freidlin, B., Rubinstein, L., et al. Acceleratedtitration designs for Phase I clinical. trials in oncology, J Nat CancInstitute 1997; 89, (15): 1138-1147) will be used to establish initialtoxicity. During the accelerated phase, initial cohorts of one subjectwill be given Compound 2 at dose increments of 100% until the firstinstance of first-Cycle grade 2 or higher toxicity suspected to bedrug-related, at which point the accelerated phase will stop and thisparticular cohort will be expanded to a total of 6 subjects.Subsequently, a standard escalation dosing schedule with approximately50% dose increments and 6 subjects per cohort will be initiated in orderto establish the NTD and MTD. Smaller increments and additional subjectswithin a dose cohort may also be evaluated, if necessary, based ontoxicity, PK/PD results or tumor biopsy findings.

Based on interim PK and PD results from initial dose cohorts, atwice-daily (BID) dosing regimen will also be evaluated in Part A. Thiswill be initiated in cohorts of 6 subjects at or below a total dailydose level already shown to be tolerable, but divided into two equaldoses administered approximately 12 hours apart. Thereafter, doseescalation for QD and BID dosing cohorts may occur independently.Intermittent dosing schedules of comparable or lower dose intensity thancontinuous daily dosing may also be considered for evaluation.

A dose will be considered to be non-tolerated if 2 or more out of 6evaluable subjects in a dose cohort experience DLT during Cycle 1. Whena NTD is defined, dose escalation will be stopped. The MTD will bedefined as the last dose tested below the NTD with 0 or 1 out of 6evaluable subjects experiencing DLT during Cycle 1. An intermediate dose(i.e., one between the NTD and the last dose level before the NTD) oradditional subjects within any dose cohort may be required to moreprecisely determine the MTD more precisely, as may alternate regimens ifemerging PK-PD results suggest these may be appropriate.

In Part B, subjects may start Compound 2 on a QD or BID regimen at theMTD and/or lower dose levels based on safety, PK and PD data from PartA. In Part B, approximately 100 subjects will be evaluated for safetyand antitumor activity after every two cycles of therapy.

All subjects who receive at least one dose of Compound 2 will beevaluable for safety. In Part A, a subject evaluable for dose-limitingtoxicity (DLT) is defined as one who, in the first 28 days after Cycle 1dosing began, either (a) received at least 21 of the planned 28 doses ofCompound 2 at the cohort-specified dose and has sufficient data forsafety evaluation by the SRC, or (b) experienced study drug-related DLT.Non-evaluable subjects will be replaced in the dosing cohort. In Part B,an efficacy evaluable subject for tumor response is defined as one whoreceived at least one cycle of Compound 2, and have baseline and atleast one post-baseline efficacy assessment.

In Parts A and B, dose reductions are permitted in any cycle, includingCycle 1. Dose reductions that occur in Cycle 1 during Part A willconstitute DLT, but subjects will be allowed to continue on study drugat the reduced dose. National Cancer Institute Common TerminologyCriteria for Adverse Events (NCI CTCAE) Version 4, 2009 will be used tograde AEs.

When a dose reduction is indicated, the next lower dose level will be ona QD or BID schedule will be selected. For BID dose reductions below thestarting dose of 10 mg BID, 8 mg BID and 4 mg BID will be selected. Twodose reductions are allowed. Additional PK evaluations may be conductedat modified dose level(s) in order to characterize intrasubject PKprofiles with alternate doses.

In Part A, intrasubject dose escalation beyond the dose initiallyassigned to a subject is not permitted in Cycle 1. Those continuing totake Compound 2 beyond Cycle 1 may, have the dose level increasedproviding the alternative dose level has been shown to be well toleratedby at least one cohort of other subjects in this study. In theseinstances, additional PK evaluation at the higher dose level may beconducted. In Part B, no dose escalation beyond the MTD is allowed.

In the following, statistical analyses will be performed by study phase,dose level, dosing regimen and tumor cohort as needed or applicable.

The study population definitions are as follows: (a) Intent-to-Treat(ITT) Population—All subjects who take at least one dose of Compound 2;(b) Safety Population—All subjects who take at least one dose ofCompound 2, which is the same as ITT population for this study; (c)Efficacy Evaluable (EE) Population—All ITT subjects who meet eligibilitycriteria, complete at least one cycle of Compound 2, and have baselineand at least one valid post-baseline efficacy assessment.

Subject enrollment will be curtailed when up to 20 evaluable subjectshave been enrolled in each tumor type and dose level/regimen. In Part Bas a whole, sample sizes are not based on statistical calculation butrather on clinical empirical and practical considerations traditionallyused for Phase 1 studies of this kind.

All efficacy evaluable subjects in the Part B portion will be includedfor efficacy analysis. Efficacy will be analyzed by each tumor type onceall subjects have withdrawn from the study or completed 6 cycles.Two-sided ninety-five percent confidence intervals of the response ratewill be provided by tumor type. A case-by-case description of allsubjects who exhibited a complete or partial response during the Part Asegment will be provided. A descriptive analysis of other evidence ofanti-tumor activity will be provided based on clinical, radiographic,and biologic assessments of efficacy.

All treated subjects will be included for the efficacy analysis. Theprimary efficacy variable is tumor respons, based on investigator'sassessment using RANO criteria, using the post resection MRI scan as thebaseline. Given the difficulty in assessing tumor response followingsalvage surgery, the primary efficacy endpoint for GBM will be theproportion of subjects progression-free at 6 months from Day 1 relativeto efficacy evaluable subjects in the GBM type. Other supplementaryefficacy variables, including CTC assessments, will be summarized usingfrequency tabulations for categorical variables or descriptivestatistics for continuous variables.

For both the dose escalation and dose expansion parts of this protocol,inclusion criteria are: (a) Understand and voluntarily sign an informedconsent document before any study-related assessments/procedures areconducted; (b) Men and women, 18 years or older, with histological orcytological confirmation of glioblasoma multiforme or gliosarcoma,including those who have progressed on (or not been able to tolerate)standard anticancer therapy or for whom no other conventional therapyexists; (c) Consent to screening tumor biopsy (Part A optional; Part Bmandatory except as specified for individual tumor types below); (d)ECOG PS of 0 or 1; (e) The following laboratory values: (1) Absoluteneutrophil count (ANC)≧1.5×109/L; (2) Hemoglobin (Hgb)≧9 g/dl; (3)Platelets (plt)≧100×109/L; (4) Potassium within normal range, orcorrectable with supplements; (5) AST/SGOT and ALT/SGPT≦2.5×Upper Limitof Normal (ULN) or ≦5.0×ULN if liver tumor is present; (6) Serum totalbilirubin≦1.5×ULN or ≦2×ULN if liver tumor is present; (7) Serumcreatinine≦1.5×ULN, or 24-hr clearance≧50 mL/min; and (8) Negative serumor urine pregnancy test within 72 hrs before starting study treatment infemales of childbearing potential; and (f) Able to adhere to the studyvisit schedule and other protocol requirements.

For the dose expansion part (Part B) of this protocol, inclusioncriteria are: (a) Subject consent to retrieve formalin-fixed,paraffin-embedded (FFPE) archival tumor tissue, either in tumor blocksor sectioned/mounted specimens; and (b) Histologically-confirmedglioblastoma multiforme or gliosarcoma, excluding WHO Grade IVoligoastrocytoma (has received prior treatment including radiationand/or chemotherapy, with radiation completed >12 weeks prior to Day 1;planned salvage surgical tumor resection on Day 15±7 days, anticipatedto yield ≧300 mg tumor tissue. Screening tumor biopsy is not required;no prior or scheduled Gliadel® wafer implant unless area of assessmentand planned resection is outside the region previously implanted; noprior interstitial brachytherapy or stereotactic radiosurgery unlessarea of assessment and planned resection is outside the regionpreviously treated; no enzyme-inducing anti-epileptic drugs (EIAED) suchas carbamazepine, phenyloin, phenobarbital, or primidone within 14 daysbefore Day 1; and able to undergo repeated magnetic resonance imaging(MRI) scans).

For both the dose escalation and dose expansion parts of this protocol,exclusion criteria are: (a) Symptomatic central nervous systemmetastases; (b) Known acute or chronic pancreatitis; (c) Any peripheralneuropathy ≧NCI CTCAE grade 2; (d) Persistent diarrhea or malabsorption≧NCI CTCAE grade 2, despite medical management. Impaired ability toswallow; (e) Impaired cardiac function or clinically significant cardiacdiseases; (f) Diabetes mellitus on active treatment; (g) Otherconcurrent severe and/or uncontrolled concomitant medical conditions(e.g. active or uncontrolled infection) that could cause unacceptablesafety risks or compromise compliance with the protocol; (h) Priorsystemic cancer-directed treatments or investigational modalities ≦5half lives or 4 weeks, whichever is shorter, prior to starting studydrug or who have not recovered from side effects of such therapy; (i)Major surgery ≦2 weeks prior to starting study drug or who have notrecovered from side effects of such therapy; (j) Pregnancy or breastfeeding; (k) Adults of reproductive potential not employing two forms ofbirth control; (l) Known HIV infection; (m) Known chronic hepatitis B orC virus (HBV/HCV) infection, unless this is comorbidity in subjects withHCC; (n) Any significant medical condition, laboratory abnormality, orpsychiatric illness, including the inability to swallow capsules, thatwould prevent subjects from participating in the study; (o) Anycondition including the presence of laboratory abnormalities, whichplaces subjects at unacceptable risk if they were to participate in thestudy; (p) Any condition that confounds the ability to interpret studydata; or (q) Concurrent active second malignancy for which the subjectis receiving therapy, excluding non-melanomatous skin cancer orcarcinoma in situ of the cervix.

For the dose expansion part (Part B) of this protocol, exclusioncriteria are: Prior treatment with agents targeting both mTOR complexes(dual TORC1+TORC2 inhibitors) and/or PI3K/AKT pathways. However, priortreatment with isolated TORC1 inhibitors (e.g., rapalogs) is allowed inboth parts of this study.

In certain embodiments, patients undergoing the clinical protocolprovide herein will show a positive tumor response, such as inhibitionof tumor growth or a reduction in tumor size. In certain embodiments,patients undergoing the clinical protocol provide herein will show animprovement in the Response Assessment for Neuro-Oncology (RANO) WorkingGroup regarding response criteria for high-grade gliomas.

Effect of Compound 20n Ultraviolet B-Stimulated Human Skin.

The inhibitory effect of Compound 2 on DNA-PK was evaluated by assessingthe phosphorylation status of DNA-PK S2056 following UV irradiation ofhuman skin before and during Compound 2 treatment. The minimal erythemadose (MED) was determined for each subject during screening. Todetermine the MED, each subject received UV-irradiation to 6 areas ontheir buttock. The UV dose on each area was increased incrementally fromthe previous dose. The starting UV dose was dependent on the subject'sskin type according to Fitzpatrick classification. The spectrum ofUV-irradiation is UV light B spectrum (UVB). MED determination was doneapproximately 22 to 24 hours post UVB exposure.

During screening, and after MED determination, subjects received a 2×MEDUV dose to one site on the buttock. Two punch biopsies (approximately 4mm in diameter by 0.8 mm in depth) were taken, one from the UVirradiated site and one from adjacent non-UV irradiated skin. The punchbiopsies were taken at 4 (±15 minutes) hours post UV exposure. On Cycle1 Day 15 to 22, subjects received a 2×MED UV dose to one site on theopposite buttock. Two punch biopsies (approximately 4 mm in diameter by0.8 mm in depth) were taken, one from the UV irradiated site and onefrom adjacent non-UV irradiated skin. The punch biopsies were taken at 4(±15 minutes) hours post UV exposure and 2 (±15 minutes) hours postCompound 2dose. All skin samples were immediately placed into 10%formalin, fixed for 24 hours, and subsequently transferred to 70%ethanol. The specimens were embedded in paraffin within 48-72 hours.Skin specimens from the biopsies were analyzed for phospho-DNA-PK usingan IHC assay. Phospho-DNA-PK was quantified using a combination ofpercentage and intensity subjective grading scales and/or objectivescoring using an automated system, i.e. Aperio, with a nuclear algorithmto evaluate staining.

UV Exposure Equipment:

The DermaPal UV unit (manufactured by Daavlin) uses a FS FluorescentSunlamp and exposure was regulated by a built-in digital timer. TheDermaPal was adapted to position a 12 oz styrofoam coffee cup over thebulbs, which thus became a device establishing all exposure distancesand preventing unwanted exposure. A separate device consisting of sixgraded neutral density filters was supplied to provide a graded seriesof UV doses to establish each patient's MED. A kodacel filter was usedin conjunction with this device.

A number of references have been cited, the disclosures of which areincorporated herein by reference in their entirety. The embodimentsdisclosed herein are not to be limited in scope by the specificembodiments disclosed in the examples which are intended asillustrations of a few aspects of the disclosed embodiments and anyembodiments that are functionally equivalent are encompassed by thepresent disclosure. Indeed, various modifications of the embodimentsdisclosed herein are in addition to those shown and described hereinwill become apparent to those skilled in the art and are intended tofall within the scope of the appended claims.

What is claimed is:
 1. A method for treating a solid tumor, non-Hodgkin lymphoma or multiple myeloma, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV) to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
 2. The method of claim 1, wherein the solid tumor is an advanced solid tumor.
 3. The method of claim 1, wherein the solid tumor is a neuroendocrine tumor.
 4. The method of claim 3, wherein the neuroendocrine tumor is of gut origin, of non-pancreatic origin, or of unknown primary origin.
 5. The method of claim 3, wherein the neuroendocrine tumor is a symptomatic endocrine producing tumor or a nonfunctional tumor.
 6. The method of claim 3, wherein the neuroendocrine tumor is locally unresectable, metastatic moderate, well differentiated, low (grade 1) or intermediate (grade 2).
 7. The method of claim 1, wherein the solid tumor is non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer or adrenal cancer.
 8. The method of claim 7, wherein the breast cancer is ER+/Her2−, ER+/Her2+, ER−/Her2+ or triple negative (TN).
 9. The method of claim 1, wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma.
 10. A method for achieving complete response, partial response or stable disease, as determined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in a patient, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV) to a patient having a solid tumor.
 11. A method for achieving complete remission, partial remission or stable disease, as determined by the International Workshop Criteria (IWC) for non-Hodgkin lymphoma in a patient, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV) to patient having non-Hodgkin lymphoma.
 12. A method for achieving a stringent complete response, complete response, or very good partial response, as determined by the International Uniform Response Criteria for Multiple Myeloma (IURC) in a patient, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV) to patient having multiple myeloma.
 13. A method for improving, Eastern Cooperative Oncology Group Performance Status (ECOG) or Response Assessment for Neuro-Oncology (RANO) Working Group for glioblastoma multiforme in a patient, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV) to a patient having non-Hodgkin lymphoma, multiple myeloma or glioblastoma multiforme.
 14. The method of any one of claims 1-13, wherein the TOR kinase inhibitor is a compound from Table A, B, C or D. 